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ABSTRACT 
 
 Aging is accompanied by a significant decline in bone mass and strength 
(osteoporosis) and in muscle mass and strength (sarcopenia).  These conditions pose a 
tremendous threat as each year, one in three older adults living in the community falls.  
Muscle weakness is a primary risk factor for falls and the associated morbidity and mortality, 
especially among older adults with osteoporosis.  Nurses are aware of the risks and are often 
in a position to effect a change.  For this reason, nurses are positioned to be involved in and 
to direct research aimed at better understanding these conditions and to make discoveries 
with translational impact.   
Until recently, bones and muscles were viewed to function in a mechanical 
partnership.  Emerging research, however, demonstrates a much more complex relationship, 
resulting not only from mechanical forces, but also from an exchange of biochemical factors.  
The purpose of this in vitro controlled trial was to explore this biochemical exchange, and 
investigate the impact of bone factors on skeletal muscle cell differentiation (myogenesis) in 
the presence of osteoporosis.  A series of studies have been completed in mouse models, and 
our concomitant goal was to expand these studies into humans.  Serum used was collected 
from research subjects in an ongoing case-control study designed to characterize defects in 
bone quality that contribute to low trauma fractures in postmenopausal women.  Using a 
iv 
combination of biophysical, biochemical, and physiological approaches, the serum from 
subjects with (CASE) and without (CNTRL) osteoporosis was applied to human skeletal 
muscle cells.  The extent of myogenesis in each group was assessed through immunostaining 
for visualization and calculation of fusion index (i.e., the myogenesis index), flow cytometry 
for cell cycle analysis, and intracellular calcium measurements for data related to cellular 
function.       
Findings from this study will contribute to the growing body of knowledge related to 
the biochemical communication between bones and muscles, bone-muscle crosstalk.  In 
addition, this study illustrates an excellent opportunity for basic scientists and clinicians to 
work together to decrease the devastating impact of sarcopenia and osteoporosis.     
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CHAPTER 1 
INTRODUCTION 
The population worldwide is aging at an unprecedented rate and is, therefore, 
receiving much attention.  Every year since 1948, the World Health Organization and 
partners convene to discuss and draw attention to a public health issue of global significance.  
The theme of World Health Day 2012 was aging and health.  In her 2012 address to delegates 
of the gerontology congress, the Director-General of the World Health Organization, Dr. 
Margaret Chan stated, ―Within the next five years, for the first time in history, the number of 
adults aged 65 and older will outnumber children under the age of five‖ (Chan, 2012).  This 
is considered the largest demographic shift in history.  In the United States, the first of the 
baby boomers, born between the years of 1946 and 1964, turned 65 years of age in 2011.  
Predictions are that by the year 2030, one in every five Americans will be 65 years or older 
(Olson, 2013).  
Aging is accompanied by a decline in cognitive and physical functioning and is listed 
as a risk factor for a myriad of chronic diseases, including diabetes, dementia, cancer, 
musculoskeletal, and cardiovascular disorders (Niccoli & Partridge, 2012; Satariano et al., 
2012). Due to the fact that average lifespans are increasing, more people each year are 
suffering from chronic diseases.  Approximately half of the population worldwide lives with 
at least one chronic disease (Clark, 2011; Yach, Hawkes, Gould, & Hofman, 2004); and the 
burden is carried not only by the individual, their family, but society.  The economic costs of 
chronic diseases include the direct costs of prevention, diagnosis, and treatment; the indirect 
costs of lost human resources and productivity; and intangible costs, including the 
psychosocial aspects of pain, bereavement, and loss of independence.    
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The 2010 Global Burden of Disease Study reported that musculoskeletal diseases 
have become the second greatest cause of disability worldwide, affecting 1.7 billion people 
(Vos et al., 2012).  Regardless the measures and tools used to diagnose, the incidence of 
musculoskeletal diseases such as sarcopenia and osteoporosis increases with increasing age 
(Cruz-Jentoft, 2013; Leboime et al., 2010).   Muscle weakness is one of the primary 
contributing factors leading to falls among persons age 65 and older (Dutta, 1997; 
Yamashita, Haesang, Bailer, Nelson, & Mehdizadeh, 2011).  The morbidity and mortality 
associated with falls in this age group is even greater in the presence of osteoporosis.  The 
aging world population and the increasing incidence of osteoporosis and sarcopenia threatens 
to impact the productivity, independence, physical, and psychosocial health of individuals; 
not to mention the widespread economic ramifications.  For these reasons, it is important to 
pursue research exploring new facets of the relationship between these two musculoskeletal 
diseases.     
Background 
Sarcopenia is the progressive loss of muscle mass and strength.  The most literal 
definition of osteoporosis is ―porous‖ bones and leads to bones that break easily.  Sarcopenia 
and osteoporosis have long been considered expected consequences of aging and are leading 
contributors to morbidity and mortality among older adults (Arthur & Cooley, 2012; Dutta, 
1997; Brotto & Abreu, 2012; Evans & Campbell, 1993; Fielding et al., 2011; Rubenstein & 
Josephson, 2006).  Mechanisms identified as contributing to the development of sarcopenia 
and osteoporosis include physical inactivity, genetics, hormones, changes in body 
composition, chronic inflammation, and oxidative stress (Arthur & Cooley, 2012; Buford et 
al., 2010; Crepaldi & Maggi, 2005; Karasik & Kiel, 2010; Romano, Serviddio, de Matthaeis, 
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Bellanti, & Vendemiale, 2010).  Research now supports what clinicians who work with the 
geriatric population have long suspected; there is a significant association between 
sarcopenia and osteoporosis, i.e. persons with one diagnosis often have the other (Di 
Monaco, Vallero, Di Monaco, & Tappero, 2011; Sirola & Kroger, 2011).  Together, 
sarcopenia and osteoporosis pose significant risks to individual safety, independence, and the 
economic health of the nation (Crepaldi & Maggi, 2005; Janssen, 2006; Janssen, Heymsfield, 
& Ross, 2002).  In the United States, the estimated direct cost of sarcopenia in 2000 was 
$18.5 billion (Janssen, Shepard, Katzmarzyk, & Roubenoff, 2004).  Adjusted to the normal 
and not the health care inflation, the current costs would surpass $25 billion per year.  
Experts have estimated the annual health care costs related to osteoporosis to be $20 billion 
or more (Becker, Kilgore, & Morrisey, 2010; Blume & Curtis, 2011).  As people are living 
longer, the need to better understand these conditions is critical to the advancement of 
therapeutic approaches to decrease associated morbidities and mortality.  Therefore, any 
intervention that would for example reduce the burden of these twin diseases by as little as 
10% would save at least $5 billion dollars, which could then be re-invested into research 
aimed at further reducing their burden.  
One strategy to develop preventative and therapeutic interventions targeting 
sarcopenia and osteoporosis is to study how these conditions are linked together and how one 
might affect the other.  The relationship between bones and muscles is emerging as more 
than simply a function of mechanical load, as recent findings have revealed an endocrine-like 
―crosstalk.‖  Crosstalk is the response in cell morphology and function to factors from distant 
sites and systems.  Crosstalk has been recognized as one of the primary means by which 
intracellular communication occurs in mammalian physiology (Gruning, Lehrach, & Ralser, 
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2010; Holz & Habener, 1992).  Preliminary research performed by the Muscle Bone Biology 
Group (MUBIG) at the UMKC Schools of Dentistry, Medicine, Nursing and others has 
provided data supporting this biochemical relationship between bones and muscles (Abreu, 
Stern, & Brotto, 2012; Dallas, Prideaux, & Bonewald, 2013; Karasik & Kiel, 2010).  
Conditioned media from skeletal muscle cells preserves osteocytes from the damaging 
effects of dexamethasone (Jähn et al., 2012), and factors from osteocytes accelerate 
myogenesis of skeletal muscle myoblasts into muscle cells (Mo, Romero-Suarez,  Bonewald, 
Johnson, & Brotto, 2012).  This crosstalk relationship between bones and muscles opens an 
entirely new area of research and provides opportunities for developing interventions to delay 
the devastating effects of sarcopenia and osteoporosis.  The experiments performed for this 
dissertation were designed to explore the factors produced by normal bone and osteoporotic 
bone and compare the impact they have on human skeletal muscle cell differentiation, also 
called myogenic differentiation, or simply myogenesis.   
Study Purpose and Working Hypothesis 
The overall objective of this study was to add to the body of knowledge related to 
bone-muscle communication in the context of osteoporosis.  This research applied what has 
been learned about the biochemical relationship between bones and muscles from the murine 
mouse model and expanded the investigation to human skeletal muscle cells.  The working 
hypothesis for this study was that human skeletal muscle myoblast (HSMM) cells treated 
with media containing serum from subjects with osteoporosis will experience decreased 
myogenesis compared to HSMM cells treated with media containing serum from subjects 
without osteoporosis as evidenced by fewer nuclei within myotubes, reduced fusion index, 
and decreased sarcoplasmic reticulum calcium release response to stimulation with caffeine. 
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This hypothesis was tested by investigating the effects of media containing serum 
from subjects with and without osteoporosis on HSMM cells through the utilization of 
optical and fluorescent microscopy, and flow cytometry (histomorphometric/ biochemical), 
MTT assay for evaluation of mitochondria function and cell proliferation (biochemical/ 
functional), and by measuring resting levels of intracellular calcium ([Ca
+2
]i) as well as upon 
stimulation with caffeine (biochemical/ functional), which induces robust release of Ca
+2 
from the sarcoplasmic reticulum. 
Specific Aim (SA) 
To investigate biochemical, histomorphometric, and functional differences in human 
skeletal muscle myoblast (HSMM) cells treated with conditioned media containing serum 
from patients with and without osteoporosis. 
Research Question (RQ) 
What is the extent of difference in biochemical, histomorphometric, and functional 
adaptations in HSMM cells treated with conditioned media containing serum from subjects 
with and without osteoporosis? 
Significance 
The significance of this research lies in its promise to provide a deeper understanding 
of factors released from bones and their effect on muscles; specifically investigating the 
impact these factors have on myogenesis in the presence and absence of osteoporosis.  
Differences discovered in the effect on myogenesis between factors from osteoporotic and 
normal bones would then lead to treatments or specific interventions (for example specific 
exercise modalities and intensities) to amplify those factors that promote myogenesis, and/or 
inhibit those factors that impede myogenesis.  This work will further research that has been 
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done by the UMKC Muscle Bone Biology Group (MUBIG) and others related to bone-
muscle communication by investigating the impact that factors from osteoporotic bone in 
vivo have on human skeletal muscle cell formation and function.    
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CHAPTER 2 
REVIEW OF LITERATURE 
This chapter provides a review of the literature related to bone muscle crosstalk.  To 
offer meaningful context, this chapter first presents a review of literature concerning older 
adults and the aging of the musculoskeletal system.  This section includes individual, 
national and global impact of musculoskeletal aging as well as significant and applicable 
theories of aging.  In order to build toward bone muscle crosstalk, the section following then 
presents an overview of the current body of knowledge related to the development and 
function of the musculoskeletal system.  Following that, a review of literature pertaining to 
the primary diseases of the musculoskeletal system; osteoporosis and sarcopenia, is 
presented.  The final section in this review of literature focuses on the interaction between 
bones and muscles:  mechanical communication and biochemical communication.  This 
chapter includes a number of proteins and other factors secreted from bones, muscles and 
tissues throughout the body.  For the purposes of clarity, Appendix A has been prepared with 
a list of factors, information related to the factors discussed, commonly used abbreviations, 
notes on their known or suspected functions and key references.   
Aging of the Musculoskeletal System 
Advances in the prevention and treatment of many diseases have resulted in people 
living longer than in centuries past.  The life expectancy in 1900 was only 47 years; in 1930 
it increased to 60 years; and by 2006 the life expectancy from birth had risen to more than 75 
years.  Looking at this from a slightly different perspective, the percentage of the population 
aged 65 and older was only 4% in 1900, but nearly tripled to 13% in 2008, and is projected to 
nearly double again to 22% by the year 2030 (Haber, 2010).  This has been reported as the 
 
 
8 
largest demographic shift in history by experts in fields from finance to sociology (Bloom & 
Canning, 2006; Hayutin, Beals, & Borges, 2013).  Many factors have contributed to this 
increased life expectancy including the development of vaccines and antibiotics, improved 
nutrition and processes to better the accessibility of clean water to more of the world‘s 
population.  The most recent National Vital Statistics Report published by the National Vital 
Statistics System (NVSS) of the US Department of Health and Human Services (USDHHS), 
Center for Disease Control and Prevention (2013) listed the life expectancy in the US to be 
78.7 years in 2010.  At this time, the segment of the U S population experiencing the greatest 
increase in numbers is the segment of those who are 65 years of age and older.  There has 
been a 15.1 percent increase in the number of individuals aged 65 years and older in the last 
ten years, compared with a 9.7 percent increase in the total population (U S Department of 
Commerce, 2011).  
This increasing age and rising life expectancy are, unfortunately, accompanied by an 
increase in disability as aging adults experience a decline in physical functioning.  In his 
article on the preoperative assessment of the older adult, Muravchick (2000) points out the 
significant decline in functional reserve that occurs with aging.  There are 291 diseases and 
injuries on the Global Burden of Disease (GBD) list, and 289 of those are known to cause 
disability.  In an extensive study, a systematic analysis was undertaken of the prevalence, 
incidence, remission, duration and excess mortality of the 1160 sequela of the 289 diseases 
and injuries known to cause disability.  In this 2010 Global Burden of Disease (GBD) study, 
researchers reported that the years lived with disability (YLD) per 100,000 people has 
remained relatively constant over the years, but with the increasing population of those who 
are 65 years of age and older, the YLD numbers have dramatically increased (Vos et al., 
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2012).  The seemingly undeniable fact of mortality is that aging is associated with the decline 
in function of nearly every biological system in the mammalian body along with the 
development of chronic conditions.  Recognizing the impact chronic diseases and disorders 
have on individual health and healthcare expenditures, several have studied the prevalence of 
chronic conditions.  The reports align and find that as many as 82% of the older population in 
the US has one or more chronic health conditions (McLaughlin, Connell, Heeringa, Li, & 
Roberts, 2009; Wolff, Starfield, & Anderson, 2002; Wu & Green, 2000).   
One of the systems that experiences significant anatomical and physiologic changes 
with aging is the musculoskeletal system.  According to the 2010 Global Burden of Disease 
Study (GBD), musculoskeletal diseases are the second greatest cause of disability, affecting 
billions of people worldwide (Vos et al., 2012).  Rubenstein and Josephson (2006) reported 
that one in three older adults living in the community falls each year.  Among older adults, 
fall-related injuries were responsible for more than two million Emergency Department visits 
and nearly 600,000 hospitalizations in 2009 (Auron-Gomez & Michota, 2008; Bradley, 
2011).   Ninety percent of hip fractures are the result of a fall, and the mortality rate one-year 
post hip fracture is an astounding 25%.  Only one in two older adults that experience a hip 
fracture, return to their baseline level of activity (Bradley, 2011).  Muscle weakness is a 
primary intrinsic risk factor for falls, and the associated morbidity and mortality, especially 
hip fractures, is greatly increased among older adults, and is a significant health risk for those 
with osteoporosis.  In addition to other chronic diseases and medication use, the decline in 
musculoskeletal health and function is a growing problem (DiMonaco, Vallero, DiMonaco, 
& Tappero, 2011; Haber, 2010; Scott, Blizzard, Fell, & Jones, 2011; Walsh, Hunter, & 
Livingstone, 2006).  Loss of muscle mass and strength can not only increase the individual‘s 
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risk of falls, it impacts the quality of life of older adults.  In a review of cross-sectional and 
longitudinal studies investigating factors contributing to successful aging, Depp and Jeste 
(2009) reported that in the majority of cases, even the definition of ―successful aging‖ is 
predicated by the absence of disability.  
In addition to the devastating effects sarcopenia and osteoporosis have on the aging 
individual, the decline in musculoskeletal function poses a significant economic burden.  
Using prevalence-based, cost of illness methods and data collected from national surveys, 
Janssen, Shepard, Katzmarzyk, and Roubenoff (2004) prepared an article focused on the 
economic costs of sarcopenia in the United States.  In it, the authors reported that healthcare 
costs attributable to sarcopenia in the year 2000 were $18.5 billion, or 1.5% of the nation‘s 
total direct healthcare costs that year.  To provide perspective, they drew from the 1995 
Report of the National Osteoporosis Foundation (Ray, Chan, Thamer, & Melson, 1997), 
adjusted for inflation and other factors to make the dollar values consistent, and reported the 
costs associated with osteoporotic fractures in the year 2000 were $16.3 billion.  These costs 
included inpatient care, nursing home care, outpatient care, emergency room visits, radiology 
services, orthopedic medical supplies, and outpatient medications.  The percentage of 1.5% 
would currently translate into more than $40 billion.  In spite of such comprehensive 
considerations, these costs may be conservative, considering that the United States Center for 
Disease Control and Prevention website, updated in September of 2013, reports the direct 
medical costs associated with fall-related injuries among the older adult population was $30 
billion in 2010, and is projected to climb to nearly $55 billion by the year 2020 (USDHHS, 
2013).    
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Theories of Aging   
To develop preventive and therapeutic strategies targeting the devastating effects of a 
decline in musculoskeletal function, a reasonable starting point is to examine the normal 
process of aging and its effect on bones and muscles.  As with so many aspects of biomedical 
research, aging presents a bit of a conundrum.  A biological organism is, almost by 
definition, one that is able to repair itself.  Aging appears to be the inability of the organism 
to continue to self-repair, whether the assault is due to trauma, infection, or injury associated 
with the physiology of living.  Many theories of aging have been developed over the years as 
researchers and clinicians have attempted to explain this paradox.  Although they take on 
varying foci and perspectives, the theories can generally be categorized into those that view 
aging as a consequence of damage to or an error in the functioning of cells within the body 
and those that view aging as a pre-programmed process, determined largely by the DNA 
profile at birth.   
Under the broad category of damage theories of aging falls the theory of 
mitochondrial free radical theory of aging.   In 1956, Harman was the first to propose that 
cellular damage from the presence of toxic free radicals might accumulate and eventually 
compromise function, to the point of death (Harman, 1956).  Although the theory attracted 
some support early on, it was not until 1972, when Harman modified his proposed theory by 
adding the hypothesis that the mitochondria could be the source of the free radicals (Harman, 
1972), that the theory gained more widespread attention and became known as the 
mitochondrial free radical theory of aging.  The theory has experienced opposition and 
support from biomedical researchers, which has contributed to its evolution to its current 
version (Knight, 1998; Miguel, Economos, Fleming, & Johnson, 1980).  Researchers who 
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subscribe to this theory have focused their investigations on the reduction in mitochondrial 
adenosine triphosphate (ATP) (Drew et al., 2003; Jackson, 2009; Jackson & McArdle, 2011).   
Oxygen plays a crucial role in the production of ATP by the mitochondria and is necessary 
for the continuation of life in aerobic organisms.  The stress induced from decreased oxygen, 
cellular hypoxia, leads to the production of mitochondrial reactive oxidative species (mROS).  
The process by which this occurs is not completely understood at this time, but research has 
found these mROS to be signaling molecules that serve to decrease the oxygen consumption 
of the cell.  While this function of the mROS appears to be cell-protective and an adaptive 
response to the stress imposed by hypoxia, these ROS have also been shown to damage 
macromolecules such as lipids, proteins, and nucleic acids (Drew et al., 2003; Hekimi, 
Lapoint, & Wen, 2011).   Drew and colleagues (2003) also report their findings that aging is 
associated with a decline in mitochondrial ATP, a state of imposed cellular hypoxia.  This 
supports the mitochondrial free radical theory of aging, which hypothesizes aging to be the 
result of a vicious cycle in which ROS damage leads to the production of more ROS with its 
accumulated toxic effects.   More recently in the literature, researchers are beginning to 
report that the toxic effects of the ROS are not due to direct damage, but alterations in cell 
signaling (Liochev, 2013; Sena & Chandel, 2012).  This continues to be an area of focused 
research, with a growing interest in the role of protein oxidation as a contributing factor in 
the process of aging (Levine, 2002; Stadtman, 2004).  In his recent review article, Poljsak 
(2011) presents benefits at the cellular level of regular exercise, stress reduction, and 
nutritional choices.  
Another closely related theory of aging that belongs to the damage category is that of 
immunologic theory of aging.  Evidence exists that the effectiveness of the immune system 
 
 
13 
declines with age (Cefalu, 2011), making the individual more susceptible to infections and 
the aging process.  Recent findings linking chronic diseases such as rheumatoid arthritis and 
diabetes to autoimmune disorders lend support to this theory of aging (Sener & Afsar, 2012).  
Diverse in many ways, the theories of aging that belong to the damage or error category 
share a common allegiance to the second law of thermodynamics: entropy.  Entropy simply 
describes the tendency of everything in the universe to fall into disorder; or, as any parent 
who has just walked into the room of their teenager will testify; energy is required to 
maintain order.   
One of the most prevalent theories of the pre-programmed category is the genetic 
theory of aging.  This theory has many facets, including the postulation that an individuals‘ 
trajectory for aging is a reflection of their genetic blueprint.  After birth, the longevity of an 
individual is either determined by pre-programmed polymorphisms, innate to their own 
genome; or, as Pucca et al. (2001) suggests, that a chromosome exists on a gene or genes that 
influences an individuals‘ longevity.  A related theory of aging focuses on the telomere, 
which is a specific repeating sequence located at the end of a chromosome in the DNA chain.  
The hypothesis of the telomere theory of aging is that shortening of the telomeres, is 
associated with accelerated aging (Ceflau, 2011).  Fortunately, recent advances in the 
technological approach to biomedical research are making possible further investigations into 
these theories of aging.     
The process of aging continues to be a complex and multifactorial phenomenon, as 
evidenced by the nearly 300 theories of aging that have been developed (Medvedev, 2008).  
And, yet, not one of these theories is accepted by all who work in the field of gerontology.  It 
is therefore important to view the myriad of theories of aging as complementary to one 
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another, with each possibly providing a portion of the answer to the question, ‗how do we 
age?‘ 
Even without the complete answer to that question, several aspects of aging are quite 
apparent.   With regard to the musculoskeletal system, aging is accompanied by a significant 
decline both in bone mass and strength (osteoporosis) and in muscle mass and strength 
(sarcopenia).  This combination of conditions poses a tremendous threat to individual safety 
and is the greatest contributor to disability among older men and women.  To develop the 
most effective therapeutic approaches aimed at preventing falls due to musculoskeletal 
weakness, it is important to gain understanding of how muscles and bones develop and 
physiologically respond to aging. 
Development and Function of the Musculoskeletal System 
Bones 
The skeletal system has four components:  bones, cartilage, tendons and ligaments.  
They work together to provide important functions, including support, protection, movement 
and mineral storage.  For the purposes of this literature review, the focus will be on one of 
the four components of the skeletal system, the bones.  Belying its inert appearance, bone is 
actually a dynamic tissue, which is in a constant state of formation and destruction.  Renewed 
throughout life, it has been estimated that the entire skeleton is replenished on an average of 
every ten years (Papapoulos & Schimmer, 2007).  Bone consists of two parts:  extracellular 
bone matrix and bone cells.  Extracellular bone matrix is comprised of approximately 35% 
organic material, collagen and proteoglycans; and 65% inorganic materials, primarily 
calcium phosphate.  The three types of bone cells are osteoblasts, osteoclasts, and osteocytes.    
Osteoclasts have a lifespan of about two weeks, during which time they function to 
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breakdown, or resorb bone.  This function is essential for the mobilization of calcium and 
phosphate ions needed for metabolic processes throughout the body.   Osteoblasts have a 
longer lifespan of about three months and function to promote bone formation.  The vast 
majority of bone cells are the osteocytes.  The functions of these bone cells have been vastly 
underestimated in the past.  Before the early 1900s, the prevailing view related to bone 
physiology was that osteoblasts promoted bone formation and osteoclasts promoted bone 
resorption, but that osteocytes were little more than part of the supporting matrix of bones.  
At the time, it was widely believed that the functions of osteoblasts and osteoclasts were 
primarily influenced by hormones, dietary calcium and other non-mechanical agents, all 
aimed at maintaining bone homeostasis (Bonewald, 2011).   
In the 1960s, that view was challenged as experts in the field of bone physiology 
began to differentiate between bone mineral density and bone strength in their research 
findings.  Interdisciplinary work hosted by the University of Utah initiated the development 
of an impressive body of evidence in support of the biomechanical relationship between 
bones and muscles.  A refinement of Wolff‘s Law from the 19th century, this new paradigm 
included the mechanostat model, which purports that bone strength and density are largely a 
function of imposed mechanical force (Frost, 1996).  Even though that model continues to 
greatly influence investigations into bone physiology, a small part of the mechanostat model, 
has been lost.  The promoter of the biomechanical model acknowledged the possible role of 
local and systemic nonmechanical agents effecting skeletal architecture.  The biochemical 
aspect of the relationship between bones and muscles has not until more recently been 
explored to any great extent.  Perhaps this was due, in large part to the need for a number of 
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basic research advancements to first be developed, such as innovative techniques, cell lines, 
and equipment, as well as new knockout and transgenic animal models. 
One of the first published evidences that bones could function in an endocrine fashion 
was the suggestion by Marotti et al. (1992) that osteocytes might play a role in osteoblast 
modulation by way of gap junction signaling.  Additional evidence of this suggestion was 
provided by studies conducted by Tanaka et al. (1995) demonstrating the production of 
soluble factors by osteocytes augmented osteoclastic development (Tanaka et al., 1995).  
Around that same time, Klein-Nulend et al. (1995) conducted experiments that revealed the 
sustained release of prostaglandins from osteocytes following mechanical stimulation (Klein-
Nulend et al., 1995).  In addition, in an attempt to explain how bone mass and structure is 
altered in response to mechanical load, Burger and Klein-Nulend (1999) postulated the 
presence of cell signaling molecules as a key portion of the cellular mechanisms.  
Winkler and associates provided evidence that osteocytes function as more than just a 
sensory cell, but also as a regulator of bone density through the secretion of sclerostin, a 
protein that inhibits bone formation (Winkler et al., 2003).   They hypothesized that the 
dysregulation in bone formation resulted from the phenotypes observed in osteosclerosis 
patients and were further supported through genetic testing and the development of 
transgenic mice with increased sclerostin production and low bone mass.   Since those early 
observations, continued research by a number of biomedical scientists have continued to 
provide evidence in support of osteoblast/osteocyte-secreted factors that impact bone 
homeostasis and also distant tissues such as kidney, prostate, and brain as detailed below 
(Bonewald & Wacker, 2012; Karsenty & Wagner, 2002; Mo, Romero-Suarez, Bonewald, 
Johnson, & Brotto, 2012). 
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In a study conducted by Shimada and colleagues (2004), evidence was reported of the 
physiological role of FGF23 in phosphate and vitamin D homeostasis as well as the 
pathophysiological role of FGF23 in osteomalacia (Shimada et al., 2004).  In their 2012 
review, Bonewald and Wacker discussed FGF23 expression in osteocytes and its role in 
cardiovascular health (Bonewald & Wacker, 2012).  Although the exact pathways through 
which this occurs is not known at this time, evidence gained from transgenic mice 
phenotypes demonstrates that osteocyte expression of FGF23 is under the influence of 
molecules such as DMP1, PHEX and MEPE (Martin et al., 2011).   
Osteocalcin is a noncollagenous protein found in bone and dentin.  In addition to 
providing structure, osteocalcin has been shown to have many functions, including energy 
metabolism, calcium ion homeostasis and male fertility (Karsenty & Wagner, 2002).  More 
than twenty years ago, bone cells were postulated to be the primary source of osteocalcin 
(Lajeunesse, Kiebzak, Frondoza, & Sacktor, 1991), however recent advances in genetic 
engineering have allowed deeper insight in support this idea (Ducy et al., 1996; Ducy, Zhang, 
Geoffroy, Ridall, & Karsenty, 1997; Karsenty, Gerard, & Wagner, 2002; Lee et al., 2007).  In 
fact, osteocalcin along with other hormone-like substances secreted by bone cells are now 
thought to interact with substances from the liver and adipose tissue that may predispose 
individuals to obesity, diabetes, non-alcoholic fatty liver disease and osteoporosis.  
Prostaglandins are a class of naturally occurring lipid autacoids that are derived from 
arachidonic acid and are produced by most cells, including bone cells.  They have a wide 
range of functions, taking part in inflammation, pain mediation, smooth muscle contraction, 
and platelet aggregation.  Prostaglandins also have been demonstrated to play a significant 
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role in bone homeostasis, particularly the E and F series of prostaglandins (Agas, Marchetti, 
Hurley, & Sabbieti, 2013; Mo et al., 2012).  
The list of bone cell secreted factors is truly impressive, continues to grow, and 
includes: ATP, calcium, DKK1, DMP1, FGF23, Mepe, nitric oxide, OPG, osteocalcin, 
prostaglandins (particularly PGE2), RANKL, sclerostin, and Sost. These factors represent a 
myriad of biochemical structures ranging from simple organic molecules to complex 
proteins, which illustrates the plasticity of bone secretory capacity. Furthermore, the diversity 
of factors implies the role of bones in the modulation of the physiology of tissues throughout 
the body (Karsenty & Ferron, 2012). As the understanding of these new discoveries 
continues to develop and begins to be translated into meaningful and innovative therapeutic 
approaches, unprecedented advances will be achieved in the fight to constrain the epidemics 
of chronic diseases such as obesity, diabetes, osteoporosis and sarcopenia. 
Muscles  
Skeletal muscle is so named for its functional connection and vicinity to the skeletal 
system.  It is responsible for voluntary movement, facial expressions, postural support, and 
respiratory expansion.  It is functionally connected to the skeletal system and also works with 
the nervous system and blood supply.  Skeletal muscle develops from myogenic precursor 
cells and myoblasts to myotubes through the process of myogenesis.  This process provides a 
predictable sequence of events with a definable end product as well as clear morphologic and 
functional changes along the way (Burattini et al., 2004; LeGrand & Rudnicki, 2007; Wagers 
& Conboy, 2005).  The precursor of the muscle cell is either the mesoderm-derived structure 
in embryonic development or the quiescent satellite cell awaiting activation as a myoblast.  
Myoblasts are small, mononucleated cells capable of either dividing by mitosis and 
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proliferating, or fusing with other myoblasts to form myotubes.  As myoblasts fuse and begin 
to form myotubes, they enlarge and take on an elongated shape.  Myogenesis occurs not only 
in the embryonic and early stages but also throughout the lifespan.  Skeletal muscle is a 
dynamic tissue, whose cells undergo myogenic differentiation repeatedly as muscles 
regenerate in response to injury (Nag & Foster, 1981; Shefer, Van de Mark, Richardson, & 
Yablonka-Reuveni, 2006). 
The process that leads to muscle contraction begins when acetylcholine (Ach) is 
released by a motor neuron across the synapse at the neuromuscular junction.  Motor neurons 
originate in the central nervous system and the cell bodies of these neurons are located in the 
spinal cord.  The neuronal fiber (axon) projects outside the spinal cord to directly or 
indirectly control muscles. At the muscle level, nerve ending terminals spread and innervate 
each muscle fiber within a given skeletal muscle.  Each muscle fiber is covered by a 
membrane called the sarcolemma, and within each muscle fiber are thousands of sarcomeres, 
which are the functional units of contraction.  The sarcomere is composed of thick 
myofilaments called myosin, and thin myofilaments called actin.  The neuromuscular 
junction is a synapse with the terminal end of the motor neuron on one side and the motor 
end plate of a skeletal muscle fiber on the other.  Release of Ach from the motor neuron 
causes stimulation of a muscle fiber through the exchange of sodium and potassium ions.  
This leads to the generation of an action potential that spreads along the sarcolemma and is 
transmitted into the interior of the muscle fiber by structures called transverse tubules, or T-
tubules.  T-tubules are juxtaposed to the calcium ion storage units, the sarcoplasmic 
reticulum (SR).  As the action potential travels along the T-tubule, it causes the voltage-
sensitive receptor named Dihydropirydine Receptor (DHPR) to change shape, and it is this 
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allosteric modification of the DHPR that allows it to physically interact with the largest 
known mammalian channels, the Ryanodine Receptors (RyR) precisely located on the 
surface of the membrane of the SR. This DHPR-RyR contact, leads to the opening of the 
RyR, which brings about the release of calcium from the SR into the cytosol of the skeletal 
muscle cell.  This rise in cytosolic calcium causes the binding sites on the actin filament to be 
exposed, allowing myofilaments heads to bind.  The myosin filaments pull the actin 
filaments in, resulting in a shortening of the sarcomere.  It is the shortening of sarcomere 
throughout the muscle fibers that causes muscle contraction.  The process by which the 
electrical stimulation, or excitation is transferred into a mechanical contraction is called the 
excitation-contraction coupling (ECC).  This process is fundamental to skeletal muscle 
physiology (Hopkins, 2006; MacIntosh, Gardiner, & McComas, 2006) and is the cellular and 
molecular reason that can be executed from very fine controlled movements to the lifting of 
several hundred kilograms of weight. 
Much has also been learned about the important relationship that exists between 
skeletal muscles and nerves, since motor neurons and the muscle fibers they innervate first 
came to be viewed as a single functional unit in the 1920s.  After Henry Dale and Otto Loewi 
were awarded the 1936 Nobel Prize for their discoveries relating to chemical transmission of 
nerve impulses, the body of knowledge continued to grow leading to an enhanced 
understanding of differing muscle fiber types.  The idea of the motor unit continues to be 
strengthened as instruments enabling molecular and genetic exploration to be undertaken.  
Investigations into muscle-to-nerve trophism led to the discovery of factors such as brain-
derived neurotrophic factor (BDNF), NT-3 and NT-4/5 (Gomez-Pinilla, 2002; Hirokawa, 
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Niwa, & Tanaka, 2010).  Discoveries in these areas continue to provide potential therapeutics 
for patients suffering from neuromuscular disorders such as the muscular dystrophies.  
In the late 1970s, evidence emerged that skeletal muscle, as well as most tissues in 
the body, secret prostaglandins in response to injury, as Goldspink testified to the importance 
of skeletal musculature in terms of its metabolic effect on the body (Goldspink & Goldspink, 
1986).  However, it was only during the last decade that skeletal muscles became recognized 
more fully for their secretory capacity (Barton, 2006; Florini, Ewton, Magri, & Mangiacapra, 
1993; Kurek et al., 1997).  Pedersen and colleagues were the first to use the term, 
‘myokines,‘ after their discovery that contracting muscles not only secrete IL-6, but that it 
leads to a significant increase in IL-6 plasma levels.  Building on earlier evidence from 
murine models that IL-6 is produced by myoblasts and myofibers in response to 
inflammation and injury, the Pedersen group showed that working muscles led to a 19-fold 
increase in arterial plasma IL-6 concentrations compared to resting muscle (Pedersen et al., 
2003; Steensberg et al., 2000).  This provided valuable evidence of skeletal muscle producing 
factors that impact not only tissues in close proximity, but also those at distant sites in the 
body.  To support this it was important to rule out that the IL-6 productions and secretion is 
not coming from immune cells.  A notable observation has been made that with sepsis, there 
is an increase in TNF, followed by an increase in IL-6.  In sepsis, it appears that monocytes 
are the primary source of the increased TNF.  This is in contrast to the increase in IL-6 that 
accompanies exercise, as it is not preceded by TNF (Andersen & Pedersen, 2008).  Keller 
and colleagues demonstrated that the nuclear transcription rate of IL-6 increased markedly 
and rapidly with the onset of exercise (Keller, 2001).  Further evidence indicated that the IL-
6 produced by exercising muscles impacted the output of hepatic glucose, thus adding 
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strength to the premise that skeletal muscles do, indeed, function as endocrine organs (Glund, 
et al., 2007; Kim, et al., 2004). 
In 2007, Chan, et al., identified more than thirty proteins expressed during the highly 
organized and predictable process of muscle development.  They performed quantitative 
proteomics to explore the activity of myoblasts and myotubes throughout myogenesis.  The 
list of factors secreted from skeletal muscles continues to grow, and includes IL-8, which has 
been shown to increase angiogenesis (Nielsen & Pedersen, 2007); IL-5, which is an anabolic 
factor being investigated for its role in muscle-fat crosstalk; IL-7, which is being studied for 
its impact on satellite cells during myogenesis (Pedersen, Akerstrom, Nielsen, & Fischer, 
2007), and brain-derived neurotrophic factor (BDNF) (Matthews et al., 2009).  Exercise has 
been found to induce a six-fold increase in mRNA of Chemokine CXC motif ligand-1 
(CXCL-1) aka KC (keratinocyte-derived chemokine) and a 2.4-fold increase in serum 
CXCL-1 (Pedersen, Olsen, Pedersen, & Hojman, 2012).  Murine CXCL-1 is a functional 
homolog for IL-8, and belongs to a group that has gained attention for its role in 
inflammation, chemotaxis, angiogenesis, neuroprotective activity and tumor growth 
regulation and is also associated with a decrease in visceral fat (Acharyya, et al., 2012; 
Addison, et al., 2000; Hol, Wilhelmsen, & Haraldsen, 2009; Rubio & Sanz-Rodriguez, 2006; 
Wang, Hamza, Wu, & Dionne, 2009). 
Most research associated with skeletal muscle secreted factors is in relation to factors 
produced in response to injury.  IL-6 and LIF are produced and have been shown to enhance 
the myocyte differentiation after injury.  Muscle regeneration is an ongoing phenomenon 
throughout the life span, and provides an excellent opportunity for investigation into the 
endocrine function of this organ, as well as hope for targeted interventions to slow the 
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process of muscle wasting.  Two additional factors secreted by injured skeletal muscle are 
TGF and TGF1 (Kurek, Bower, Romanella, Koentgen, Murphy,F & Austin, 1997; Li & 
Huard, 2002).  These factors have an inhibitory effect on muscle cell proliferation and 
differentiation.  It is believed that TGF1 triggers connective tissue proliferation and tissue 
fibrosis.  The worldwide epidemics of obesity and diabetes type 2 continues to propel the 
concept that lack of exercise might favor an unbalance or reduced secretion of myokines, 
thereby contributing to these chronic diseases (Pedersen, Olsen, Pedersen, & Hojman, 2012).  
Last year, a new myokine brought hope for the development of molecules to target fat tissue 
accumulation, since irisin was shown to regulate the conversion of ‗bad‘ (white) fat into 
‗good‘ (brown) fat that is essential for thermogenesis in mice (Seale et al., 2008).  Since the 
original publication, 49 papers have been published on effects of irisin and a recent study by 
Park (2013) concluded that irisin might be directly associated with a higher risk of 
cardiovascular diseases and metabolic syndrome in humans, suggesting that augmented 
secretion of irisin by either adipocytes or muscle cells might occur to overcome an 
underlying irisin resistance (Park et al., 2013).   
Diseases of the Musculoskeletal System 
Osteoporosis   
As stated earlier, bones are in a constant state of destruction and rebuilding.  In 
young, healthy individuals, the balance between bone formation and resorption is maintained.  
The decrease in bone density that has come to be known as osteoporosis appears to be the 
result in a growing imbalance of these two processes.  The body of knowledge surrounding 
osteoporosis continues to grow and develop as it is now recognized as the most common 
metabolic bone disease in the United States.  Age related bone loss has afflicted mankind for 
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centuries (Zaki, Hussein, & Abd El-Shafy El Banna, 2009).  However, the first 
documentation of osteoporosis has been attributed to the English surgeon, Sir Astley Cooper, 
who kept meticulous notes on his observations.  Cooper observed significant changes in the 
bones of older adults:   
―with respect to the neck at the thigh-bone, a very principal cause of con-
consolidation by bone is the advanced age at which it becomes obnoxious to fracture 
through that peculiar change which the part undergoes at this period of life without 
any apparent cause, but which renders it incapable of sustaining the superincumbent 
weight, and even in the continuity insufficient to maintain its function; therefore it 
may be fairly supposed, when broken incompetent to set up a restorative action‖ 
(Cooper, 1844, p.136).   
 
The actual term, osteoporosis is attributed to the French pathologist, Jean Lobstein, 
although, in retrospect, it seems likely that he was actually using the term to describe 
osteogenesis imperfecta rather than osteoporosis (Schapira & Schapira, 1992).  In 1941, the 
American endocrinologist, Fuller Albright described his observation of postmenopausal 
osteoporosis and proposed the idea that the decreased bone density was due to an estrogen 
deficiency (Albright, Smith, & Richardson, 1941).   
A simple PubMed search with the single term, osteoporosis, yields a staggering 
61,164 results.  The first publication listed in this search is from 1967, during which year 
PubMed reveals 246 publications related to osteoporosis.  This annual number of 
publications remained remarkably stable until a slow, but steady rise in began in 1982 with 
340 published articles.  Since the mid-1990s, the annual number of publications related to 
osteoporosis has never been less than 1000, with a remarkable 3151 listed before the end of 
2013.  The spike in publications coincides with the time that the World Health Organization 
(WHO) introduced the definition of osteoporosis.  According to the WHO criteria, 
osteoporosis is defined as a bone mineral density (BMD) that falls greater than or equal to 
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2.5 standard deviations (SD) below the average value for young healthy women (WHO, 
1994).    
The risk of osteoporosis is higher among women than among men.  The literature has 
established several additional risk factors for osteoporosis including increased age, Caucasian 
or Asian ethnicity, postmenopausal status, late menarche or early menopause, low peak bone 
mass, a family history of osteoporosis or low trauma fracture, low dietary calcium, vitamin D 
and vitamin K, low levels of physical activity, smoking, excessive alcohol intake and the use 
of certain medications such as steroids, anticonvulsants, immunosuppressants, and heparin 
(Cummings et al., 1993; Schwartz, Nevitt, Brown, & Kelsey, 2005; Taylor et al., 2004; 
Vermeer, Knapen, & Schurgers, 1998; Versluis et al., 2001).  
Treatment plans for patients diagnosed with osteoporosis are related to the identified 
risk factors.  The initial approach begins with lifestyle modification such as increased 
physical activity if possible as well as smoking cessation, and decreasing alcohol intake, if 
needed (Body et al., 2011; Habib, Eshra, & Dawood, 2012).   Beyond these lifestyle 
medications to reduce the risk of injury, treatment goals are aimed at slowing or stopping 
bone loss and/or facilitating bone formation.  Supplementations often recommended include 
calcium, vitamin D, and, in some cases, hormone replacement therapy (Rizzoli et al., 2008).  
The primary pharmacologic intervention is the classification of bisphosphonates, which have 
revolutionized the treatment of osteoporosis.  Interestingly, bisphosphonates have been 
known as chemical entities for the past 100 years, as they have been widely used as industrial 
water softeners.  Their introduction into the clinical realm was due to work conducted by 
Fleisch in the late 1960s (Fleisch, Graham, Russell, & Francis, 1969).  At that time, and for 
the decade following, their primary use in the clinical setting was to treat Paget‘s disease.  
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Bisphosphonates inhibit osteoclast activity.  They do this by binding to surfaces that are 
experiencing active bone resorption, which thwarts the osteoclasts attempt to form a ruffled 
border and continue the bone resorptive activity.  It was through the work of Bijvoet and, in 
another area, van Breukelen that eventually ushered the use of these pharmacologic agents 
into the management of osteoporosis (Valkema, Vismans, Papapoulos, Pauwels, & Bijvoet, 
1989; Van Breukelen, Bijvoet, & Van Oosterom, 1979).  Bisphosphonates have been shown 
to have a protective effect on bone density, with effects noted even within the first week of 
administration.  Research has demonstrated a reduction in biomarkers of bone resorption by 
as much as 90% early on in the course of administration (Christiansen et al., 2003).  In spite 
of the identification of many risk factors for osteoporosis, and the success of such 
interventions as the bisphosphonates, osteoporosis continues to pose a significant risk to 
older adults.   
Sarcopenia    
Skeletal muscle represents the largest organ in the human body, accounting for 38% 
and 31% of the total body weight in the men and women, respectively (Janssen & Ross, 
2005).  Therefore, the age-related anatomical and physiologic changes in skeletal muscle 
have a significant impact on the overall health of the individual.  Irwin Rosenberg first 
proposed the term ‗sarcopenia,‘ in 1988 to describe age related muscle wasting.  The term 
derives from the two Greek words, sarx (flesh) and penia, (loss).  All individuals experience 
muscle wasting with age, therefore the prevalence of sarcopenia with age is essentially 
100%.  However, Rosenberg and others recognized that in many, the muscle loss that 
accompanied aging happened at a seemingly accelerated rate and contributed significantly to 
disability (Rosenberg, 1989).  In 1988, a group of researchers and clinicians convened for a 
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meeting in Albuquerque, New Mexico to discuss various measurements being used to assess 
the health and nutritional status of the elderly population.  It was in a summary report 
following that historic meeting that Rosenberg first coined the term, ‗sarcopenia.‘ Part of his 
rationale for coining the term was to draw attention to this all too common physiologic 
phenomenon, for as mentioned elsewhere in this review of literature; age-related changes in 
the musculoskeletal system are one of the most frequent causes of disability.  Since the time 
that Rosenberg proposed the term, sarcopenia, much research has been conducted into the 
process and effects of age-related skeletal muscle wasting.  A recent PubMed search with 
sarcopenia as the only term entered, yielded 2113 results, beginning in the year 1993.  
Interestingly, this does not include Rosenberg‘s 1989 summary comments.  The number of 
published articles prior to the year 2000 was a mere 75, according to this PubMed search; 
237 articles in the years 2000 through 2004; 535 articles in the years 2005 through 2009; and 
1266 articles cited from 2010 through November of 2013.  These numbers reflect both the 
growing acceptance of sarcopenia as a condition with specific and measureable signs and 
symptoms as well as the recognition of the significance this condition has in the lives of 
individuals, the nation and the world. 
In the mid-1990s, the measurement used to identify the presence or absence of 
sarcopenia among older adults, whether in the community or institutional setting, was upper-
arm circumference.  Even with this crude method of identification, researchers recognized a 
correlation between the presence of sarcopenia and the older adults‘ mortality risk 
(Muhlethaler, Stuck, Minder, & Frey, 1995; Protho & Rosenbloom, 1995).  In 1998, 
Baumgartner and his team suggested a modified approach to determining whether the muscle 
mass in an older adult was within normal limits, or whether it reflected a state of 
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compromised health, i.e. sarcopenia.  From the research he and his colleagues were 
conducting on older adults, Baumgartner defined sarcopenia as a height adjusted to muscle 
mass of two standard deviations (SD) or more below the mean of a young reference 
population.   With this as his measurement, he reported the prevalence of sarcopenia in the 
New Mexico Elder Health Survey to be 14% in those 65 to 69 years of age, compared with 
greater than 50% in those 80 years of age and older (Baumgartner et al., 1998).  Other 
researchers in the field of gerontology adopted this measurement standard in their 
investigation of age-related loss of muscle mass.  Nearly all of the studies conducted prior to 
2005 were cross-sectional, and focused on a correlation between sarcopenia and not only 
decreased muscle mass, but also the associated functional impairment leading to physical 
disability (Janssen, Heymsfield, & Ross, 2002; Morley, Baumgartner, Roubenoff, Mayer, & 
Nair, 2001; Newman et al., 2003; Roubenoff & Castenada, 2001; Vandervoot & Symons, 
2001).  At least one study in the early 2000s looked at the impact of muscle size and strength 
over time.  Following a sample of 120 adults aged 46 to 78 for a period of ten years; Hughes 
et al. (2001) reported a less than 5% change in strength that was attributable to a 
corresponding change in muscle size.   In an eight-year follow up to the Cardiovascular 
Health Study, Janssen (2006) reported a 27% increased risk of developing disability with 
sarcopenia when compared with individuals with normal muscle mass.   Interestingly, at the 
beginning of that same study, the reported likelihood of having disability was 79% greater in 
those with severe sarcopenia than in those with normal muscle mass.  The longitudinal 
analysis was three times smaller than the cross-sectional analysis, reported at the baseline.  
This suggests that the sarcopenia-associated risk of functional impairment and physical 
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disability reported in cross-sectional studies of older adults in the early 2000s may have been 
overestimated. 
The questions surrounding a universally accepted definition of sarcopenia continue 
even to today.  Ultimately, clinicians and researchers are in search of specific age-related 
musculoskeletal changes that correlate most strongly with the risk of disability.   Evidence is 
growing that the rate at which muscles become weaker is much faster than the rate at which 
they become smaller (Mitchell et al., 2012).  Subsumed in the concept of muscle strength are 
important considerations such as fatigability, power and force of contraction, all of which 
confound the overall question.  Researchers are finding that it is the loss of muscle strength, 
even more than the loss of muscle mass, that carries the greatest risk of disability in the aging 
adult (Goodpaster et. al, 2006; Manring, Abreu, Brotto, Weisleder, & Brotto, 2014; Mitchell 
et al., 2012).  
Baumgartner reported in 2000 his observations that as many of 15% of individuals 
with sarcopenia are also obese.  The sarcopenic-obese older adult drew his attention because 
in his cross-sectional study examining older adults in the New Mexico Aging Process Study, 
he found this subsector of the elderly population to be at especially high risk of physical 
disability (Baumgartner, 2000).  Jensen and Friedmann (2002) reported similar findings of an 
increased risk among obese older adults.  As researchers and clinicians even more fully 
appreciate the risk to independence and safety posed by the decline in both lean muscle mass 
and bone density with increasing age, the body of knowledge related to these phenomena 
continues to grow.  Studies have shown an increase in catabolic cytokines such as 
interleukin-6 (IL-6), as well as inflammatory markers such as C-reactive protein and 
sedimentation rate (Roubenoff, 2007; Roubenoff & Hughes, 2000; Zoico & Roubenoff, 
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2002).  These same factors are not only observed in the development of obesity; many are of 
secreted by adipocytes (Roubenoff, 2008; Schrager et al., 2007).  Findings such as these 
motivate additional investigation into connections between sarcopenia and obesity.  Some 
research findings supported an increase risk in disability when sarcopenia and obesity occur 
together (Baumgartner, 2000; Jensen & Friedman, 2002).  However, research conducted by 
others at that time did not support the notion that sarcopenic-obese older adults are at greater 
risk for physical disability (Davison, Ford, Cogswell, & Dietz, 2002; Zoico et al., 2004).  In 
2004, a group of researchers set out to replicate as a longitudinal study, the findings of their 
2000 cross-sectional study, based upon the same cohort of individuals in New Mexico 
(Baumgartner et al., 2004).  They reported that looking at the problem over time, that neither 
sarcopenia alone nor obesity alone increased the older adult‘s risk of functional impairment 
when compared with those with a normal body composition.  However, they found that those 
sarcopenic-obese individuals had a 2.5 times greater risk (Baumgartner et al., 2004).  Perhaps 
related to these findings, Lammes and Akner (2006) also reported that, as expected with a 
reduced skeletal muscle mass, the presence of sarcopenia leads to a decrease in resting 
metabolic rate.  Since the mid-2000s, several researchers have investigated the combination 
of sarcopenia and obesity, specifically concerned with the risk for physical disability.  The 
findings of some support an increased risk of physical disability in sarcopenic-obese older 
adults (Bouchard & Janssen, 2009; Janssen, 2007; Rolland et al., 2009), while the findings of 
other researchers do not support this notion (Bouchard, Dionne, & Brochu, 2009; Choquette, 
et al., 2010).  
Attempts to understand the cause of age related loss of muscle mass and strength have 
predominantly focused on the loss of skeletal muscle fibers, especially type II fibers.  In an 
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exquisite review of the pathophysiological mechanisms of sarcopenia, however, Walrand, 
Guillet, Salles, Cano, and Boirie (2011) delve into a wide variety of mechanisms involved 
including nutritional factors, activity levels, alterations in protein metabolism, and the impact 
of changing levels of hormones.  In that review the authors suggested that sarcopenia 
impacted the development of other chronic conditions such as cardiovascular and metabolic 
diseases.  These researchers were observing that sarcopenia apparently leads to dyslipidemia, 
insulin resistance and hypertension as well as a decline in immunologic function (Cosqueric 
et al., 2006; Karakelides & Nair, 2005).  
Another point of view that is gaining momentum is that age-related decreases in 
muscle strength result from a combination of loss of muscle mass (atrophy) and reduced 
muscle specific force (i.e., muscle force per unit of cross-sectional area), suggesting reduced 
muscle quality.  However, accumulating data show that it is principally the weakness that 
accompanies sarcopenia, not the loss of muscle size per se, that contributes to disability 
(Clark & Manini, 2008; Goodpaster et al., 2006; Hughes et al., 2001; Visser et al., 2000).  
For example, in one four-week study of muscle unloading in young adults, researchers 
observed a greater loss in strength than loss in muscle mass (Clark, Fernhall, & Ploutz-
Snyder, 2006).  These scientists, along with others, suggest the un-matching in loss of mass 
that is significantly surpassed by the loss of force and power originates inside the muscle 
fibers themselves, due to defects on the ECC process that ultimately lead to reduced 
availability of calcium to be released during each cycle of contraction-relaxation (Clark et al., 
2006; Manring et al., 2014).      
Additional health risks that have been observed in sarcopenic older adults include 
insulin resistance and the development of type 2 diabetes mellitus.  Srikanthan, Hevener, and 
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Karlamangla (2010) conducted a study to investigate the relationship between sarcopenia, 
obesity and age-related insulin resistance.  In their cross-sectional analysis of the National 
Health and Nutrition Examination Survey III (NANES III), they concluded that sarcopenia, 
independent of obesity, is associated with compromised glucose metabolism.  Another study 
conducted around the same time concurred that type 2 diabetes was associated with an 
increased risk of sarcopenia (Kim et al., 2010).  This suggests a relationship between diabetes 
and sarcopenia that skeletal muscle represents the largest target tissue for insulin-mediated 
glucose uptake.  A decline in muscle mass with aging is, therefore, associated with a decrease 
in sites for glucose uptake, which would be further exacerbated by a decline in physical 
activity.  Along with this, data support an increase in triglycerides with aging, which have 
been indicted both in age-related mitochondrial damage and with blocking of ability of 
insulin to facilitate glucose entry into the muscle cell.  All of these phenomena contribute to 
an increase in blood glucose.  Insulin may play a significant role in all of this, as it is a potent 
anabolic hormone that impacts glucose, protein and lipid metabolism.  It facilitates glucose 
uptake, inhibits hepatic glucose uptake and triglyceride production, inhibits skeletal muscle 
protein synthesis and inhibits adipose tissue lipolysis (Magkos, Wang, & Mittendorfer, 
2010).  Recognizing this relationship, a recent study by Lee et al. (2011) provides data 
supporting a direct relationship between insulin resistance, the loss of lean muscle mass and 
the gain of fat mass in men aged 65 and older.  The chronic complications of diabetes 
mellitus impact systems throughout the body; including bones.  Individuals with type 1 
diabetes mellitus have lower bone mass density, with impaired bone formation believed to be 
the primary cause (Hofbauer, Brueck, Singh, & Dobnig, 2007).  Patients with either type 1- 
or type 2-diabetic patients experience hypercalciuria during times of glycosuria.  This 
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increased loss of calcium has been hypothesized to contribute to impaired bone quality 
observed with diabetes, although the direct effects of this loss of calcium on skeletal muscle 
function remains elusive.  As more is understood about these chronic conditions, the 
connections between them are becoming undeniable.  Recognizing these connections and 
conducting research from this multifactorial perspective will increase understanding and 
further the development of interventions.   
Communication of the Musculoskeletal System 
Bone-Muscle Crosstalk   
The mechanical relationship between bones and muscles has been extensively 
studied, and it can be observed and understood in the context of the three major ontogenetic 
periods in the bone-muscle relationship; embryonic patterning, postnatal allometric growth, 
and the homeostatic relationship of adult life (Orestes-Cardoso et al., 2001).  Bones and 
muscle cells not only share a common mesenchymal precursor, but also experience 
organogenesis through a tightly orchestrated network of genes during intrauterine 
development.  The commonalities between these two tissues are reinforced through the 
mechanostat theory that postulates loads that create strains below a certain threshold 
stimulate bone loss through the inhibition of growth, while strains above a certain threshold 
stimulate growth and inhibit haversian remodeling (Pearson & Lieberman, 2004).  Some 
researchers refer to the ‗bone-muscle unit‘ in deference to these observations that bones 
respond to varying levels of mechanical strain imposed by muscle mass and strength.  The 
varying levels of mechanical strain appear to be modulated primarily by hormonal effects 
systemically, citing gender differences over time as evidence (Lang, 2011).  There is 
 
 
34 
undeniably much evidence in support of the strong correlation between bone and muscle 
strength (Wang et al., 2007; Zanchetta, Plotkin, & Filgueira, 1995).   
A deeper understanding of the physiological relevance of these bone and muscle 
endocrine properties may serve to bridge the gap between the mechanical and biochemical 
theories of bone-muscle interaction.  A feasible way of interpreting the role of these 
interactions is that they may serve to sense and transduce biomechanical signals such as 
unloading, loading, inactivity, or exercise, and even perhaps the translation of systemic 
hormonal stimulation into effective biochemical signals. Another way of interpreting and 
bridging these two theories is that one specific form of interaction could work as a priming 
for the other, in that, the physical effects of contraction on bone cells may prime these cells 
for the simultaneous, consecutive or ulterior effects of a secreted molecule.   The growing 
evidence of a mismatch between changes in muscle mass and muscle strength that 
accompany muscle unloading also lends support to the biochemical communication between 
tissues (Clark et al., 2006).  The suggestion that in addition to mechanical force, other factors 
contribute to increasing muscle strength came more than three decades ago.  In their work 
with isometric training, McDonagh and colleagues (1983) made experimental observations 
that led them to postulate ―that the increase in the force of maximal voluntary isometric 
contraction must be related to factors other than the force-generating capacity of the muscle 
fibres themselves.‖ (McDonagh, Hayward, & Davies, 1983, p. 355). 
The close anatomical proximity of skeletal muscle and bone lends itself to 
hypothesize a relationship of paracrine nature, especially at the muscle fiber insertion sites 
along the periosteal interface.  For evidence of such a relationship, we turn our attention to 
pathology and reflect upon conditions such as some of the bone stress syndromes where 
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inflammation localized to the muscle area underneath the periosteal region spreads into the 
bone itself.  These situations are consistent with the paracrine relationship hypothesis, 
suggesting inflammatory molecules from adjacent muscle fibers may penetrate into this 
region of the bone.  Another powerful clinical example of this paracrine relationship is the 
application of muscle flaps around compounded bone fractures and their effects in promoting 
significantly faster healing for these fractured bones.  Although the specific molecular 
mechanism of action is not completely understood, the introduction of muscle flaps has been 
used as a successful therapeutic approach to treat chronic osteomyelitis and to accelerate the 
healing of bone fractures (Chan, Harry, Williams, & Nanchahal, 2012).  These mechanisms 
might display further and specific importance during bone and muscle healing after 
musculoskeletal injury.  Studies performed by our group in osteocyte and muscle cell lines, 
have determined that PGE2 secretion from osteocytes is more than 1000 times larger than 
PGE2 secretion from muscle cells.  This excess amount of PGE2 from osteocytes could 
interplay with injured muscles, which would aid in muscle regeneration and repair.  Recent in 
vitro studies from our lab have provided support for a role of osteocyte secreted PGE2 in 
aiding with the process of myogenesis (Mo et al., 2012).   
To gain further insight into bone-muscle crosstalk, it is helpful to examine the 
phenotypic presentations of recently developed transgenic animal models.  Myostatin was 
discovered in the late 1990s to be a potent inhibitor of muscle growth.  It is expressed during 
development and in adult skeletal muscle, serving as an important negative regulator of 
skeletal muscle growth (Jouliaekaza & Cabello, 2007; McPherron, Lawler, & Lee, 1997).  
Myostatin appears to decrease myoblast proliferation.  The myostatin-deficient mouse model 
has increased muscle size and strength, with individual muscles weighing significantly more 
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than wild type mice (Zimmers, 2002). Hamrick and collaborators used this myostatin 
deficient mouse model to investigate the effects of increased muscle mass on bone mineral 
content and density.  They found that although a consistent correlation was not found in all 
regions of the skeletal system, there was increased cortical bone mineral density in the distal 
femur and an increased periosteal circumference along the humerus (Hamrick, 2003; 
Hamrick, McPherron, & Lovejoy, 2002; Hamrick, Samaddar, Pennington, & McCormick, 
2005).  Another group used the same myostatin-deficient mouse model to look at the impact 
of the chronic loss of myostatin on multiple organ systems and found that it appeared to 
preserve bone density (Morissette et al., 2009).  From a contrasting perspective, Zimmers 
investigated the effects of myostatin overexpression in an animal model and observed a 
profound loss of muscle and fat, mimicking the presentation seen in chronically ill patients 
and commonly referred to clinically as cachexia (Zimmers, 2002). The authors encourage 
further research into the disruption of myostatin in an effort to preserve muscle mass in 
patients with chronic diseases.  
As mentioned earlier, osteocalcin serves as a splendid example of the endocrine 
function of bone cells (Karsenty & Ferron, 2012).  This osteoblast-derived factor, circulating 
levels of which increase with exercise, is not only effectively secreted by osteoblasts, but also 
affects distant tissues through the activation of its receptor, GPRC6A, in cells such as 
adipocytes, pancreatic  cells and Leydig cells of the testis.  Perhaps to balance the 
physiologic scales, osteoblasts also naturally express the osteotesicular phosphatase gene 
(Esp), which inhibits the function of osteocalcin (Coiro et al., 2012).  With this information 
in mind, it is of specific interest to the discussion of bone-muscle crosstalk that Gprc6a 
knockout mice display the phenotype of decreased muscle mass, while Esp knockout mice 
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have increased muscle mass.  Through these observations, it can be proposed that 
osteocalcin, a known bone cell factor, may play a role in the regulation of muscle mass.  This 
new knowledge could contribute to a better understanding of sarcopenia, and this osteoblast-
derived factor could be a target for the development of therapies to prevent, delay or slow the 
progression of this highly prevalent disorder associated with aging.  If this is useful for 
sarcopenia, it is possible that it will also be useful for its associated disorder, osteoporosis.  
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CHAPTER 3 
THEORETICAL FRAMEWORK AND METHODOLOGY 
This study is an in vitro case-control trial in which the myogenesis of human skeletal 
muscle cells bathed in media containing serum from patients with osteoporosis was 
compared with the myogenesis of human skeletal muscle cells bathed in media containing 
serum from patients without osteoporosis.   
Theoretical Framework 
The skeletal myogenesis model provides the conceptual framework for this study.  
Skeletal muscle develops from myogenic precursor cells.  Myoblasts proliferate in response 
to factors; some of which have been identified and many of which continue to be discovered.  
Proliferation continues until the myoblast exits the cycle of proliferation and begins 
differentiation into myotubes.  Different factors continue to be identified as facilitators of 
differentiation.  This process provides a predictable sequence of events with a definable end 
product as well as clear morphologic and functional changes along the way (Burattini et al., 
2004; Le Grand & Rudnicki, 2007; Wagers & Conboy, 2005).  The precursor of the muscle 
cell is either the mesoderm-derived structure in embryonic development or the quiescent 
satellite cell awaiting activation as a myoblast.  Myoblasts are small, mononucleated cells 
capable of either dividing by mitosis and proliferating, or fusing with other myoblasts to 
form myotubes (Figure 1).  As myoblasts fuse and begin to form myotubes, they enlarge and 
take on an elongated shape.  Myogenesis occurs not only in the embryonic and early stages 
but also throughout the lifespan.   
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  Skeletal muscle is a dynamic tissue, whose cells undergo myogenic differentiation 
repeatedly as muscles regenerate in response to injury (Nag & Foster, 1981; Shefer, Van de 
Mark, Richardson, & Yablonka-Reuveni, 2006).  Genes, proteins, ligands and other factors 
all play a role in determining the timing and route each myoblast will take along the path to 
differentiation (Burattini et al., 2004; MacIntosh, Gardiner, & McComas, 2006).  Insight into 
just how these factors communicate with muscle cells and impact myogenesis is provided by 
an overview of cellular signaling pathways.  A practical application of the Bertalanffy‘s 
(1969) General Systems Theory (GST), mammalian physiology demonstrates repeatedly how 
Figure 1.  Skeletal Muscle Cell Myogenesis Model 
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systems are in constant communication with one another.  According to the GST, a system is 
a ―complex of interacting maintaining entity or process.‖ (Bertalanffy, 1969, p. 55).  Russell 
Ackoff (1981) identified three predominant propositions of this theory.  He stated that within 
a system: 1) each element has an effect on the functioning of the whole, 2) each element is 
affected by at least one other element in the system, and 3) all possible subgroups of the 
elements also have the first two properties. 
These propositions provide an exquisite reflection of mammalian physiology, and in 
this way pertain directly to this dissertation study, providing the framework that guides the 
investigation into bone-muscle crosstalk, especially in the presence and absence of 
osteoporosis.  One of the primary ways the various elements, or systems within the body 
affect one another is at the molecular level, through the signaling pathways that regulate 
nearly all functions (Rappolee & Armant, 2009).  Cells communicate in three ways:  with 
distant tissues via the circulatory system (endocrine); with one another, via cell-to-cell 
communication (paracrine); and within the cell itself, intracellularly (autocrine) (Campbell & 
Reece, 2004).  The presence of factors produced by specific tissues, such as bones and 
muscles, as well as these cell-signaling pathways offer further support for the framework for 
this research.  Bonewald (2011) and others who have recognized bone cells to be the source 
of factors that regulate physiologic changes locally and in distant tissues (Bonewald, 2011; 
Bonewald & Wacker, 2012; Mundy, 1993). 
Aging brings about many physiologic changes in the body.  Two well-defined 
changes that occur with aging are a decrease in muscle size and strength (sarcopenia) and a 
decrease in bone density and strength (osteoporosis) (Arnold, Egger, & Handschin, 2011; 
Evans & Campbell, 1993).  Literature supports the identification of factors produced by 
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muscle cells and by bone cells (Abreu et al., 2012; Arnold et al., 2011; Bonewald, 2011).  
Additionally, evidence exists that factors secreted from bone cells change with aging 
(Hamrick et al., 2006).  As mentioned, research has already demonstrated that factors from 
muscles impact bone cells (Jähn et al., 2012), and preliminary findings demonstrate that 
factors from bones impact skeletal muscle cells (Mo et al., 2012).  One-way to further 
explore the presence of factors from bone impacting skeletal muscle cells is to compare 
muscle formation in the presence of factors from healthy bones with muscle formation in the 
presence of factors from osteoporotic bones.  Thus, this dissertation study addressed the 
myogenesis of human skeletal muscle cells under these two conditions.   
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Figure 2.  Research Design.  Flow of experiment from seeding of HSMM cells 
through myogenesis and fixation for data collection. 
 
 
 
 
Methodology 
Research Design   
The design of this experimental study was an in vitro controlled trial (Figure 2).  In 
vitro studies or those performed outside the living body are often performed in preclinical 
research to provide a stronger foundation for ongoing studies.  They are the most reliable 
way of determining cellular and molecular insights that have led to important discoveries 
including a number of new drugs and molecules.  In vitro studies offer several advantages 
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over in vivo studies including reduced cost, the ability to more directly assess the effects of 
the treatment and the ability to avoid many of the ethical considerations that must be weighed 
when human or animal participants are involved (Polli, 2008).  While there was human 
involvement in the form of serum sample collection, this portion of the research had already 
occurred, with the due diligence that accompanies the successful IRB approval.  All 
measures were taken to assure that the same diligence was applied to the IRB board approved 
addendum for ―post collection‖ use of the serum collected (Appendix A).  A commercially 
available cell line was used for this in vitro controlled trial.  Commercially available cell 
lines provide the opportunity to work with cells of uniform morphology and functions, with 
predictable activity in predetermined environments.  The cell line proposed contains normal 
human skeletal muscle myoblasts, usually from quadriceps or psoas tissue.  Comparable 
groups of cells were optimized, with an increase in reliability, by using the same subculture 
passage.  Passage refers to a cell culturing technique designed to maintain the life and health 
of the cell line.  Additionally, optimization of comparable groups was enhanced by seeding 
each well with the same number of cells.  The possibility of extraneous variables was 
reduced by holding constant as many of the influences as possible on the dependent variable 
of myotubes formation.  The design of this study was for one group of cells to be treated with 
media containing serum from subjects with osteoporosis (CASE), and one group of cells to 
be treated with media containing serum from subjects without osteoporosis (CNTRL).  
(Appendices C, D, E, and F provide detailed study protocols).  To maintain the fidelity of the 
procedures, the experiments were conducted with the investigator blinded to the patient 
information related to each serum sample.  Also, this research was completed following only 
those protocols reviewed and approved by either the Director of the Muscle Bone Biology 
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Group (MUBIG) and/or the company from which the human skeletal muscle cell line was 
purchased.   
Sample/ Subjects   
Clonetics™ Skeletal Muscle Myoblast Cell System (HSMM) was the cell line used 
for this study.  These cells are isolated from normal donor quadriceps or psosas tissue.  
According to the materials published by the manufacturer, Lonza (2012), Certificates of 
Analysis (CA) for the cells are shipped with each order, the cells are performance assayed 
and test negative for HIV-1, mycoplasma, Hepatitis-B, Hepatitis-C, bacteria, yeast and fungi.  
This information is important to ensure the safety of those working with the cells, to assure 
that the cells have not mutated, and to preserve the reliability of the data collected. 
Serum samples used for this study were obtained from women enrolled in the 
ongoing Bone Quality Study at the Osteoporosis Research Center at Creighton University.  
Half of the patients have been diagnosed as having osteoporosis (CASE) and the other half 
have no evidence of osteoporosis (CNTRL).  Those subjects in the CASE group are women 
who have experienced a fracture during the previous five years from little or no trauma.  The 
serum samples were provided by the Creighton University Osteoporosis Research Center in 
Omaha, Nebraska, where IRB approval had already been obtained.  For the purposes of their 
study, researchers at Creighton University defined low-trauma fracture as any fracture caused 
by trauma that is less than or equal to a fall to the floor from standing height (Recker & 
Barger-Lux, 2004).  Fractures of digits, face or skull are not included.  The serum samples 
used were from patients between the ages of 50 and 75, who were otherwise healthy and who 
were matched for age.  Subjects excluded from the Bone Quality Study are those with history 
of cancer, except for superficial basal or squamous cell carcinoma of the skin, or another 
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malignancy that was treated curatively at least ten years prior to the study; serious effects 
from cerebral vascular disease; diabetes mellitus; kidney disease with a serum creatinine > 
1.9 mg/dl; chronic liver disease or alcoholism; treatment with bisphosphonates or other bone 
active agents; treatment with calcitonin, estrogen or a selective estrogen-receptor modulator 
within the previous six months, any corticosteroid therapy within the previous six months; 
systemic corticosteroid therapy at pharmacologic levels for more than six months duration; 
treatment with anticonvulsants within the previous year; cardiovascular diseases including 
unstable angina, uncontrolled hypertension, or infarction within one year prior to the study; 
evidence of metabolic bone disease; active rheumatoid arthritis or collagen disease; major 
gastrointestinal disease within the previous year; or any disease or treatment judged to have a 
significant effect on the skeletal system.  A minimum of ten patients is needed to detect a 
difference (median effect size 0.5; 0.05 significance level; power of 0.70).   
Prior to initiating the experiments, a series of dose response experiments were first 
conducted to determine the optimum concentration of serum to use.  Although the 
concentration of 10% serum appears to provide the greatest impact on proliferation and 
myogenesis, the concentrations of 3% and 1% appear to be very close in their impacts on the 
HSMM cells.  For these reasons, the decision was made that the concentration of the serum 
samples provided to us by the Osteoporosis Research Center at Creighton University to use 
for the dissertation studies was 1.0%.  (Appendix C provides protocols used for the HSMM 
cells).   
Procedures for Data Collection   
Using standard procedures and approved protocols, wells in six-well plates and optic 
dishes were seeded each with 35K HSMM cells.  The cells were initially plated with Skeletal 
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Muscle Basal Medium-2 (SkBM-2) as recommended by Lonza, and incubated at 37 C and 
5% CO2.  This media contains Skeletal Muscle Basal Medium, 0.1% human epidermal 
growth factor (hEGF), 10% fetal bovine serum (FBS), 0.1% dexamethaxsone, 2% L-
glutamine, and 0.1% gentamicin/ amphotericin-B (GA).  The cells were observed daily and 
the media was changed every 48 hours according to established protocols.  It was important 
not to allow the cells to become any more than 60% confluent to avoid spontaneous myotube 
formation prior to the application of fusion media.  In the CNTRL group, cells were treated 
with fusion media containing 1% serum from patients without osteoporosis.  In the CASE 
group, cells were treated with fusion media containing 1% serum from patients with 
osteoporosis.  The decision to use a concentration of 1% serum was based upon results from 
the dose response experiments performed prior to the initiation of this study.  The day that 
the fusion media was applied was considered DAY 0.  Photographs were taken using the 
LEICA inverted light microscope every day beginning DAY 1, just hours after the initial 
application of the fusion media, through the time of optimal myotubes formation, usually 
DAY 7.  At that time, the appropriate protocol was followed for either immunostaining for 
Fusion Index calculations, fixation in preparation for cell cycle analysis through Flow 
Cytometry using the MUSE™ Cell Analyzer by EMD Millipore.  Cells cultivated in the 
optic dishes were prepared for Calcium Imaging, a technique for measuring intracellular 
function.  
Measures   
To evaluate the effect of media containing serum from patients with and without 
osteoporosis, several techniques were performed including Myogenic Differentiation, 
Calcium Imaging, and Cell Cycle Analysis using Flow Cytometry. 
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Myogenic Differentiation.  Fusion indexing provides quantitative evaluation of the 
efficiency of myoblast fusion into myotubes by determining the fraction of total nuclei that 
are incorporated into myotubes.  Fusion indexing is commonly used to quantify the extent of 
differentiation in skeletal muscle cells (Veliça & Bunce, 2011).  This researcher selected 
fusion index as the primary biophysiologic instrument for measuring the dependent variable 
of myotube formation because it is an established method for quantifying myogenic 
differentiation, is one with which the researcher has experience, and is one to which the 
necessary equipment and solutions the researcher has access.  At the peak of myotube 
formation, the media was removed and the cells were fixed for immunostaining, following 
the approved protocol (Appendix D).  The fusion index was determined by randomly 
selecting five fields per well using the LEICA imaging system to assure a significant level of 
conclusion. 
 Intracellular Calcium Homeostasis, Calcium Imaging.  Intracellular Ca
2+
 
homeostasis is critical for myogenesis and for contractile function of muscles (Berchtold, 
Brinkmeier, & Müntener, 2000).  The intracellular calcium was evaluated as recently 
described in the article by Mo (2012) by loading the cells from each group with Fura-2AM, a 
Ca
2+ 
indicator.  A PTI automatic spectrofluorometer (Photon Technology International, 
Birmingham, New Jersey), was used to determine the average resting ratio of bound- to 
unbound Ca
2+
, the magnitude of changes in caffeine-induced intracellular Ca
2+
, and the total 
amount of intracellular Ca
2+
.  For meaningful statistics, data from nine to fifteen myotubes 
from each serum sample were collected.  (Appendix E). 
Cell Cycle Analysis using Flow Cytometry (FC).  Flow Cytometry provides the 
ability to measure several properties of individual cells as they are suspended in liquid and 
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passed through a laser light.  The parameters of cell size, cell complexity and DNA content 
are evaluated using this technique.  This method of biophysiologic measure has been used to 
identify morphologic, functional and apoptotic characterization of skeletal muscle cells 
(Burattini et al., 2004; Salucci et al., 2010).  To maintain the reliability of the data collected 
from FC, a number of technologies were used in the MUSE™ Cell Analyzer and 
accompanying software to maintain alignment and linearity, absolute cell counting beads, 
compensation tools and cell sizing beads.  Results obtained through FC have been deemed 
comparable to results achieved with reverse transcription (RT)-PCR (Campana, 2003).  For 
use in cell cycle analysis, Heiden, Auer and Tribukait (2000) found FC to be analogous to 
Image Cytometry, noting the importance of both adequate cell count in the samples tested 
and the user‘s experience and judgment.  (Appendix F). 
Plan for Data Analysis 
The data included immunostaining and resulting photographs of the cells from each 
treatment condition; the total number of nuclei, the number of nuclei within myotubes, and 
the calculated fusion index.  This information was gathered from each well containing serum 
sample treated cells.  Using Origin Statistical Software, the data were tested for normality.  
Independent t-tests were conducted to examine the differences in myogenesis between the 
two groups, CASE and CNTRL. 
The data collected from Calcium Imaging were used to evaluate the functional 
differences in cells from both groups.  Nine to 15 myotubes from each serum sample were 
tested for calcium levels:  resting, peak and area under the curve, which reflects the total 
amount of calcium in response to stimulation.  These data were also tested for normality 
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using the Origin Statistical Software before conducting independent t-tests to look at 
functional differences between the groups. 
Flow Cytometry allows the data to be collected both in a linear run and, for DNA 
content, a logarithmic run.  The software that is used with FC provides a full range of 
intrinsic methods for statistical analysis of the data collected.  For the linear scale data, an 
arithmetic mean is used; and for the logarithmically displayed data, the geometric mean is 
chosen.  In FC, the spread of a distribution, which is usually expressed in other settings as the 
Standard Deviation (SD), will be expressed as the coefficient of variation (CV).  In the case 
of FC, it is the distribution, for example cell size and complexity that is being recorded.  
Therefore, the CV is preferred because it is dimensionless and, for the linear run, does not 
depend upon where on the histogram the data are recorded.  Another feature of the FC data 
are that it provides the percentage of particular subset of cells, using an electronic sizing 
(Coulter) counter.  This feature allowed for analysis of subsets within the cell population for 
both groups, since myogenesis leads to increasing cell size, complexity and DNA content.  
Values obtained, such as percentage of cellular subsets, were then entered into Origin to 
conduct independent t-tests for additional insight into differences between the two groups 
with regard to myogenesis. 
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CHAPTER 4 
RESULTS 
The Specific Aim (SA) of this study was to investigate biochemical, 
histomorphometric and functional differences in human skeletal muscle (HSMM) cells 
treated with conditioned media containing serum from patients with and without 
osteoporosis.  Serum samples were obtained from patients enrolled in the ongoing Bone 
Quality (BQ) Study being conducted at the Osteoporosis Research Center at Creighton 
University.  Researchers involved in the BQ Study selected serum samples from sixteen 
participants in the BQ study, eight who belong to the group with osteoporosis (CASE) and 
eight who belong to the group without osteoporosis (CNTRL).  The experiments were all 
conducted with this researcher blinded to which of the groups each serum sample belonged.  
The first section of this chapter presents a summary of the data collected for the HSMM cells 
treated with each of the serum samples with regard to myogenic differentiation, intracellular 
calcium homeostasis and cell cycle analysis.  Data collected for each serum sample are 
presented in Appendices G, H, and I.    
The Research Question (RQ) that this dissertation study sought to answer was: “What 
is the extent of difference in biochemical, histomorphometric and functional adaptations in 
HSMM cells treated with conditioned media containing serum from subjects with and 
without osteoporosis?‖  As presented in Chapter 3, this research question was explored by 
evaluating the differences between the CNTRL and CASE groups in three ways:  Myogenic 
Differentiation, Intracellular Calcium Homeostasis, and Cell Cycle Analysis.  According to 
researchers at the Osteoporosis Research Center, patients who have experienced a fracture 
from little or no trauma during the previous five years are considered to have osteoporosis, 
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and are entered into the CASE group of the BQ Study.  Those who have not sustained a 
fracture within the previous five years are in the CNTRL group.  Upon completion of all 
experiments, this researcher obtained from the Osteoporosis Research Center, patient 
information associated with each serum sample.  Statistical analyses were performed to 
evaluate the differences between the CNTRL and CASE groups using the Origin Statistical 
Software, version 6.0.  A significance level of 0.05 was set for the research question.  The 
results of that statistical analysis are presented in section two of this chapter.    
The patient information provided upon completion of the experiments provided 
insight into which of the serum samples belonged to patients who had sustained a non-
traumatic fracture within the previous five years.  It also provided the patients ages and 
results of dual energy x-ray absorptiometry (DXA) performed on each patient‘s lumbar spine 
(T-Spine), and hip (T-Hip).  The National Osteoporosis Foundation (2010) defines 
osteoporosis as bone density of 2.5 standard deviations (SD) below the mean of a young 
adult, or a DXA score of less than or equal to -2.5.  It is interesting to note that none of the T-
Scores reported for any of the patients whose serum was used in this dissertation study had a 
T-Score of less than -2.5.  It is undeniable that the patients in the CASE group had sustained 
non-traumatic fractures, and therefore suffered from decreased bone integrity.  This 
researcher conducted a second data analysis; this time grouping the data based upon T-
Scores.  Data obtained from cells treated with serum from patients who had a T-Score less 
than -1.0 of either the lumbar spine or the hip were placed in the T-Score status, CASE 
group.  In addition, data obtained from cells treated with serum from patients with T-Scores 
of both their lumbar spines and hip above -1.0 were placed in the T-Score status, CNTRL 
group.  With these new groups defined, the data were once again analyzed using the Origin 
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Statistical Software.  The results of that statistical analysis are presented in section three of 
this chapter.    
Summary of Data Collected 
This section presents a general summary of data collected in Phase I, Phase II, and 
Phase III of this dissertation study.  During the time that the experiments were conducted, 
this researcher was blinded to the patient information associated with each serum sample. 
Phase I:  Immunostaining for Fusion Index Calculations, Data Gathered.  According 
to the myogenesis model, myoblasts leave the cell cycle to enter into the differentiation 
pathway.  It is along this pathway that myocytes fuse together to form myotubes.  Fusion 
index provides a quantitative evaluation of the efficiency of this process by determining the 
fraction of total nuclei that are incorporated into myotubes.  For this study, the fusion index 
was determined by randomly selecting five fields per well for each serum sample using the 
LEICA imaging system, and was calculated as the ratio of the number of nuclei inside 
myotubes to the number of total nuclei 100 at day 7 of myogenic differentiation.  (Appendix 
G provides immunostaining images collected of HSMM cells for fusion index calculations 
for each of the serum samples and the control conditions).  
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Figure 3.  Myogenic Differentiation, Nuclei Counted.  Myotube and total nuclei counted in 
HSMM cells treated with serum samples. The HSMM cells were fixed and stained on Day 7 
after seeding. 
 
 
 
Figure 3 provides a graphic representation of the number of nuclei counted for each 
of the experimental conditions, as well as a control well of HSMM cells.  In this figure, the 
green bars present an average of the number of nuclei within myotubes and the blue bars 
represent an average of the total number of nuclei counted in a minimum of five fields for 
each experimental condition. The highest number of both myotube and total nuclei were 
counted in cells treated with media containing 1% serum sample number 480.  The lowest 
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number of both myotube and total nuclei were counted in the control cells, which were 
cultured in media with no human serum added. 
 
 
 
 
Figure 4.  Myogenic Differentiation, Fusion Index.  Fusion Index of HSMM cells treated with 
serum samples.  Fusion Indexes were calculated as the ratio of nuclei within the myotubes to 
the total number of nuclei, multiplied by 100.  
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  Figure 4 provides a graphic representation of the fusion index calculated for each of 
the experimental conditions and the control cells.  The fusion index is calculated as a ratio of 
nuclei within myotubes to the total number of nuclei, multiplied by 100 and presented as a 
percentage.  The highest fusion index, 85%, was observed in those cells treated with 1% 
serum sample number 480.  The control cells had a fusion index of 77%, and the lowest 
fusion index, 68%, was observed in cells treated with 1% serum sample number 391. 
Phase II:  Calcium Imaging, Data Gathered.  Intracellular calcium (Ca
2+
) plays an 
important role in skeletal muscle cell function, and its homeostasis is critical both for the 
process leading to myogenesis and for the contractile function of skeletal muscles.  Using the 
fluorescent dye, Fura-2AM which binds to free intracellular calcium, the ratio of emissions at 
specific wavelengths is directly correlated to the amount of intracellular calcium.  In the 
system used in our lab, the wavelength at which Fura-2AM is excitable when bound to 
intracellular calcium is 350 nanometers (nm).  It is excitable at 375 nm when unbound.  With 
the use of a PTI (Photon Technology International, Birmingham, New Jersey) 
spectrofluorometer the average resting ratio of bound- to unbound Ca
2+
, the magnitude of 
changes in  caffeine-induced intracellular Ca
2+
, and the total amount of intracellular Ca
2+
 was 
determined.   Please refer to Appendix H for images of calcium imaging tracings collected 
for each serum sample and control.   An approximate average of ten tracings was obtained 
for each of the experimental conditions. 
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Figure 5.  Calcium Imaging, Resting and Peak Levels.  This graph presents a comparison of 
the fluorescence intensity of HSMM cells loaded with the calcium sensitive dye, Fura-2AM, 
before and following application of 20mM caffeine. The ~0.1 increase in the ratio while 
apparently small represents a substantial increase in the free levels of intracellular from 
~100nM to 300nM. 
 
 
 
Figure 5 provides a graphic representation of the both the resting and peaks levels of 
intracellular calcium; data collected from calcium imaging performed on cells treated with 
each of the serum samples.  For the control cells, the resting and peak levels were observed 
to be 0.66 and 0.77, respectively.  The highest resting level, 0.72, and the highest peak level, 
0.82, were both observed in cells treated with media containing 1% serum sample number 
489.  The lowest resting level, 0.63, was observed in cells treated with media containing 1% 
serum sample number 428.  But, the lowest peak level, 0.74, was observed in cells treated 
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with media containing 1% serum sample number 496.  The resting level of cells treated in 
media containing 1% serum sample number 496 was the same as the resting level of the 
control cells. 
 
 
 
 
Figure 6.  Calcium Imaging, Change in Level of Fluorescence Intensity. This graph presents 
a comparison of the change in fluorescence intensity of HSMM cells loaded with the calcium 
sensitive dye, Fura-2AM, following application of 20mM caffeine. The ~0.1 increase in the 
ratio while apparently small represents a substantial increase in the free levels of 
intracellular from ~100nM to 300nM. 
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Figure 6 provides a graphic representation of the change in fluorescence level with 
the introduction of 20mM caffeine for cells treated with 1% of each of the serum samples.  
The greatest change in level was observed in cells treated with media containing 1% serum 
sample number 482.  Although the change in level for the control cells was 0.11, a lower 
level of change was observed in cells treated with all of the serum samples except 428, 463, 
482, 489 and 495. 
 
 
 
 
Figure 7.  Calcium Imaging, Time to Peak.  This graph presents a comparison of time to 
peak fluorescent intensity of HSMM cells loaded with the calcium sensitive dye, Fura-2AM, 
following application of 20mM caffeine. 
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Figure 7 provides a graphic representation of the time, in seconds, from resting to 
peak levels upon the introduction of 20mM caffeine.  The time to peak observed in the 
control cells was 6 seconds.  A quicker time to peak was observed in cells treated with media 
containing two of the serum samples, 439 and 463.  The longest time to peak was observed in 
cells treated with media containing 1% serum sample number 391. 
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Figure 8.  Calcium Imaging, Calcium Transients.  This graph presents a comparison of the 
amount of calcium as determined by the area under the curve, which is the integral ( ) 
of the fluorescent intensity of HSMM cells loaded with the calcium sensitive dye, Fura-2AM, 
before and following application of 20mM caffeine.  Each serum sample is listed along the y-
axis, with the exception of 439.  No data were collected for serum sample 439 due to data 
corruption or loss during experiment. 
 
 
 
Figure 8 provides a graphic representation of the calcium transients, measured as the 
area under the curve following the introduction of 20mM caffeine for each of the 
experimental conditions.  Data from cells treated with media containing 1% serum sample 
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number 439 were omitted due to logistical challenges in the collection of calcium imaging 
data for this dish.  The calcium transients observed in the control cells was 267.  The only 
experimental condition in which a lower level of calcium transients was observed was in the 
cells treated with media containing 1% serum sample number 428.  All other experimental 
conditions yielded a higher level of calcium transients, with the highest level observed in 
cells treated with media containing 1% serum sample number 489. 
Phase III:  Flow Cytometry for Cell Cycle Analysis.  As discussed, myogenesis leads 
to increasing cell size, complexity and, therefore, an increase in the DNA content, each of 
which can be evaluated using flow cytometry.  Prior to differentiation, myoblasts progress 
through the four phases of the cell cycle:  two gap phases, G1 and G2, a synthesis or S phase, 
as the 46 chromosomes are duplicated; and a mitosis, or M phase, as the genetic material and 
the cell divides.  In order to enter into differentiation, the myocyte must exit the cell cycle.  
In this portion of the current project, data were gathered on cell cycle subsets and on DNA 
content for cells treated with each of the serum samples.  Please refer to Appendix I for 
images of data collected from the MUSE™ Cell Analyzer.   One run was completed for each 
experimental condition, and two for the control. 
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Table 1. Cell Cycle Analysis.  This table compares HSMM cells treated with each 
serum sample and presents data on the number of events (cells) within each of the cell 
cycles listed:  G0/G1, S, and G2/M collected from flow cytometry using the tabletop 
MUSE™ Cell Analyzer.  
 
Sample ID Number of Events 
 
G0/ G1 S G2/M 
CNTRL 
 
11928 83.90 12.20 2.30 
228 
 
14097 84.35 11.55 2.36 
368 
 
8487 83.24 13.79 1.75 
380 
 
11887 79.83 15.45 2.82 
390 
 
11704 85.32 12.5 1.17 
391 
 
12326 85.52 11.7 0.98 
397 
 
21903 75.85 17.84 4.86 
403 
 
15948 79.59 15.34 3.04 
428 
 
17870 79.55 15.96 2.76 
435 
 
9287 79.4 15.93 3.14 
439 
 
9771 80.53 14.47 3.04 
463 
 
12360 85.95 10.6 1.87 
480 
 
17515 83.76 12.51 1.96 
482 
 
13213 79.82 15.58 2.34 
489 
 
15060 84.38 13.37 1.20 
495 
 
15752 80.95 13.29 3.80 
496 
 
14691 75.88 17.54 4.18 
 
 
 
 
 
 
63 
 Table 1 provides the number of events recorded as well as the number of cells in each 
phase of the cell cycle for cells treated with media containing 1% of serum samples.  The 
greatest number of events was observed in the cells treated with 1% of serum sample number 
397.    This was also the experimental condition in which the greatest number of cells was 
observed to be in the G2/M (mitosis) phase of the cell cycle.  The greatest number of cells in 
the S phase was observed in those cells treated with media containing 1% serum sample 
number 397.  The largest number of cells observed in the G0/G1 phase of the cell cycle was 
observed in cells treated with 1% serum sample number 463; although those treated with 
serum samples 391 and 390 were close behind.   
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Figure 9.  Cell Cycle Analysis.  This figure provides a graphic representation of the cell 
cycle analysis performed comparing HSMM cells treated with each serum sample and 
presents data on the number of events (cells) within each of the cell cycles listed:  G0/G1, S, 
and G2/M collected from flow cytometry using the tabletop MUSE™ Cell Analyzer.  
 
 
 
Figure 9 provides a graphic representation of the distribution of cells throughout the 
phases of the cell cycle in each experimental condition.  These are the same data presented in 
Table 2. 
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Data Analysis:  Fracture Status Groups Compared 
Subjects with osteoporosis are identified in the Creighton University Osteoporosis 
Research Center Bone Quality Study as those who have experienced a fracture during the 
previous five years from little or no trauma.  Therefore, when all the experiments were 
completed and the associated patient information was provided for serum samples used for 
this study, data were grouped according to the Bone Quality Study definition of osteoporosis.  
Data collected from cells treated with serum from subjects who had sustained a fracture were 
placed in the CASE group and data collected from cell treated with serum from subjects who 
had not sustained a fracture were placed in the CNTRL group.  With the groups identified, 
data were analyzed using the Origin Statistical Software (Version 6.0).   
The serum samples were collected from patients between the ages of 50 and 75, who 
are otherwise healthy.  Although based upon the patient information provided, it is not clear 
whether the subjects were matched for co-morbidities, share similar medical profiles with no 
history of cancer, diabetes mellitus, kidney disease, chronic liver disease, unstable angina, 
uncontrolled hypertension, or recent infarction.  Their pharmacologic profiles were similar in 
that none had been treated with bisphosphonates or other bone active agents, calcitonin, 
estrogen or a selective estrogen-receptor modulator within the previous six months.  In 
addition, none had recently received any corticosteroid therapy, or anticonvulsant agents.  
The patient information provided included their age as well as results of a dual energy x-ray 
absorptiometry (DXA) of their lumbar spine (T-Spine), and of their hip (T-Hip).  This 
information is presented in Table 2.   
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Table 2.  Descriptive Characteristics, Fracture Status Groups. Comparison of fracture 
status groups, descriptive characteristics.  At the 0.05 level, the two means are not 
significantly different with regard to any of the parameters listed. 
 
  
Fracture Status, CNTRL Group 
 
  
Fracture Status, CASE Group 
 
 
 
 Mean 
 
SE Range  Mean SE Range p-value 
Age 
(years) 
63.16 2.37 21.3 
(52.3 to 73.6) 
 
 64.18 2.30 20.1  
(50.7 to 70.8) 
0.76373 
T-Spine -0.44 0.35 2.703 
(-1.948 to 0.755) 
 
 -0.93 0.34 3.220 
(-2.389 to 0.831) 
0.33627 
T-Hip -0.75 0.18 1.703 
(-1.780 to -0.077) 
 
 -1.11 0.37 0.934 
(-1.506 to -0.572) 
0.13564 
 
Figure10a .    Figure 10b .  
 
Figure 10.  Immunostaining of HSMM Cells.  Immunostaining with DAPI (blue) for nuclei 
and with anti-MHC Antibody (green) for myotubes.  10a. HSMM cells treated with media 
containing 1.0% serum (sample 495).  10b. HSMM cells treated with media containing 1.0% 
serum (sample 391).  
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Myogenic Differentiation.  Figure 10 presents images of the HSMM cells upon 
immunostaining and are representative of each of the fracture status groups, Figure 10a is 
from the CNTRL group and Figure 10b from the CASE group.  After normalizing the data, 
independent t-tests were performed comparing the two groups with regard to myotubes 
nuclei, total nuclei, and fusion indexes.  At the 0.05 level, the two groups were shown to be 
significantly different for all three of these myogenic differentiation parameters.  Table 3 
presents the results of these statistical analyses. 
 
 
 
 
Table 3.  Myogenic Differentiation, Fracture Status Groups.  Comparison of fracture status 
groups, myogenic differentiation.  *At the 0.05 level, the two means are significantly different 
with respect to myotube nuclei, total nuclei, and fusion index.   
 
 
Myotube Nuclei 
 
CNTRL 
(n=39) 
 
CASE 
(n=37) 
 
p-value 
 
Mean 
 
1121 
 
 
1012 
 
 
p = 0.00273* 
 
Total Nuclei 
 
CNTRL 
(n=38) 
 
CASE 
(n=38) 
 
p-value 
 
Mean 
 
1412 
 
 
1342 
 
 
p = 0.03708* 
 
Fusion Index 
 
CNTRL 
(n=37) 
 
CASE 
(n=40) 
 
p-value 
 
Mean 
 
81% 
 
 
76% 
 
 
p = 0.00036* 
 
 
 
 
These data are represented graphically in Figures 11 and 12. 
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Figure 11.  Myogenic Differentiaion, Myotube and Total Nulcei, Fracture Status Groups.  
Immunostaining of HSMM cells treated with 1% serum from either the CNTRL or CASE 
group.  Graphic depiction of the significantly different means between the Fracture Status 
Group means.  
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Figure 12.  Myogenic Differentiaion, Fusion Index, Fracture Status Groups.  
Immunostaining of HSMM cells treated with 1% serum from either the CNTRL or CASE 
group.  Graphic depiction of the significantly different means between the Fracture Status 
Group means.  
 
 
 
 
As the immunostained images were analyzed, there appeared an undeniable 
difference in the size of myotubes treated with different serum samples.  For that reason, it 
was decided to also collect data with regard to the diameter of the myotubes captured in the 
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myotubes of medium size, and two (2) smaller myotubes as representatives.  The lengths of 
measurements were first collected as pixels using Image J.  These images had all been taken 
at 10X magnification using the inverted Leica microscope and were saved as 1125 X 1125 
pixel images.  Next, an image also at 10X magnification that had a scale of 100 micrometers 
(µm) on it was selected and sized to match these images at 125 X 1125 pixels.  Matching this 
to the immunostained images, it was possible to calculate the measured lengths in 
micrometers.    
The data were grouped first according to Fracture Status and next according to T-
Score.  After normalizing the data, independent t-tests were performed comparing the two 
groups with regard to myotube diameter.  At the 0.05 level, when grouped according to 
Fracture Status, the two groups were shown to be significantly different for all with regard to 
myotube diameter.  Table 4 presents the results of these statistical analyses. 
 
 
 
Table 4.  Myotube Diameter, Fracture Status Groups.  Comparison of fracture status 
groups, myotube diameter.  *At the 0.05 level, the two means are significantly different with 
respect to myotube diameter.   
 
 
Myotube Diameter 
 
CNTRL 
(n=225) 
 
CASE 
(n=229) 
 
p-value 
 
Mean + SEM 
(µm) 
 
 
73 + 3.5 
 
 
 
54 + 2.8 
 
 
p = 0.00002* 
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Intracellular Calcium Homeostasis.  Figure 13 presents representative images from 
the calcium imaging performed on each of the fracture status groups, Figure 13a from the 
CNTRL group and Figure 13b from the CASE group.  After normalizing the data, 
independent t-tests were performed comparing the two groups with regard to resting 
intracellular calcium levels, peak levels, time to peak, and area under the curve.  At the 0.05 
level, the two groups were not significantly different for any of these parameters of 
intracellular calcium homeostasis.  Table 4 presents the results of these statistical analyses. 
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Figure 13a                                                                              Figure 13b 
 
Figure 13c 
Figure 13.  Calcium Imaging, Representative Tracings.  13a. Calcium imaging performed on 
nine myotubes bathed in media containing 1% serum from one of the serum samples from the 
CNTRL group (sample # 435).  This tracing also includes a tracing of the background for 
validation. 13b. Calcium imaging performed on eleven myotubes bathed in media containing 
1% serum from one of the serum samples from the CASE group (sample # 390). This tracing 
also includes a tracing of the background for validation. Figure 13c.  Representative 
tracings of the averages for CNTRL and CASE of T-Score Status Groups illustrate well the 
relative differences between the two groups. 
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Table 5.  Intracellular Calcium Homeostasis, Fracture Status Groups.  Comparison of 
fracture status groups, intracellular calcium homeostasis.  At the 0.05 level, the two means 
were not significantly different with regard to any of the parameters listed.   
 
Average Resting 
Levels 
 
CNTRL 
(n=81) 
 
CASE 
(n=86) 
 
p-value 
 
Mean 
 
0.68111 
 
 
0.68039 
 
 
p = 0.91482 
 
Average Peak Levels 
 
CNTRL 
(n=83) 
 
CASE 
(n=87) 
 
p-value 
 
Mean 
 
0.78559 
 
 
0.78325 
 
 
p = 0.72496 
 
Average ∆ Level 
 
CNTRL 
(n=86) 
 
CASE 
(n=88) 
 
p-value 
 
Mean 
 
0.10112 
 
 
0.09810 
 
 
p = 0.62337 
 
Average Time to Peak 
(seconds) 
 
CNTRL 
(n=81) 
 
CASE 
(n=84) 
 
p-value 
 
Mean 
 
8.923 
 
 
10.47924 
 
 
p = 0.06424 
 
Calcium Transients 
(Area Under the Curve) 
 
CNTRL 
(n=75) 
 
CASE 
(n=85) 
 
p-value 
 
Mean 
 
282.63261 
 
 
282.32682 
 
 
p = 0.90002 
 
 
 
 
Cell Cycle Analysis.  Figure 14 presents representative images from the cell cycle 
analysis performed on each of the fracture status groups, Figure 14a from the CNTRL group 
and Figure 14b from the CASE group.  After normalizing the data, independent t-tests were 
performed comparing the two groups with regard to the number of cells in each phase of the 
cell cycle, G0/G1, S, and G2/M.  At the 0.05 level, the two groups were not significantly 
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different for any of these parameters of cell cycle analysis.  Table 6 presents the results of 
this statistical analysis.  
 
 
analyses. 
 
 
 
Figure 14.  Cell Cycle Analysis, Representative Graphs.  14a. Cell cycle analysis of HSMM 
cells treated with 1% of serum from the CNTRL group (sample #428).  Figure 14b.  Cell 
cycle analysis of HSMM cells treated with 1% of serum from the CASE group (sample #403). 
 
Table 6.  Cell Cycle Analysis, Fracture Status Groups.  Comparison of fracture status 
groups, cell cycle analysis.  At the 0.05 level, the two means were not significantly different 
with regard to any of the parameters listed. 
 
 
G0/G1 phase 
 
CNTRL 
(n=8) 
 
CASE 
(n=8) 
 
p-value 
 
Mean 
 
80.6075 
 
 
82.3825 
 
 
p = 0.28816 
 
S phase 
 
CNTRL 
(n=8) 
 
CASE 
(n=8) 
 
p-value 
 
Mean 
 
14.71125 
 
 
13.71625 
 
 
p = 0.37149 
 
G2/M phase 
 
CNTRL 
(n=8) 
 
CASE 
(n=8) 
 
p-value 
 
Mean 
 
2.8525 
 
 
2.30625 
 
 
p = 0.33852 
  
Figure 14a Figure 14b 
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Data Analysis:  T-Score Status Groups Compared 
This researcher explored the research question also by evaluating the differences 
between groups according to the T-Scores.  Cells treated with media containing serum from 
patients who had a T-Score less than -1.0 of either the lumbar spine or the hip were placed in 
the T-Score status, CASE group.  Cells treated with media containing serum from patients 
with T-Scores of both their lumbar spines and hip above -1.0 were placed in the T-Score 
status, CNTRL group.  With these new groups defined, the data were analyzed using the 
Origin Statistical Software.  In addition to comparing the groups with regard to their 
descriptive characteristics, differences between the groups were evaluated by performing 
independent t-tests with regard to Myogenic Differentiation, Intracellular Calcium 
Homeostasis, and Cell Cycle Analysis. 
 
 
 
Table 7.  Descriptive Characteristics, T-Score Status Groups.  Comparison of T-Score status 
groups, descriptive characteristics.  *At the 0.05 level, the two means are significantly 
different with regard to T-Scores of the lumbar spine. 
 
  
T-Score Status, CNTRL Group 
 
  
T-Score Status, CASE Group 
 
 
 
  
Mean 
 
 
SE 
 
Range 
  
Mean 
 
SE 
 
Range 
 
p-value 
Age 67.7 1.7 15.8 
(57.7 to 73.5) 
 
 61.6 2.2 20.1 
(50.7 to 70.8) 
0.06086 
T-Spine 0.21 0.17 1.48 
(-0.65 to 0.83) 
 
 -1.34 0.23 2.18 
(-2.39 to -0.21) 
5.14155E-5* 
T-Hip -0.85 0.06 0.54 
(-0.97 to -0.43) 
 -1.01 0.20 1.70 
(-1.78 to -0.08) 
 
0.44969 
 
 
 
 
76 
Myogenic Differentiation.  When the data were grouped according to T-Scores, 
independent t-tests were performed.  With these data groups, analysis resulted in no 
significant difference between the means regarding any of the parameters for myogenic 
differentiation.   
 
 
 
Table 8.  Myogenic Differentiation, T-Score Status Groups.  Comparison of T-score status 
group means. At the 0.05 level, the two means were not significantly different. 
 
Myotube Nuclei 
 
CNTRL 
(n=34) 
 
CASE 
(n=43) 
 
p-value 
 
Mean 
 
1051 
 
 
 
1108 
 
 
p = 0.15114 
 
Total Nuclei 
 
CNTRL 
(n=35) 
 
CASE 
(n=41) 
 
p-value 
 
Mean 
 
1361 
 
 
 
1393 
 
 
p = 0.35732 
 
Fusion Index 
 
CNTRL 
(n=35) 
 
CASE 
(n=44) 
 
p-value 
 
Mean 
 
78% 
 
 
79% 
 
 
p = 0.46511 
 
 
 
 
As mentioned in the previous section there appeared an undeniable difference in the 
size of myotubes treated with different serum samples.  After measuring representative 
myotubes for each image, the data were analyzed using the Origin Statistical Software.  After 
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normalizing the data, independent t-tests were performed comparing the two groups with 
regard to myotube diameter.  At the 0.05 level, when grouped according to T-Score Status, 
the two groups were shown not to be significantly different for all with regard to myotube 
diameter.  Table 5 presents the results of these statistical analyses. 
 
 
 
Table 9.  Myotube Diameter, T-ScoreStatus Groups.  Comparison of fracture status groups, 
myotube diameter.  At the 0.05 level, the two means were NOT significantly different with 
respect to myotube diameter.   
 
Myotube Diameter 
 
CNTRL 
(n=197) 
 
CASE 
(n=258) 
 
p-value 
 
Mean + SEM 
(µm) 
 
 
66 + 3.6 
 
 
62 + 2.9 
 
 
p = 0.41552 
 
 
 
 
Intracellular Calcium Homeostasis.  When these data were grouped according to T-
Scores, independent t-tests were once again performed.  With these data groups, analysis 
resulted in significant differences between the means regarding several of the parameters for 
intracellular calcium homeostasis.   
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Table 10.  Intracellular Calcium Homeostasis, T-Score Status Groups.  *At the 0.05 level, 
the two means were significantly different with regard to average resting level, average peak 
level and calcium transients. 
 
Average Resting 
Levels 
 
CNTRL 
(n=69) 
 
 
CASE 
(n=94) 
 
p-value 
 
Mean 
 
0.69278 
 
 
0.67352 
 
 
p = 0.00293* 
 
Average Peak Levels 
 
CNTRL 
(n=70) 
 
 
CASE 
(n=99) 
 
p-value 
 
Mean 
 
0.79903 
 
 
0.77474 
 
 
p = 0.00025* 
 
Average ∆ Level 
 
CNTRL 
(n=70) 
 
 
CASE 
(n=97) 
 
p-value 
 
Mean 
 
0.09528 
 
 
0.09592 
 
 
p = 0.91133 
 
Average Time to Peak 
(seconds) 
 
CNTRL 
(n=70) 
 
 
CASE 
(n=95) 
 
p-value 
 
Mean 
 
10.29399 
 
 
9.43535 
 
 
p = 0.32098 
 
Calcium Transients 
(Area Under the Curve) 
 
 
CNTRL 
(n=71) 
 
 
CASE 
(n=88) 
 
p-value 
 
Mean 
 
285.6046 
 
279.40629 
 
 
p = 0.01126* 
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Figure 15.  Calcium Imaging, Resting and Peak Levels, T-Score Status Groups.  Calcium 
Imaging of HSMM cells treated with 1% serum from either the CNTRL or CASE group.  
Graphic depiction of the significant difference between means of the T-Score Status Groups.  
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Figure 16.  Calcium Imaging, Calcium Trasients, T-Score Status Groups.  Calcium Imaging 
of HSMM cells treated with 1% serum from either the CNTRL or CASE group.  Graphic 
depiction of the significant difference between means of the T-Score Status Groups.  
 
 
 
Cell Cycle Analysis.  When these data were grouped according to T-Scores, 
independent t-tests were once again performed.  With these data groups, there were no 
significant differences between the means regarding parameters for cell cycle analysis.   
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Table 11.  Cell Cycle Analysis, T-Score Status Groups.  Comparison of T- Score status 
groups, cell cycle analysis.  At the 0.05 level, the two means were not significantly different 
for any of the parameters listed.  
 
G0/G1 phase 
 
CNTRL 
(n=7) 
 
 
CASE 
(n=9) 
 
p-value 
 
Mean 
 
80.62143 
 
82.17444 
 
 
p = 0.35904 
 
S phase 
 
CNTRL 
(n=7) 
 
 
CASE 
(n=9) 
 
p-value 
 
Mean 
 
14.68143 
 
13.8500 
 
 
p = 0.46086 
 
G2/M phase 
 
CNTRL 
(n=7) 
 
 
CASE 
(n=9) 
 
p-value 
 
Mean 
 
3.03143 
 
 
2.22778 
 
p = 0.15391 
 
 
 
 
Two tables have been prepared presenting these data collected on cells treated with 
each of the serum samples provided.  Table 10 provides the information organized by 
Fracture Status Groups and Table 11 provides the information organized by T-Score Status 
Groups.  These Tables can be found in Appendix J. 
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CHAPTER 5 
DISCUSSION 
Aging brings about a decline in physical strength and functioning that leads to 
disability and loss of independence.  Osteoporosis and sarcopenia are two conditions 
associated with aging that contribute directly to this decline in function.  Bones and muscles 
are connected anatomically and functionally, and over the years, research has demonstrated 
that the connection between these two systems is more complex than first believed.  The 
objective of this dissertation study was to add to the growing body of knowledge related to 
the multifaceted relationship between bones and muscles.  The working hypothesis was that 
human skeletal muscle cells treated with media containing serum from patients with 
osteoporosis will experience decreased differentiation and function than cells treated with 
media containing serum from patients without osteoporosis.  This led to the specific aim, 
which was to investigate the biochemical, histomorphometric and functional differences in 
human skeletal muscle cells treated with conditioned media containing serum from patients 
with and without osteoporosis.  The question this researcher set out to answer was: What is 
the extent of difference in biochemical, histomorphometric, and functional adaptations in 
HSMM cells treated with conditioned media containing serum from subjects with and 
without osteoporosis?  The study results provided some insight into this research question, 
and raised additional questions to be explored.   
All of the experiments were performed with this researcher blinded to the patient 
information associated with each of the serum samples.  A member of the research team at 
Creighton University‘s Osteoporosis Research Center selected serum samples for this 
dissertation study from patients enrolled in their ongoing Bone Quality (BQ) Study.  Eight 
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serum samples were selected that had been collected from patients with osteoporosis 
(CASE), and eight serum samples were selected from patients without osteoporosis 
(CNTRL).  Even before the patient information was received, this researcher observed that 
serum from different patients effected in distinct ways the differentiation and function of 
human skeletal muscle (HSMM) cells.  These differences came about in spite of the fact that 
every effort was made to maintain the same environments, media components, and 
procedures for all HSMM cells throughout each phase of the study.  The observation that 
differences occurred supports the premise that factors are present in serum that influence the 
growth, development, and function of human skeletal muscle cells.  
Myogenic Differentiation 
After the experiments were completed, patient information was provided to this 
researcher by the research team at Creighton University.  The information provided on each 
patient from whom serum samples had been used included the patient‘s age, fracture status, 
and results of dual-energy X-ray absorptiometry (DXA) performed on their lumbar spine (T-
Spine) and hip (T-hip).  First the data were grouped according to their fracture status: 
whether or not the patient had sustained a non-traumatic fracture within the previous five 
years, as this is the definition used by the Osteoporosis Research Group for 
osteoporosis.  When the data were grouped according to fracture status, the means of the two 
groups were found by independent t-tests to be significantly different with regard to myotube 
nuclei, total nuclei and fusion index.  This analysis supports the proposed hypothesis and 
indicates that the presence of osteoporosis negatively impacts the myogenesis of human 
skeletal muscle cells.  A decline in muscle mass and strength (sarcopenia) leads to decreased 
protection from falls, and therefore leads to an increased risk of fracture among older 
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adults.  The data suggest there is a reciprocated relationship.  In other words, a decreased 
bone mass (osteoporosis), as evidenced by non-traumatic fractures, contributes to a decline in 
muscle mass.  This provides support for another dimension to the relationship that exists 
between bones and muscles. 
The significant difference observed in myotube diameter when the data were grouped 
according to fracture status is an important finding, especially with the growing appreciation 
of muscle mass loss in older adults as a meaningful predictor of mortality (Brotto & Abreu, 
2012; Chen et al., 2012; Kamel, 2003).  Researchers are even suggesting that in older adults, 
muscle mass index is a more reliable predictor of longevity than body mass index (BMI) 
(Srikanthan & Karlamangla, 2014).  As discussed in Chapter 2, skeletal muscle is a dynamic 
tissue; constantly experiencing growth and repair.  A key player in muscle regeneration and 
repair is the muscle satellite cell.  There is growing evidence that with aging, there is a 
decline in the ability of these satellite cells to proliferate and differentiate into mature muscle 
fibers (Karakelides & Naiar, 2005).  Findings from this study suggests that factors in the 
conditioned media of osteoporotic patients may inhibit the development of skeletal muscle 
mass, further increasing the health risks of these aging individuals.  
Clinicians are aware of the significant disability as well as the psychologic and 
financial burden of osteoporotic fractures.  For this reason, clinicians are motivated to assess 
accurately the risk of fracture in their aging patients.  One of the diagnostic criteria that 
clinicians rely on most heavily to assess the risk of osteoporotic fractures is the dual-energy 
X-ray absorptiometry (DXA).  Since the early 1990s, osteoporosis has been defined as a T-
score of -2.5 or less performed at the lumbar spine, femoral neck, total hip, or one-third 
radius sites (Baim, 2011; National Osteoporosis Foundation, 2010; World Health 
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Organization, 1994).  The findings of several large epidemiologic studies that the majority of 
low-trauma fractures occur in women in the osteopenic range compared with those in the 
range of osteoporosis (Pasco, J. A. et al. 2006; Sornay-Rendu, E., Munoz, F., Garnero, P., 
Duboeuf, F., & Delmas, P. D., 2005; Wainwright, S. A. et al., 2006).  Due to the important 
role that T-Scores play in determining the course of treatment related to fracture risk, this 
researcher grouped these data again; this time according to T-Scores.  When grouped in this 
manner, the CASE group was comprised of patients with T-Scores less than -1.0.  None of 
these patients had a T-Score below -2.5, but all had T-scores between -1.0 and -2.5, which 
categorizes them as osteopenic.  The remaining seven patients had T-scores greater than -1.0, 
categorizing them as normal.  When the data were grouped in this way, the means of the two 
groups were not found by independent t-tests to be significantly different.  From this, it can 
be concluded that the presence of a non-traumatic fracture reflects a decrease in myogenic 
differentiation more accurately than a T-Score in the osteopenic range.  The clinical goal, 
however, is to accurately forecast the risk of fracture rather than to treat it after is has 
occurred.  Evidence uncovered in this portion of the dissertation study indicates that the 
determination of fracture risk, and therefore, the proper course of treatment for aging 
patients‘ needs to be based on more than just bone mineral density (BMD) as reflected by T-
Scores.   
With the revelation that BMD, as reflected in DXA scan T-Scores, is not the 
definitive measure of fracture risk, the WHO Fracture Risk Assessment Tool (FRAX) was 
developed (McCloskey, 2009).  In addition to T-Scores, this tool includes a number of 
parameters to calculate a patient‘s 10-year probability of fracture including age, gender, and 
body mass index, family history of hip fracture, smoking, alcohol intake, and rheumatoid 
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arthritis.  As more information is uncovered about the biochemical relationship between 
bones and muscles, it may be prudent to begin to include in the list of parameters a measure 
of the patient‘s muscle mass and strength.   
Intracellular Calcium Homeostasis 
Skeletal muscle uses calcium (Ca
2+
) as an important regulatory and signaling 
molecule.  Fluctuations in intracellular Ca
2+
 determine to a large degree the force and speed 
of muscle contraction.   It is for these reasons that calcium imaging was employed as one of 
the methods to evaluate the impact of different serum samples on the function of 
differentiated HSMM cells.  Within skeletal muscle cells, through the process of excitation-
contraction coupling (ECC), depolarization of the external membrane and T-tubules lead to 
the release of Ca
2+
 from the sarcoplasmic reticulum (SR) into the cytosol.  This release of 
Ca
2+
 overwhelms the contractile myofilaments, myosin and actin, and leads to the induction 
of muscle contraction.  Key to this process is the ryanodine receptors (RyR1), which serve as 
gatekeepers to the release of Ca
2+
 from the SR.   For the calcium imaging experiments in this 
study, a solution of 20mM caffeine was introduced to the cells to sensitize the RyR1 to Ca
2+
 
and to trigger SR Ca
2+
 release from the SR into the cytosol that can be accurately measured 
by the ratiometric dye Fura-2.  From these calcium-imaging experiments, data on the 
intracellular calcium homeostasis were collected as resting levels, peak levels, time to peak, 
and calcium transients. 
When the data gathered were grouped according to fracture status, the means of the 
two groups were not found by independent t-tests to be significantly different with regard to 
resting intracellular calcium level, peak intracellular calcium level, time to peak, or calcium 
transients, as measured by area under the curve.  This analysis would seem to indicate that, 
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while factors present in the serum of patients with osteoporosis do influence the myogenesis 
of skeletal muscle cells, they do not affect the function of those cells.  However, when the 
data gathered from calcium imaging were grouped according to T-Scores, the two means 
were significantly different with regard to resting intracellular calcium levels (100 vs 80nM 
in CNTRL vs CASE), peak intracellular calcium levels (~300nM vs ~260nM in CNTRL vs 
CASE), and calcium transients.  The T-Score status CNTRL group mean had higher resting 
and peak levels, as well as higher calcium transients than the T-Score status CASE group 
mean.  This would appear to contradict the indication of the first analysis.  When the calcium 
imaging data were grouped according to T-Scores, it would appear that factors in the serum 
do affect the function of skeletal muscle cells.  One observation that can be made from these 
two analyses of the data would again be that the parameters of T-Scores and fracture status 
are not consistent in their reflection of bone and muscle health; at least with regard to the 
intracellular calcium homeostasis of skeletal muscle cells.  The T-Scores reflect the density 
of bones, which may be a good surrogate for calcium measurements.  
Much has been learned about the role of intracellular calcium in the health and 
function of skeletal muscles.  Recent research demonstrated in murine myoblasts that the 
inhibition of calcium channels, and therefore a decrease in intracellular calcium levels, 
inhibits myoblast differentiation (Porter, Makuck, & Rivkees, 2002).  This is supported by 
the data from this dissertation study, which when grouped according to fracture status, 
revealed a significant difference in fusion index, or myogenic differentiation.  The resting 
and peak intracellular calcium levels were also lower with this group, and although not 
significantly different when grouped according to fracture status, may provide a partial 
explanation for the decline in myoblast differentiation.  These data support the research that 
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demonstrated a correlation between a decrease in intracellular calcium level and myoblast 
inhibition.   
  It is generally accepted that aging brings with it a reduction in size and number of 
muscle fibers, especially Type II (fast-twitch) muscle fibers (Andersen, 2003; Deschenes, 
2004).  Research has also shown that the amount of calcium that is released in fast twitch 
muscle fibers is three-to four-fold greater than the amount released in slow twitch fibers 
(Baylor & Hollingworth, 2012).  It would then follow that with aging skeletal muscle cells 
would experience a decrease in the amount of resting intracellular calcium.  This is consistent 
with the data obtained from this dissertation study, and significantly when these data were 
grouped according to T-Score status.    
While many factors impact the aging of skeletal muscle, recent research has 
demonstrated, in murine models, that mitochondrial dysfunction, oxidative stress, and 
impaired RyR1 may all play a role in age-related muscle weakness (Andersson, et al., 2011; 
Berchtold, Brinkmeier, & Muntener, 2000).  Of special clinical significance, researchers have 
also come to believe that the magnitude of the Ca
2+
 released from the SR is related to the 
force of contraction (Berchtold, Brinkmeier, & Muntener, 2000; Capes, Loaiza, & Valdivia, 
2011).  The data obtained in this dissertation study suggest that the group with lower 
intracellular calcium levels would be the group with decreased muscle strength and increased 
risk for injury.  An additional layer to this physiologic conundrum is that calcium also 
regulate/modulate genetic function, and therefore may be influencing many signaling 
pathways.  The overall calcium transient in the control group was characterized by higher 
resting level, higher peak, and higher post-peak levels of calcium.  Thus, calcium-induced 
gene regulation may be enhanced in the control group as compared to the case group. 
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Additional research is needed to better understand the role of intracellular calcium 
homeostasis in skeletal muscle cell function, bone density, and the overall health of the aging 
patient. 
Cell Cycle Analysis 
As myoblasts proliferate, they proceed through the two phases of the cell 
cycle:  interphase and mitosis.  G1 is the first and typically, the longest part of interphase, as 
components of the cell grows.  A sub-portion of this is the G0 phase, for those cells in G1 
that are not ready to progress along the cell cycle.  Cells in the G0 phase are in holding 
pattern.   The second part of interphase is the S phase, during which DNA is duplicated.  The 
third and final portion of interphase is the G2 as cells ready themselves for mitosis.  The 
shorter phase of the cell cycle is mitosis, during which the cells divide.  Myoblasts 
continually travel through this process as they proliferate and until they enter differentiation.   
Flow cytometry was performed using the MUSE™ Cell Analyzer for HSMM cells 
treated with media containing 1% of each of the serum samples.  One of the features of the 
MUSE™ Cell Analyzer is a graphic representation of the DNA content of each 
run.  Although myocytes exit the cell cycle when they enter differentiation, it was believed 
that the myotubes, or differentiated cells, would be observed along the far right of the graph, 
having increased DNA as the myocytes fuse together to form myotubes.   
Data were collected and then analyzed to evaluate the differences between the CASE 
and CNTRL groups with regard to the number of cells in each phase of the cell cycle as well 
as the magnitude of DNA content.  The data were grouped and independent t-tests were 
performed to compare the group means.  Whether the data were grouped according fracture 
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status or T-Score status, there was no significant difference observed between the group 
means.   
With regard to the DNA Content Profile, it was expected that an increased amount of 
myogenic differentiation would be reflected in a greater number of cells toward the far right 
of the graph, representing the increased DNA content associated with myotubes.  
Unfortunately, the graphic representation of DNA Content Profile provided a limited range 
of DNA content index along the x-axis.  For this reason, the amount of DNA content 
exceeded the limits of the scale provided, thus there was no evidence of it on the graph.  It is 
believed that more myotubes would have been represented, had it been possible to expand 
the range of the horizontal axis.  Until this technical issue is resolved, the use of Flow 
Cytometry for cell cycle analysis will be limited to research focused on myoblast 
proliferation.   
Limitations 
One of the limitations of this preliminary study was the inability to match perfectly 
the profiles of patients from case and control groups.  As described, the participants were 
matched according to age, gender, and general health.  However, for this dissertation study, 
there was no match for environmental and other potentially confounding factors such as 
nutritional intake, genetic profiles or emotional status.  Health of bones and muscles are 
dependent upon multiple variables, and the more variables that can be examined in studies, 
the greater the likelihood of clarifying the magnitude of the impact each variable has on 
patient outcomes.   
The World Health Organization (WHO) has established criteria for making a 
diagnosis of osteoporosis based upon bone mineral density as determined by DXA scan 
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results, or T-Scores.  Patients with T-Scores that fall below -2.5 are diagnosed as 
osteoporotic; those with T-Scores between -1.0 and -2.5 are diagnosed with osteopenia; and 
those with T-Scores greater than -1.0 are considered normal.  Another potential limitation of 
this dissertation study is that none of the serum samples included in this study was from 
patients with T-Scores below -2.5, or according to the WHO definition, osteoporotic.  It 
would be interesting to repeat these experiments with the CASE group comprised of patients 
who had not only experienced a non-traumatic fracture, but who also had evidence of 
osteoporosis based upon DXA scan results.   
Although the serum samples are collected in vivo, another limitation of this proposed 
study was that the experiments will be performed in vitro.  The behavior of cells is altered 
when in vivo due to dynamic conditions of the individual and their environment.  These 
dynamic conditions cannot be replicated in the setting of a cell culture.  Additionally, two of 
the three phases of this study supported the hypothesis that myogenesis is impacted by 
factors present in the serum of patients with and without osteoporosis.  No specific 
information was collected that clearly identified which the factor(s) altered the samples.  
Thus, additional studies will need to be performed to determine this.   
Future Directions 
Data collected in this study will contribute to the growing body of knowledge related 
to bone-muscle interactions.  Insight was gained into the differing effects of serum from 
patients with and without osteoporosis on human skeletal muscle cell differentiation and 
function.   In addition to repeating Phases I and II of the study, this researcher is interested in 
performing a factor analysis of elements that have shown to increase the aging patient‘s risk 
for injury.  Elements such as age, gender, level of activity, body mass index (BMI), T-Score, 
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muscle strength as measured by grip strength, medication profile and co-morbidities.  It will 
also be essential to identify genes/proteins that are responsible for the effects observed by the 
serum samples of patients with osteoporotic fractures, since they could lead into new 
therapeutic targets to perhaps treat both osteoporosis and sarcopenia.  
The ultimate goal of this research is at least two-pronged:  first, to accurately identify 
those who are at greatest risk for fractures and other injuries that are so often the 
consequence of aging, and second, to identify biochemical factors that influence bone and 
muscle health.  In so doing, interventions can be developed to make a meaningful difference 
in the quality of life for each member of our aging population.   
Observations made throughout this study support the biochemical communication 
that exists between bones and muscles.  However, the observations made have also led to 
more questions.  For example, with regard to myogenic differentiation, what specific 
signaling pathways are involved that lead to muscle wasting and/or a decline in muscle repair 
with aging?   What is the role of satellite cells in this process?  What activities or exercises 
could reduce muscle wasting with age?  Moreover, with regard to intracellular calcium 
homeostasis, what level of intracellular calcium correlates with optimal function of skeletal 
muscles cells?  At what point is an increased resting level of intracellular calcium due to 
impaired myogenesis, and when is it the result of defective release from the SR?  
Additional studies will also need to be performed related to changes that occur in 
bone-derived factors with aging, comparing the effect on myogenesis in human skeletal 
muscle cells of serum collected from patients ranging from young adults (20 to 40 years of 
age), from middle-aged adults (41 to 65 years of age), and from older adults (age 65 and 
older).  That information would provide additional insight into the bone-muscle crosstalk, 
 
 
93 
and the degree to which age versus disease (e.g. osteoporosis) impacts human skeletal muscle 
formation and function.   
Further research opportunities exist in the expansion of this work to include other 
tissues in the bone-muscle unit: cartilage, ligaments, and tendons.  Advances are being made 
in these areas, but are becoming even more important to bridge the gap between bench 
research and clinical practice.  The dynamic and ongoing interplay between bones and 
muscles must be embraced and inculcated into all aspects of biomedical research, if it is to 
translate into meaningful therapeutic and preventive approaches to patient care. 
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Appendix B 
List of Identified Factors:   
Exploring the biochemical relationship between bones, muscles and other tissues. 
 
Factor Full Name/ 
Abbreviation 
Tissues/ Cells 
Secreted From 
 
Actions/ Information References 
Adiponectin adipocytes 
Secrete > 50 
adipokines! 
The only known adipokine 
that is downregulated in 
obesity. 
 
Positively influences insulin 
sensitivity. 
 
Low plasma levels used as 
an indicator/ predictor of 
insulin resistance and 
diabetes. 
 
Possibly an autocrine 
regulator of adipocytes 
secretion? 
 
Sell, Dietz-Schroeder & 
Eckel, 2006 
Adenosine triphosphate/ 
ATP 
osteocytes 
 
―molecular currency‖ 
 
transports chemical energy 
within cells for metabolism 
 
 
Brain-derived 
neurotrophic factor/ 
BDNF 
Myocytes Plays a role in peripheral 
metabolism, myogenesis 
and muscle regeneration. 
 
Levels of this protein 
increase with exercise. 
 
Matthews et al., 2009 
 
 
 
Sakuma & Yamaguchi, 
2011 
Dickkopf-related/ 
DKK-1 
 
osteocytes  
 
Inhibits the Wnt signaling 
pathway. 
 
Elevated levels of this 
protein in bone marrow, 
plasma and peripheral blood 
are associated with 
osteolytic bone lesions in 
patients with multiple 
myeloma. 
 
One of the most up-
regulated proteins in 
androgen-potentiated 
balding. 
 
In humans, is encoded by 
the DKK1 gene. 
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Dentin matrix acid 
phosphoprotein 1/ 
DMP-1 
Found in bone 
and tooth tissue 
An extracellular matrix 
protein; critical for the 
mineralization of bone and 
dentin. 
 
Diseases associated with 
this protein include 
osteomalacia and rickets. 
 
 
Chemokine CXC motif 
ligand-1/ CXCL-1 
 
(also known as 
keratinocyte-derived 
chemokine/ KC) 
 
Myocytes Exercise induces a six-fold 
increase in mRNA and a 2.4 
fold in serum. 
Pedersen, Olsen, 
Pedersen, & Hojman, 
2012 
Free fatty acids/ FFA  Become elevated in non-
adipose tissue in obesity. 
 
 
Lipotoxic effects on skeletal 
muscle and other peripheral 
tissues (Sell, 2006) 
 
Interfere with insulin 
signaling in skeletal muscle 
as the level of IRS-1 serine 
phosphorylation 
 
 
Fibroblast growth factor 
23/ FGF-23 
osteocytes 
 
 
osteoblasts and 
osteoclasts – in 
response to 
calcitrol 
Regulates phosphorous and 
vitamin D metabolism 
 
Regulation of serum 
phosphate levels;  site of 
action is the kidneys 
 
Bonewald & Wacker, 
2012 
 
Shimada et al., 2004 
Yamashita et al., 2000 
Interleukin-5 
 
Myocytes Role in muscle fat 
crosstalk? 
Pedersen, Akerstrom, 
Neilsen & Fischer, 
2007 
 
Interleukin 6/ IL-6 adipocytes 
 
 
 
myocytes  
Pro-inflammatory cytokine 
 
Biomarker for low grade 
inflammation; Upregulated 
in obesity 
 
Increases with exercise. 
Increases insulin sensitivity 
in skeletal muscle cells. 
Activates lipolysis in 
adipose tissue 
 
 
 
 
Duzova, 2012 
Interleukin-7/ IL-7 
 
myocytes Role in satellite cell 
recruitment in muscle 
regeneration 
Pedersen, Akerstrom, 
Neilsen & Fischer, 
2007 
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Interleukin-15/ IL-15 
 
myocytes  Alters muscle protein 
metabolism. 
 
In rodents, influences lipid 
partitioning by limiting free 
fatty acid uptake and 
favoring oxidations – 
resulting in the reduced 
mass of white adipose 
tissue. 
 
Increases adiponectin 
secretion in 3T3 adipocytes. 
 
 
Leptin adipocytes Crucial role in regulation of 
body weight.  Increases 
insulin sensitivity 
Impairs action of insulin in 
hepatocytes, adipocytes and 
myocytes in vitro. 
 
 
Leukemia inhibitory 
factor/ LIF 
 
myocyte Associated with increased 
myocyte differentiation 
after injury 
Kurek, Bower, 
Romanella, Koentgen, 
Murphy, & Austin, 
1997 
Monocyte chemotactic 
protein/ MCP-1 
 
monocytes 
endothelial cells 
adipocytes 
 
 
Can induce insulin 
resistance in adipocytes and 
myocytes. 
 
Elevated expression of 
MCP-1 is believed to 
increase the inflammatory 
processes in heart and 
arteries. 
 
 
Matrix extracellular 
phosphoglycoprotein/ 
MEPE 
osteocytes Regulation of phosphate 
homeostasis and 
mineralization 
 
 
Nitric oxide/ NO osteocytes 
 
Increased production is 
associated with rheumatoid 
arthritis, inflammation 
 
Pro-inflammatory cytokines 
such as IL-1 and TNF cause 
activation of the iNOS 
pathway in bone cells and 
NO derived from this 
pathway potentiates 
cytokine and inflammation 
induced bone loss.  
 
Relevant to the pathogenesis 
of osteoporosis in 
inflammatory diseases such 
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as rheumatoid arthritis, 
which are characterized by 
increased NO production 
and cytokine activation. 
 
Neurtrophin-3/ NT-3; 
NT-4/5 
Myocytes Protein growth factor 
known to have activity with 
neurons of the central 
nervous system 
 
 
Osteoprotegerin/ OPG osteocytes 
 
Traffic regulator of RANKL 
– possibly as a decoy 
receptor? 
 
Critical for 
osteoclastogenesis. 
  
 
osteocalcin 
 
(also known as the bone 
gamma-
carboxyglutamate acid-
containing protein/ 
BGLAP) 
osteoblasts Involved in regulation of 
metabolism 
 
Acts on beta cells of 
pancreas to secrete insulin 
 
Acts on fat cells to secrete 
adiponectin 
 
Possible role in male 
fertility? 
 
In humans, encoded by the 
BGLAP gene 
 
Karsenty, Gerard, & 
Wagner, 2002 
Prostaglandins/ PG 
Especially E- and F-
series (PGE and PGF) 
osteocytes 
myocytes 
Bone homeostasis 
Inflammation 
Pain mediation 
Platelet aggregation 
Smooth muscle contraction 
 
Agas, Marchetti, 
Hurley, & Sabbieti, 
2013 
Receptor activator of 
nuclear factor kappa-B 
ligand/ RANKL 
 
(also known as tumor 
necrosis factor ligand 
superfamily member 
11/ TNFSF11) 
 
(also known as TNF-
related activation-
induced cytokine/ 
TRANCE)  
 
(also known as 
osteoprotegerin ligand/ 
OPGL)  
 
osteocytes 
 
A protein that in humans is 
encoded by the TNFSF11 
gene. 
 
Found on osteoblasts; 
critical for activation of 
osteoclasts. 
 
Overproduction is 
associated with bone 
degenerative diseases, such 
as rheumatoid arthritis; 
osteoporosis 
Karsenty, Gerard, & 
Ferron, 2012  
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(also known as 
osteoclast 
differentiation factor/ 
ODF) 
 
  
Retinol-binding protein/ 
RBP-4 
adipocytes Contributes to insulin 
resistance in vivo. 
 
 
Sclerostin osteocytes Inhibition of bone 
formation. 
 
Winkler et al., 2003 
 
Tissue growth factor / 
TGFα 
myocytes Secreted by injured skeletal 
muscle 
Kurek, Bower, 
Romanella, Koentgen, 
Murphy, & Austin, 
1997 
Li & Huard, 2002 
 
Tissue growth factor 
1/ 
TGFβ1 
myocytes Secreted by injured skeletal 
muscle 
Kurek, Bower, 
Romanella, Koentgen, 
Murphy, & Austin, 
1997 
Li & Huard, 2002 
 
Tissue inhibitor of 
metalloproteinases/ 
TIMP-1 
adipocytes May play a role in 
maintaining adipose tissue 
mass in obesity? 
 
 
Tumor necrosis factor/ 
TNFα 
Adipocytes 
 
 
 
 
 
 
 
 
 
myocytes 
Biomarker for low grade 
inflammation; Upregulated 
in obesity 
Induces insulin resistance in 
hepatocytes and adipose 
tissue in vitro. 
 
 
 
 
 
 
Dyck, et al., 2011 
 
 
 
 
 
Castellano, V., 2006 
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Appendix C 
HSMM Protocols 
PROTOCOL C1:  Media Preparation, Skeletal Muscle Growth Media-2 
 
Gather supplies 
 SkGM™-2 Basal Medium 
 SkGM™-2 SingleQuots™ Kit (Catalog # CC-3244), which contains 
o human Epidermal Growth Factor (hEGF) (0.5ml) 
o Dexamethasone (0.5ml) 
o L-glutamine (10ml) 
o Fetal Bovine Serum (FBS) (50ml) 
o Gentamicin/ Amphotericin-B (GA) (0.5ml) 
 Pipettes 
 
Working in the cell culture hood and observing aseptic technique,  
1. Spray external surfaces of all vials, medium bottle and reagent bottles with 70% ethanol. 
2. Using pipette, transfer contents of the SkGM™-2 SingleQuots Kit to the SkGM™-2 Basal 
Medium 
3. Rinse the vial with medium to recover as much of the contents as possible. 
4. Transfer the label provided to the Basal Medium bottle, taking care not to obscure the lot # 
and expiration date. 
5. Store in 4° C refrigerator. 
 
 
PROTOCOL C2: Thawing of HSMM Cells/ Initiation of Culture Process  
 
The recommended seeding density for HSMM is 3500 cells/cm
2
.  Therefore, to thaw a cryovials 
containing > 500,000 cells, I will use two (2) T75 flasks, since each T75 flask would accommodate 
approximately 250, 000 cells (3500 cells/cm
2
 X 75 cm
2
 =262,500 cells) 
 
Also, the manufacturer recommends the appropriate amount of medium to be 1ml/ 5 cm
2
, so for each 
T75 flask, I will plan to use 15ml (1ml/5cm
2
 X 75 cm
2
 = 15ml) 
 
One last point to note:  the manufacturer reports that centrifugation should not be performed to 
remove cells from the ―cryoprotectant cocktail,‖ as this action is more damaging than the effects of 
DMSO residue in the culture. 
 
Gather supplies 
 Cryovial (Normal HSMM, >500,000 cells; Catalog # CC-2580) 
 T75 flasks (2) 
 Skeletal Muscle Growth Medium-2 
 Pipettes 
 Beaker for discard  
 
Working in the cell culture hood and observing aseptic technique,  
1. Spray external surfaces of all vials, medium bottle and reagent bottles with 70% ethanol. 
2. Transfer 15 ml of the Skeletal Muscle Growth Medium-2 into each of two T75 flasks. 
3. Place in incubator at 37° C and 5% CO2. 
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4. In the cell culture hood, briefly twist the cap of the cryovials a quarter turn to relieve 
pressure, and then retighten. 
5. Thaw cryovials in a 37° C warm water bath, taking care not to submerge the vial.  
(Note:  thawing the cells for longer than 2 minutes may yield less than optimal results)  
As soon as ice crystals disappear, swab the outside of the vial with 70% ethanol. 
6. Resuspend the cells in the cryovial, gently pipetting up and down to distribute evenly. 
7. Using a pipette, transfer half the contents of the cryovial into each of the T75 flasks. 
8. Gently rock the flasks to evenly distribute the cells and return to the incubator at 37° C and 
5% CO2. 
9. Let cells recover for 16 hours in the incubator at 37° C and 5% CO2 for 16 hours. 
10. The next morning, aspirate out the diluted DMSO-containing shipping cryopreservation 
medium from the cell layer and discard. 
11. Add 15 ml Skeletal Muscle Growth Medium-2 into each of two T75 flasks. 
 
 
PROTOCOL C3:  Subculturing HSMM cells 
 
Subculture the cells when they are 50% to 70% confluent. 
 
Gather supplies 
 Solutions 
a. Dulbecco‘s Phosphate Buffered Saline (DPBS) 
b. Trypsin/ EDTA 
c. Trypsin Neutralizing Solution (TNS) 
d. SkGM-2 Growth Medium 
 15ml conical tube(s) 
 Culture vessel(s) of choice:  T75 flasks, six-well plates, optic dishes 
 Pipettes 
 Beaker for waste 
 
1. Propagate cells until they reach 50% to 70% confluence. 
2. Allow solutions to come to room temperature. 
a.  Dulbecco‘s Phosphate Buffered Saline (DPBS) 
b. Trypsin/ EDTA 
c. Trypsin Neutralizing Solution (TNS) 
d. SkGM-2 Growth Medium 
3. Aspirate and discard medium from T75 flask. 
4. Wash cells with 15 ml DPBS. 
5. Aspirate and discard DPBS wash. 
6. Cover cells with 2 ml of Trypsin/ EDTA solution. 
7. Incubate for 2 to 6 minutes at 37°C and 5% CO2. 
8. Examine cells using microscope.  When ~ 90% of cells are rounded up, rap the flask against 
the palm of hand to release majority of cells from the surface of the flask.  
9. Add 4 ml Trypsin Neutralizing Solution.   
10. Using pipette, wash the bottom of the flask several times. 
11. Quickly transfer contents to 15 ml conical tube. 
12. Rinse flask with 2 to 5 ml of PBS, add this to 15 ml conical tube. 
13. Observe harvested flask under the microscope to assure fewer than 5% of cells left behind 
Centrifuge at 220 x g for five (5) minutes.  
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NOTE:  The centrifuge we use has a radius of 8 cm, therefore, using the G-Force to  rpm 
conversion calculator retrieved from:  http://www.geneinfinity.org/sp/sp_rotor.html  
 
220 x g = 1569 rpm 
 
14. Aspirate and discard the supernatant, leaving 100 to 200 µL  
15. Flick the tube to loosen the pellet 
16. Dilute the cells to a final volume of 2 to 5 ml of growth medium, pipetting up and down 
gently to ensure uniform suspension.  (be certain to note the total volume of the diluted cell 
suspension) 
17. After performing cell count, prepare flasks/ plates/ dishes in which to transfer/ seed the cells. 
18. Carefully transfer growth medium to new culture vessels by adding 1 ml/ 5 cm2 surface area 
of the flask (e.g. Add 15ml growth medium to each  T75 flask; or 2ml/well of a 6-well plate)  
19. Plate the cells at the recommended seeding density of 3500/ cm2.  (e.g. 35K/ well in a 6 well 
plate or optic dish) 
 
PROTOCOL C4:  Cryopreservation of HSMM cells 
 
Clonetics™ HSMM Cryopreserved cultures are assured for experimental use for 10 population 
doublings.  I would like to store as many cells as possible from the initial purchase of 1 cryovial, 
containing > 500,000 cells. 
 
Desired Volume of 
Cryopreservation 
Media 
 
Base Media DMSO FBS 
Clonetics™ (Lonza) 
suggestions 
70% SkGM-2  
base media 
 
10% DMSO 
 
20% FBS 
 
20ml 
 
14ml 2ml 4ml 
10ml 
 
7ml 1ml 2ml 
5ml 
 
3.5ml 0.5ml 1ml 
 
Gather supplies 
 Solutions: 
a. Dulbecco‘s Phosphate Buffered Saline (DPBS) 
b. Trypsin/ EDTA 
c. Trypsin Neutralizing Solution (TNS) 
d. SkGM-2 Growth Medium 
e. Cryopreservation Medium components 
 Filters, 0.2micron  
 15ml conical tube(s) 
 Cryovials 
 Styrofoam or propanol freezing canister 
 Pipettes 
 Beaker for waste 
 
1. Prepare the cryopreservation media as described in the Table above. 
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2. Sterile filter the cryopreservation media using a 0.2 micron filter. 
3. Harvest and centrifuge cells to pellet. (see Protocol C:  Sub culturing HSMM cells) 
4. Aspirate and discard supernatant. 
5. Resuspend cells in cold cryopreservation media at 500,000 cells/ml 
6. Pipette aliquots of 1ml each into cryopreservation vials and seal. 
7. Place in styrofoam or propanol freezing canister (?) 
8. Store the cells at -80° C overnight 
9. Within 12 to 24 hours, place cells in liquid nitrogen for long-term storage. 
 
 
PROTOCOL C5:  Differentiation to Form Myotubes  
 
Gather supplies 
 T75 flasks with HSMM cultured to approximately 50% to 60% confluence. 
 Fusion Medium 
DMEM: F-12 supplemented with 2% horse serum 
 
Total Volume DMEM Horse Serum 
 
500ml 
 
490ml 10ml 
250ml 
 
245ml 5ml 
100ml 98ml 2ml 
 
50ml 49ml 1ml 
 
 
 Beaker to receive discarded medium 
 Pipettes 
 
Working in the cell culture hood and observing aseptic technique,  
1. Spray external surfaces of all vials, medium bottle and reagent bottles with 70% ethanol. 
2. Remove the growth medium and discard. 
3. Replace with an equal volume of Fusion Medium (DMEM F-12 supplemented with 2% horse 
serum) 
4. Replace with fresh Fusion Medium every other day for about 3 to 5 days or until myuotubes 
are observed throughout the culture.   
 
NOTE:  If the myotubes are to be used in assays that require an extended period in culture, 
following differentiation, remove the fusion medium and add growth medium.  For best 
performance, replace growth medium every other day to maintain the culture for ~2 to 3 weeks 
post differentiation.  Myotube cultures are best used by 2 weeks post differentiation. 
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Appendix D 
Protocol:  HSMM, Immunostaining for Fusion Index Calculations 
Fixation of cells 
1. Working in the chemical hood, discard media from wells. 
2. Gently add 2ml PBS to each well, adding slowly at the side of the well.   
3. Incubate at room temperature for 5 minutes 
4. Repeat for a total of three (3) washings with PBS. 
5. Fix cells by adding 1ml/well of 10% NPF (Neutral Buffered Formalin) 
6. Incubate at room temperature for 7 to 8 minutes (Do not exceed 10minutes!) 
7. Discard 10% NPF in special container in chemical hood. 
8. Gently add 2ml PBS to each well, adding slowly at the side of the well.   
9. Incubate at room temperature for 5 minutes 
10. Repeat for a total of three (3) washings with PBS, making certain all the NBF is 
removed. 
 
NOTE:  If not staining immediately, may store cells by adding 2ml/well of 70% 
ETOH; wrap the plate in saran wrap and store in chemical hood at room temperature. 
 
Staining of cells, (Solution Preparation for two (2) six-well plates) 
 
Prepare 0.1% Trition X -100 from the 100% Triton stock: 
 
  C1V1     =  C2V2 
100V1     =  0.1(30ml) 
        (0.03ml)V1   =  30µL of 100X Triton 
Therefore, add 30 µL of 100X Triton to 29.97 ml PBS for a total of 30 ml 0.1% Triton X-
100. 
NOTE:  Take care to aspirate Triton very slowly, as it is incredibly viscous and 
difficult to work with.  Also, mix slowly with PBS for the same reason. 
Working in the cell culture hood, transfer 29.97 ml PBS into a 50 ml Conical tube.  Then, 
moving to the PTI room, and working under red light, carefully withdraw 30 µL 100X Triton 
X-100.  It is extremely important to do this slowly to be accurate (d/t to the viscosity and 
surface tension of the Triton X-100).  Then, add this to the tube containing 29.97 ml PBS.  
Again, inject this slowly and rinse the pipette tip several times to remove as much of the 
Triton X-100 as possible. 
  
Prepare 1X TBST, which is PBS with 0.1% Triton and 0.1% Tween 
 
Prepare  12 ml of 1X TBST, anticipating 0.8ml / well for 12 wells. 
(TIP – I learned the importance of making a little extra to account for pipetting error, 
etc….) 
 
 
109 
 
The TWEEN I am using is 20 TWEEN, and Julian shared with me that I am to 
calculate it as it if is 100X—just like the Triton.  Therefore     
 
 12  µL 100X Triton 
               12  µL  40TWEEN 
    +   11976 µL PBS             . 
    12000 µL 1X TBST (12 ml, total of 1X TBST) 
 
 
To this, add 20 µL/ ml MHCAb;  20 µL/ml X 12 ml = 240 µL MHC Ab 
Remember to document the Lot# of the MHCAb used 
 
1. Permeabilization on the shaker, with 1ml/ well 0.1% TritonX-100 for 12 minutes (use 
setting 1 on the shaker) 
2. Repeat PBS wash steps – total of three times, incubating for 5 minutes each time at 
RT 
3. Stain the cells by adding just 800 µL of this MHCAb/ 1X TBST solution to each well.  
This should just cover the bottom surface of the well. Wrap the plate in foil and place 
of the shaker for 30 minutes. 
4. At 30 minutes, go back into the PTI room and, under red light, add 1 µL DAPI-1 
µg/µL (1:1000, or 10mg/ml)) to each well.  Mix solution well.  Cover again with foil 
and place on shaker for another 5 minutes on shaker. 
5. Wash cells three times in 1X PBS, working in red light. 
6. Add 2ml/well of 1X PBS and place on microscope for visualization/ photography. 
 
Taking photos of cells 
 Turned on components in order:  #2-fluorescent light source, #4 - microscope, #5 – 
camera attached to microscope, computer. 
 Clicked on µManager icon on Desktop 
 PTI-Config\Hamamatsu-PTI-Leica.cfg 
 OKAY 
 Select Multi channel, and make certain that DAPI and MHC are selected. 
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Appendix E 
Protocol:  HSMM, Calcium Imaging 
1. Remove media and discard. 
2. Turn the oven on allowing plenty of time for it to warm up to the desired 37°C. 
3. Wash three (3) times with 1 ml Ringers with 2.5mM Ca2+,  adding drops to side of the dish to 
avoid dropping fluid directly onto the cells.  Leave the last 1ml solution in dish while 
preparing Fura 2 solution. 
Note:  When working with the fluorescent dye, Fura-2AM, take care to only work in red 
light. 
4. Prepare the Fura 2 solution:  Add 500 µL Ringers with 2.5mM Ca2+ to a 1.5ml eppendorf 
tube.  Then add 4 µL of the Fura, pipetting up and down several times to mix.  Sonicate for at 
30 to 40 seconds to further mix.  Then add 500 µL Ringers with 2.5mM Ca
2+
 to the tube for a 
total of 1ml solution.  
5. Remove last wash of Ringers with Ca2+ from optic dish containing cells.  Then add Fura-2 
solution to the dish.  Cover completely with foil. 
6. Incubate in an oven preheated to 37°C for 30 minutes to allow the Fura time to enter the 
cytoplasm of the cells.  (See PTI System below for steps to turn on components at this time.) 
Note:  If cells are plated at high densities, increasing the loading period to 40-45 minutes 
would be helpful.  
7. After the 30-minute loading period, remove the Fura 2 solution and discard.  Wash three (3) 
times with 1 ml Ringers with 2.5mM Ca
2+
, to remove any residual Fura 2.  Leave the last 1ml 
solution in dish while preparing Fura 2 solution. 
8. Cover with foil and incubate at room temperature for 30 minutes for desterification.   
9. Just prior to removing dish from the oven, prepare BTS solution –  Add 1 ml Ringers with 
2.5mM Ca2+ to an eppendorf tube;  To this add 2µL of 10mM BTS (for a final concentration 
of 20µM) no need to sonicate this BTS preparation, simply mix using the pipette several 
times 
10. After the 30 minutes incubation at room temperature, still working in room with only red 
light, mount the dish on the microscope stage and locate area of interest at 10X magnification 
on TL PH.  
11. Once area is identified, increase magnification to 40X on TL PH, making sure myotubes are 
visible in field as well as an area to use for background. 
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PTI System 
 
 While the dish is incubating at room temperature for 30 minutes or more, it is a good 
time to turn on the PTI system, following the numbers on the red tape: 
 
#1 – Lamp Power Supply, waiting for it to reach 75 watts prior to  
#3 -- Xenon Lamp  
     (30K volts or 6 amps go to the lamp – so be certain to have everything else off when     
      this is turned on….);  
# 5 -- the power to the camera;  
#6 --  Photon Technology International;   Make certain it is switched to ‗C‘ and that the 
switch on the back of the microscope to ‗X‘ (turn knob to the right) 
#7 --  there is no #7 
#8 – only if you wish to use this board as your control for images (did not turn on) 
#9 – computer tower; the computer is the last one to be turned on to decrease the risk of a 
power surge to the computer. 
#11 controls the perfusion system that has been developed…. 
Computer: 
Select the PTI/Leica Programs icon on the Desktop.   
Click on the ―Easy Pro-Ratio‖ program, then  
Click on Fura-2 from the menu along the top of the screen.  
OK or continue. 
Select ‗Open Session/Template‘ as file type to open 
Go to E Drive  Janalee  Calcium Imaging 
Select drop down to select Template; Fura2.est will appear.  Open this file. 
*** Important*** save file in proper folder, and name file to include cell type, 
treatment, sample and date… 
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 Use the 10X magnification (TL PH or fluorescence) to find fibers – then, switch to 
40X before changing to Furo PH by depressing top button on right side of the 
microscope. 
 
Note:  To preserve the fluorescence, look for area in the dish using fluorescence setting on 
microscope.  Again, look first at 10X magnification – then change to 40X, adjust the focus, set 
the perfusion system and then pull the lever on the left side of the microscope to send the image 
to the computer screen.    Note the exposure – and keep it consistent between samples.  I like to 
focus on the grey scale palette and then select the green scale to run the imaging.  (The rainbow 
palette is helpful to identify areas that are overexposed.) 
 
 Pull the lever to direct the image to the computer screen; making sure the Shutter is 
open on the microscope. 
 Using the mouse, click on the ―R‖ for each column fura 350 (fura bound to calcium), 
fura 375 (unbound fura) and ratio.  Also highlight the bottom bar on each of these 
columns.  Then, when ready to get image to appear, click on small round icon to 
record.  Select ‗S‘ on 380 column. 
 Once the image is set, locate regions of interest (ROI) including one from the 
background.  Use polygon to identify tubes, and rectangle to identify background. 
 Click on the Run button to begin (blue arrow).   I like to toggle visibility of the fura 
350 and the fura 375 so that just the ratio is streaming on the graph.  I also toggle the 
visibility of the background ratio, once I determine there is a difference between that 
and the ROIs from within the cells/ fibers selected. 
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Appendix F 
Protocol:  HSMM, Flow Cytometry, MUSE™ Cell Cycle Assay 
 
Muse™ Product Specifications 
 
Input Cell Numbers  
 
• User selected; Cell concentration range of 10,000-500,000/mL (Craig 
recommends 300K to 500K/ml) 
 
Sample format  
 
• Single loader, <2 minutes per sample 
• Sample volume and number of cells counted can be specified 
 
Cell Types  
 
• Homogeneous or heterogeneous, 
suspension or adherent, primary cells 
or cell lines 
 
Cell Size • 2-60+ microns (μm) in diameter 
 
Data handling • Data analyzed on system, with USB export of graphs, CSV files, and 
raw data files 
 
 
Synchronize cells 
 
After seeding cells at appropriate density (35K/ well for six-well plates).  Allow to acclimate 
for 24 hours in SkGM-2 Growth Media, incubating at 37 °C and 5% CO2. 
 
Then,to synchronize the HSMM cells to G0/G1, prepare the SkGM-2 Growth Media with no 
hEGF (human epidermal growth factor) and with only 1% FBS.  The reason for omitting the 
hEGF, which is a component of SkGM-2, is due to the mitogenic role it plays.  Since I was 
hoping to ‗stall the cell cycle‘, it seemed prudent to withhold this component as well as 
providing only 1% FBS, compared to the 10% FBS that is normally present in the SkGM-2 
Growth Media.   
 
Working under the cell culture hood and observing aseptic technique, add the following to 
the 500ml of SkBM Basal Media: 
 10 ml L-Glutamine, Cat. #:  CC-4422W; Lot #:  0000428210; Expires, 25 Jul 2015 
 0.5ml Gentamycin Sulfate/ Amphotericin B, Cat. #: CC-4419W; Lot #:  0000428205; 
Expires, 29 Jul, 2015 
 0.5 ml Dexamethasone, Cat. #:  CC-4421W; Lot #:  0000428209; Expires, 24 Jul 
2015 
 5 ml FBS, Cat. # CC-4423W; Lot #:  0000428211; Expires, 25 Jul 2015 
 
Once the Synchronization Media is prepared,  
 remove and discard the media on the cells.   
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 wash the cells with DPBS. 
 add 2 ml of this SkGM-2 with only 1% FBS (Synchronization Media) to each well 
 incubate at 37 °C and 5% CO2 for up to 24hours (I left it on for 18 hours) 
 After incubation with Synchronization Media, remove and discard before adding 2ml 
SkGM-2 (with all components again) to cells. 
 
Grow cells to optimal myogenesis, DAY 6 or 7 following synchronization 
 
 
Preparing Fixative Solution 
 
Prepare fresh 70% ethanol.  NOTE: Due to the stability of 70% ethanol, it is recommended 
that fresh, cold 70% ethanol using high-grade absolute ethanol be prepared on the cell 
fixation day. 
 
1. Mix the cold absolute ethanol (200 proof) with cold DI water. See the following table 
for amounts. Store 70% ethanol at –20°C until use. Keep 70% ethanol on ice at all 
times during usage.  NOTE: It is essential to keep the fixative very cold for optimal 
fixation and high quality cell cycle resolution. 
 
2. Proceed to "Fixing Samples" in the following section. 
 
Fixing Samples 
It is important to have a single cell suspension prior to ethanol fixation. Otherwise, the 
ethanol fixation process will result in a high percentage of aggregated cells and/or debris, 
affecting the accuracy of your results. 
 
1. Transfer the cell sample to a 12 x 75-mm polystyrene tube or 15-mL or 50-mL 
conical tube (depending on the total cell number) if the cells are not already in a tube. 
The minimum recommended number of cells for fixation in a tube is 1 x 10
6
 cells. 
2. Centrifuge the tube at 300 x g for 5 minutes. 
3. Remove and discard the supernatant without disturbing the cell pellet.  After 
centrifugation, the cell pellet forms either a visible pellet or a white film on the 
bottom of the tube. 
4. Add appropriate volume of PBS to each tube (ie, 1 mL of PBS per 1 x 106 cells). Mix 
the cells well by pipetting several times or gently vortexing. 
5. Centrifuge the cells at 300 x g for 5 minutes. 
6. Remove and discard the supernatant without disturbing the cell pellet. Leave 
approximately 50 μL of PBS per 1 x 106 cells. 
7. Resuspend the cell pellet in the residual PBS by repeated pipetting several times or 
gently vortexing. 
8. Add the resuspended cells drop-wise into the tube containing 1mL of ice cold 70% 
ethanol while vortexing at medium speed. 
9. Cap and freeze the tube at –20°C for at least 3 hours prior to staining. Fixed cells are 
stable for 2 to 3 months at -20°C. 
10. Proceed to the "Staining Protocol" protocol in the following section. 
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Staining Protocol 
 
1. Obtain a uniform ethanol-fixed cell suspension for staining. For more information on 
cell preparation and fixation see "Cell Sample Fixation in Tubes" above and Cell 
Preparation section in Appendix A. 
NOTE: If cells appear to be in clumps, see “Troubleshooting”  page to determine 
how to proceed. 
2. Add 200 μL of ethanol-fixed cells to a 12 x 75-mm polystyrene test tube. The cell 
concentration should be between 5 x 10
5
 to 1 x 10
6
 cells/mL. 
NOTE: The manufacturer recommends using 12 x 75-mm polystyrene tubes to 
minimize cell loss. 
3. Centrifuge ethanol-fixed cells at 300 x g for 5 minutes at room temperature. 
4. Remove and discard the supernatant. 
5. Resuspend the cell pellet in 0.25 mL PBS per 5 x 105 cells. 
6. Centrifuge cells at 300 x g for 5 minutes at room temperature. 
7. Remove and discard the supernatant. 
8. Resuspend the cell pellet in 200 μL of Muse™ Cell Cycle Reagent. 
9. Incubate for 30 minutes at room temperature, protected from light. 
10. Transfer cell suspension sample to a 1.5-mL microcentrifuge tube prior to analysis on 
Muse™ Cell Analyzer. 
 
Prepare the Muse Cell Analyzer 
 
1. Make sure the tubes on the back of Muse are not pressed and/or squeezed up 
against anything  
a. Red bottle: waste, blue bottle: wash. 
 
2. Place flow cell (if using for the first time like during the training).  This should 
need to be replaced infrequently – only if it becomes clogged and none of the 
trouble shooting works to clear it or if it gets broken.  (Note:  there is an extra one 
of these that came with the system – just in case!) 
a. Open the lid on the top. 
b. Flip the notch on the left side. 
c. Make sure that the sample arm is down. 
d. Connect the fluid tube of the probe. 
 
3. On the touch screen, select ―Complete System Clean.‖ 
a. Need to run each time when we use Muse. 
 
4. Select, ―Run Complete Clean.‖ 
 
5. Place the Instrument Cleaning Fluid (ICF) in a 1.5 ml tube (without lid) till the 
top. Place the tube onto the sample holder.  The ICF is stored at RT in a green 
topped squeeze bottle on the counter next to the Muse Cell Analyzer. 
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6. Raise the sample arm. 
 
7. Click ―Run.‖ 
a. Make sure no bubbles in the flow cell tube of the probe (inside the lid). 
i. If bubbles are formed, it means that the solution is low, the 
connection screw is loose, or the tube is not intact. Continuous 
bubbles in ICF mean something is wrong. 
8. Run DI water (Craig suggested to use Nanopure H2O unless we can 100% trust 
DI H2O). 
a. Place Nanopure H2O in 1.5 ml tube (without lid) till the top. Place the tube 
onto the sample holder. 
 
9. Click ―Continue.‖ 
 
Priming 
 
1. Thaw system check beads & system check diluent (bring them to room temp). 
Mix well.  These are kept at 4 ° C in the common area in the refrigerator, in the 
Muse System Check Kit. 
 
2. Add 380 μl of diluent into 1.5ml centrifuge tube. 
 
3. Vortex beads. 
 
4. Add 20 μl of beads into the tube. 
 
5. Place the tube onto the sample holder. Raise the sample arm. 
 
6. Select ―System  Close  Run System Check.‖ 
 
7. Type: bead lot #, expiration date, and check code. 
 
8. Click ―Next.‖ 
 
9. Mix the tube by flicking the tube (or pipetting up/down). 
 
10. Click ―Close,‖ then ―Run.‖ 
 
11. Run 3 replicates. Each time mix the tube by flicking or pipetting up/down. 
 
12. If it says PASS, proceed to the samples 
<5%CV = ok. (Today, our %CV was 2.95%) 
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Sample preparation 
 
1. After the incubation, add 150 μl of diluted 7-AAD into each cell suspension tube. 
Mix by pipetting up/down, and then vortex. 
a. Can use dark color tube (so we don‘t need to wrap with foil). 
2. Incubate in dark (room temp, 5 min) by placing them in a drawer. 
3. During the incubation, place H2O tube in the tube holder.  
4. After the 5min incubation, click ―eject‖ and remove the H2O tube. 
5. Cut the lid of cell suspension tube off. 
6. Select ―test,‖ then ―run assay.‖ 
7. Flick and mix the sample. 
8. Place the tube on the tube holder. 
 
Clean up 
 
1. Select ―complete system clean.‖ 
2. Run ICF. 
3. Raise the sample arm, run. 
4. Place Nanopure H2O tube in the sample holder.  
a. Keep the probe in H2O. 
 
Saving the experiment 
 
 Option  save as current settings. 
o So next time we don‘t need to set up again (e.g. day 1, day 2…)  
o Next time, ―retrieve settings.‖ Select the previous setting, and ―run.‖ 
 
NOTES 
 To use Muse, ~15 min to start, ~10 min to finish cleaning up, and ~1 hour experiment 
(depends on # of experiments). 
 System check  clean - 
o Cap rinse – actually nothing it does.  
o Quick – DI H2O 
o Back flush – empty tube and flush ICF back 
o Complete – 10% bleach/DI H2O. 
 If flow tubes clogged, 
o Use syringe (that came with Muse) to flush out. 
o Flush the tube with 10% bleach using syringe. (Place bleach in a syringe, connect 
to the tube, flush). 
o Place the tip of probe in 10% bleach for overnight.   
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Appendix G 
Data Collected:  HSMM, Immunostaining for Fusion Index Calculations 
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Appendix H 
Data Collected:  HSMM, Calcium Imaging 
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Calcium Imaging, HSMM 
CNTRL A, 20140926 
 
Overview 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak  
Area 
CNTRL A, 
BG 
0.894929 
 
0.909999 
 
0.01507 
 
NA 359.27763 2.26281 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak  
Area 
CNTRL A, 
P1 
0.745651 
 
0.822826 0.077175 
 
8.051103 
 
303.67829 8.77822 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak Area 
CNTRL A, 
P3 
0.642623 
 
0.729303 
 
0.08668 
 
8.051103 
 
261.62826 8.44850 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
CNTRL A, 
P5 
0.727718 
 
0.822909 
 
0.095192 
 
8.051103 
 
289.47561 4.64138 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
CNTRL A, 
P6 
0.677588 
 
0.817368 
 
0.13978 
 
10.73468 
 
280.04012 10.08337 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
CNTRL A, 
P7 
0.682992 
 
0.803704 
 
0.120711 
 
8.051103 
 
276.90563 9.97577 
 
 
 
I do not plan to use data from this tracing, as the myotube must have moved out of range upon 
stimulation with the 20mM caffeine. 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the 
Curve 
 
Peak 
Area 
CNTRL A, 
P8 
0.759535 
 
0.805633 
 
0.046334 
 
Unable to 
measure 
NA NA 
 
Calcium Imaging, HSMM 
CNTRL C, 20140927 
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Overview 
 
 
 
 
 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
BG 
0.890472 
 
0.913951 
 
0.023479 
 
NA 356.60390 
 
3.30095 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P1 
0.609661 
 
0.736234 
 
0.126573 
 
8.051138 
 
257.70647 
 
14.94170 
 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P2 
0.634226 
 
0.708983 
 
0.074757 
 
4.025553 
 
255.36600 
 
5.91512 
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 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P3 
0.746669 
 
0.801659 
 
0.05499 
 
4.025553 
 
298.79073 
 
5.06828 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P4 
0.613649 
 
0.767619 
 
0.15397 
 
8.051138 
 
256.47530 13.59520 
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 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P5 
0.658719 
 
0.729933 
 
0.071214 
 
4.025553 
 
272.57786 
 
9.01723 
 
 
 
 
 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P6 
0.600577 
 
0.780981 
 
0.180404 
 
4.025553 
 
250.64563 
 
12.71607 
 
 
162 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
Peak Area 
CNTRL C, 
P7 
0.664071 
 
0.77412 
 
0.110049 
 
4.025553 
 
272.91870 
 
9.67276 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P8 
0.663004 
 
0.751822 
 
0.088818 
 
8.051138 
 
273.08709 
 
9.35460 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P9 
0.579244 
 
0.72626 
 
0.147016 
 
8.051138 
 
246.69825 
 
15.55078 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P10 
0.624523 
 
0.724571 
 
0.100048 
 
12.07676 
 
256.86649 
 
10.53180 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P11 
0.65709 
 
0.739034 
 
0.081944 
 
4.025553 
 
268.90175 
 
10.55403 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  597.13 
 
Peak Area 
CNTRL C, 
P12 
0.609097 
 
0.825425 
 
0.216327 
 
4.025553 
 
258.00132 
 
15.57382 
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Calcium Imaging, HSMM 
228, 20140926 
 
Overview 
 
 
 
 
 
 Average 
resting 
level 
 
Peak Δ Level Time to Peak Area Under the Curve  
Low X:  201.278 
High X:  598.467 
 
Peak  
Area 
228, 
BG 
0.895094 
 
0.904952 
 
0.009859 
 
NA 357.46819 0.93483 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.278 
High X:  598.467 
 
Peak 
 Area 
228, 
P1 
0.675183 
 
0.851763 
 
0.176581 
 
8.05102 
 
280.87457 12.45487 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
Peak  
Area 
228, 
P2 
0.704742 
 
0.761679 
 
0.056937 
 
10.73474 
 
283.54444 5.42949 
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 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.278 
High X:  598.467 
 
Peak  
Area  
228, 
P3 
0.713041 
 
0.808925 
 
0.095883 
 
5.367426 
 
287.54207 6.05005 
 
 
 
 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.278 
High X:  598.467 
 
Peak  
Area 
228, 
P4 
0.733512 
 
0.812356 
 
0.078844 
 
10.73474 
 
296.88430 5.36465 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.278 
High X:  598.467 
 
Peak  
Area 
228, 
P5 
0.680908 
 
0.76959 
 
0.088683 
 
10.73474 
 
281.00744 8.52524 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
228, 
P6 
0.712359 
 
0.798712 
 
0.086353 
 
10.73474 
 
292.45145 9.36121 
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 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.278 
High X:  598.467 
 
Peak  
Area 
228, 
P9 
0.757595 
 
0.825766 
 
0.068171 
 
Unable to 
detect 
306.23825 4.03008 
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368, 20140927 
 
 
Overview 
 
 
 
 
 
I did not keep this data on the Excel file – because I have so many other tracings of Background… 
 
 
171 
 
 
 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
368, 
P1 
0.647625 
 
0.719902 
 
0.072277 
 
2.683591 
 
264.36438 8.59591 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.28 
High X:  598.475 
Peak  
Area 
368, 
P2 
0.652673 
 
0.753595 
 
0.100921 
 
26.83716 
 
283.28749 16.96522 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
368, 
P3 
0.662877 
 
0.756867 
 
0.09399 
 
21.46966 
 
272.95525 9.88087 
 
 
 
 Average 
resting 
level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
368, 
P4 
0.719001 
 
0.809502 
 
0.0905 
 
8.050969 
 
293.23553 8.23952 
 
 
173 
 
 
Did not include in analysis, because this myotube drifted away upon contraction…. 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
368, 
P6 
0.614816 
 
0.679626 
 
0.064809 
 
18.78625 
 
249.88525 6.35996 
 
 
 
174 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
368, 
P7 
0.626432 
 
0.707148 
 
0.080716 
 
13.41884 
 
263.36239 11.40369 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak   
Area 
368, 
P8 
0.680316 
 
0.791707 
 
0.111391 
 
8.051455 
 
279.33024 8.59806 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
368, 
P9 
0.774037 
 
0.84717 
 
0.073133 
 
8.051455 
 
314.31274 6.49135 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
368, 
P10 
0.697172 
 
0.817674 
 
0.120502 
 
5.367265 
 
293.84289 11.49776 
Calcium Imaging, HSMM 
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380, 20140927 
 
 
Overview 
 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964  
High X:  601.158 
 
Peak  
Area 
380, 
BG 
0.925621 
 
0.932803 
 
0.007183 
 
NA 368.56308 0.42837 
 
 
 
177 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
380, 
P1 
0.664107 
 
0.738742 
 
0.074636 
 
16.10246 
 
272.12901 8.76775 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X: 601.158 
 
Peak 
Area  
380,  
P2 
0.663651 
 
0.703156 
 
0.039505 
 
21.46992 
 
262.43486 5.47867 
 
 
178 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X: 601.158 
 
Peak 
Area 
380,  
P3 
0.672032 
 
0.738216 
 
0.066184 
 
10.73498 
 
281.23388 13.00693 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X: 601.158 
 
Peak  
Area 
380, 
P4 
0.785737 
 
0.85455 
 
0.068813 
 
10.73495 
 
320.64774 5.60320 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
Peak 
Area 
380, 
P5 
0.636808 
 
0.742035 
 
0.105227 
 
10.73495 
 
263.47590 11.26519 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
380, 
P6 
0.672548 
 
0.807031 
 
0.134484 
 
10.73495 
 
289.37347 16.64545 
 
 
180 
 
 
 Average 
resting level 
Peak Δ Level Time to 
Peak 
Area Under the Curve Peak 
Area 
     Low X:  203.964 
High X:  601.158 
 
 
380, 
P7 
0.733344 
 
0.823623 
 
0.090279 
 
5.367451 
 
299.42321 7.77508 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area  
380, 
P8 
0.7236 
 
0.826956 
 
0.103356 
 
5.367451 
 
296.02820 9.56682 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
380, 
P9 
0.756679 
 
0.844523 
 
0.087844 
 
5.367451 
 
309.52542 8.40852 
 
 
I do not plan to include this data in my analysis, as it looks as though the myotube moved so that the 
ROI was no longer true…. 
 Average 
resting level 
Peak Δ Level Time to Peak Area Under 
the Curve 
Peak 
Area 
380, 
P10 
0.723359 
 
 
0.790576 
 
0.067218 
 
177.127 
 
  
 
 
182 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area  
380, 
P11 
0.753215 
 
0.827809 
 
0.074594 
 
5.367451 
 
301.12695 4.65324 
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Calcium Imaging, HSMM 
390, 20140927 
 
Overview 
 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  202.625 
High X:  598.475 
 
Peak  
Area 
390, 
BG 
0.904409 
 
0.913479 
 
0.00907 
 
NA 359.11677 0.80679 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area 
390,  
P1 
0.658304 
 
0.729773 
 
0.07147 
 
8.051234 
 
278.24481 12.71425 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area 
390,  
P2 
0.720274 
 
0.800628 
 
0.080354 
 
8.051215 
 
295.12265 8.26396 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve  
Low X:  202.625 
High X:  598.475 
 
Peak 
Area 
390, 
P3 
0.659591 
 
0.727412 
 
0.067821 
 
8.051215 
 
273.42330 9.23176 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area  
390,  
P4 
0.693513 
 
0.798951 
 
0.105439 
 
8.051215 
 
281.06191 7.02472 
 
 
186 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area  
390,  
P5 
0.682415 
 
0.825374 
 
0.142959 
 
8.051215 
 
280.27161 11.67871 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area  
390,  
P6 
0.702768 
 
0.783631 
 
0.080862 
 
14.75776 
 
292.71500 11.18713 
 
 
187 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak  
Area 
390,  
P7 
0.630656 
 
0.782134 
 
0.151478 
 
22.80899 
 
266.22273 15.33531 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area 
390,  
P8 
0.681262 
 
0.764354 
 
0.083092 
 
8.051215 
 
280.10416 10.15740 
 
 
188 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area 
390,  
P9 
0.655768 
 
0.788037 
 
0.132268 
 
8.051215 
 
271.21267 13.01252 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area 
390,  
P10 
0.681569 
 
0.79803 
 
0.116461 
 
16.10245 
 
281.26457 11.13052 
 
 
189 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  202.625 
High X:  598.475 
 
Peak 
Area 
390,  
P11 
0.72347 
 
0.815189 
 
0.091719 
 
8.051215 
 
289.65757 7.34744 
 
 
I plan to discard this data, as I believe the myotube floated away and/or moved with contraction. 
 
 Average 
resting level 
Peak Δ Level Time to Peak Area Under 
the Curve 
Peak 
Area 
390,  
P12 
0.697541 
 
0.775896 0.078355 120.7686   
Calcium Imaging, HSMM 
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391, 20140927 
 
 
Overview 
 
 
 
 
 Average 
resting level 
 
Peak Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
391, 
BG 
0.907616 
 
0.915491037 NA 361.09957 0.60566 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
391, 
P1 
0.663989 
 
0.834853 
 
0.170865 
 
16.10237 
 
274.02795 14.00249 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
391, 
P2 
0.593635 
 
0.737571 
 
0.143936 
 
16.10237 
 
246.70153 13.61755 
 
 
192 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area  
391, 
P3 
0.660597 
 
0.844989 
 
0.184392 
 
16.10237 
 
267.88969 11.42192 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
391, 
P4 
0.688779 
 
0.7983 
 
0.109522 
 
16.10237 
 
286.82469 12.21385 
 
 
193 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve Peak 
Area 
     Low X:  201.28 
High X:  598.475 
 
391, 
P5 
0.664354 
 
0.722538 
 
0.058184 
 
16.10237 
 
264.83327 2.56588 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area  
391, 
P6 
0.660386 
 
0.724468 
 
0.064082 
 
Unable to 
assess 
279.38954 12.62908 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
391, 
P7 
0.608556 
 
0.698025 
 
0.089469 
 
18.78611 
 
252.42774 9.31762 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
Peak 
Area 
391,  
P8 
0.552377 
 
0.642797 
 
0.09042 
 
26.83737 
 
229.39595 10.05722 
 
 
 
195 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area  
391, 
P9 
0.695681 
 
0.744597 
 
0.048917 
 
18.78611 
 
284.42673 8.64955 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
391, 
P10 
0.736837 
 
0.804625 
 
0.067788 
 
16.10237 
 
302.32587 5.30206 
 
 
196 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area  
391, 
P11 
0.674532 
 
0.779226 
 
0.104693 
 
16.10237 
 
277.93735 5.31181 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area  
391, 
P12 
0.671642 
 
0.838306 
 
0.166663 
 
26.83737 
 
292.86326 18.18648 
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 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
391, 
P13 
0.732279 
 
0.775309 
 
0.04303 
 
21.46989 
 
289.42468 3.87444 
 
 
 
 Average 
resting level 
 
Peak Δ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area  
391, 
P14 
0.720866 
 
0.820043 
 
0.099177 
 
13.41865 
 
298.65521 8.15479 
 
 
 
198 
 
Calcium Imaging, HSMM 
397, 20140927 
 
 
Overview 
 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
397, 
BG 
0.917101 
 
 
0.926035 
 
0.008934 
 
NA 360.64185 -0.64068 
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 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
397, 
P1 
0.637608 
 
0.861114 
 
0.223506 
 
8.051153 
 
287.76858 24.70659 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
397, 
P2 
0.671766 
 
0.764842 
 
0.093076 
 
8.051153 
 
268.95770 7.83936 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
397, 
P3 
0.638692 
 
0.688595 
 
0.049903 
 
8.051153 
 
243.50800 -0.82070 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the 
Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area  
397, 
P4 
0.621852 
 
0.713885 
 
0.092033 
 
24.15355 
 
260.45776 12.233572 
 
 
201 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area  
397, 
P5 
0.664295 
 
0.758091 
 
0.093797 
 
20.12795 
 
276.16072 12.12479 
 
 
I do not plan to use this tracing, as it did not behave as the others.  Perhaps my ROI was off a bit? 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.279 
High X:  599.813 
 
Peak 
Area  
397, 
P7 
0.618222 
 
0.637635 
 
0.019413 
 
28.17909 
 
242.51549 2.89787 
 
 
202 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
397, 
P8 
0.72183 
 
0.804515 
 
0.082685 
 
8.051121 
 
301.63892 8.17591 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area  
397, 
P9 
0.704704 
 
0.808753 
 
0.104049 
 
 
4.025537 
 
291.65523 9.88994 
 
 
203 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
397, 
P10 
0.629636 
 
0.689708 
 
0.060072 
 
4.025584 
 
259.01102 7.40709 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
397, 
P11 
0.684153 
 
0.768352 
 
0.084199 
 
12.07674 
 
276.32190 5.37847 
 
 
204 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
397, 
P12 
0.634308 
 
0.790793 
 
0.156485 
 
8.051121 
 
271.06944 15.59008 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
Peak 
Area 
397, 
P13 
0.677587 
 
0.76088 
 
0.083293 
 
4.025537 
 
279.03675 8.57676 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area  
397, 
P14 
0.5948 
 
0.645781 
 
0.050981 
 
8.051153 
 
237.90593 6.12087 
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Calcium Imaging, HSMM 
403, 20140927 
 
Overview 
 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak  
Area 
403, 
BG 
0.887064 
 
0.895164 
 
0.0081 
 
NA 353.02003 0.36768 
 
 
 
 
207 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area 
403, 
P1 
0.746927 
 
0.831495 
 
0.084568 
 
16.1023 
 
304.22930 4.38179 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area  
403, 
P2 
0.704225 
 
0.829883 
 
0.125658 
 
16.1023 
 
288.77451 8.74654 
 
 
 
208 
 
 
 Average 
resting level 
 
Peak ∆ Level  Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area 
403, 
P3 
0.701905 
 
0.828117 
 
0.126212 
 
16.1023 
 
290.76347 10.86140 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area 
403, 
P4 
0.695638 
 
0.79502 
 
0.099382 
 
10.73492 
 
286.20551 7.94899 
 
 
209 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area 
403, 
P5 
0.661406 
 
0.774056 
 
0.11265 
 
5.367463 
 
274.99995 11.28649 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area  
403, 
P6 
0.615961 
 
0.72211 
 
0.10615 
 
16.1023 
 
250.22343 6.07411 
 
 
210 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area 
403, 
P7 
0.593949 
 
0.789955 
 
0.196006 
 
16.1023 
 
253.22180 13.99581 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area 
403, 
P8 
0.725843 
 
0.806851 
 
0.081007 
 
16.1023 
 
303.59170 11.45349 
 
 
211 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area  
403, 
P9 
0.724888 
 
0.839221 
 
0.114333 
 
16.1023 
 
304.11123 11.87683 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak 
Area  
403, 
P10 
0.706653 
 
0.830469 
 
0.123816 
 
16.1023 
 
293.27794 12.44882 
 
 
212 
 
 
 Average 
resting level 
Peak ∆ Level Time to 
Peak 
Area Under the Curve Peak 
Area  
     Low X:  203.963 
High X:  601.155 
 
 
403, 
P11 
0.724526 
 
0.781531 
 
0.057005 
 
5.367463 
 
288.19091 3.69274 
 
 
I will not use this tracing, as the myotube moved from the ROI with contraction. 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.963 
High X:  601.155 
 
Peak  
Area 
403, 
P12 
0.792582 
 
0.84273 
 
0.050148 
 
 328.17647 5.50077 
 
 
213 
Calcium Imaging, HSMM 
428, 20140927 
 
Overview 
 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
BG 
0.863276 
 
0.893298 
 
0.030022 
 
NA 350.75964 1.78144 
 
 
 
214 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P1 
0.547533 
 
0.730508 
 
0.182975 
 
16.10236 
 
242.61531 20.22137 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P2 
0.581416 
 
 
0.691618 0.110202 16.10237 
 
242.21715 11.85322 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P3 
0.746218 
 
0.851979 
 
0.105761 
 
4.025575 
 
299.90895 6.82660 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P4 
0.568868 
 
0.690528 
 
0.12166 
 
8.05119 
 
239.94082 13.41411 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
425, 
P5 
0.614012 
 
0.750171 
 
0.136158 
 
4.025615 
 
259.43741 13.99989 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P6 
0.627396 
 
0.725547 
 
0.098151 
 
4.025575 
 
251.24470 6.49882 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P7 
0.629234 
 
0.825151 
 
0.195916 
 
12.07679 
 
264.84018 14.23565 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P8 
0.652614 
 
0.797607 
 
0.144992 
 
8.051176 
 
272.01551 13.98259 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P9 
0.693855 
 
0.780592 
 
0.086737 
 
8.05119 
 
281.02529 6.98890 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P10 
0.647486 
 
0.77246 
 
0.124974 
 
4.025575 
 
273.78770 12.72328 
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 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the 
Curve 
Low X:  201.279 
High X:  599.813 
Peak  
Area 
428, 
P11 
0.652009 
 
0.758368 
 
0.10636 
 
4.025575 
 
269.21490 9.30972 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak  
Area 
428, 
P12 
0.638695 
 
0.753905 
 
0.11521 
 
8.05119 
 
267.51436 13.94986 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
Peak  
Area 
428, 
P13 
0.674849 
 
0.75254 
 
0.077691 
 
4.025615 
 
278.02638 6.09213 
 
 
I do not plan to use this in my data, as it appears the myotube may have moved from ROI with 
stimulation.   
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
Peak  
Area 
428, 
P14 
0.683495 
 
0.708903 
 
0.70812905 
0.025408 
 
0.0247525 
NA 276.16165 5.63700 
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Calcium Imaging, HSMM 
Row B, 435, 20140926 
 
Overview 
 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
BG 
0.911124 
 
0.919731 
 
0.008606 
 
NA 363.72147 0.95167 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P1 
0.696259 
 
0.764281 
 
0.068022 
 
13.41852 
 
287.11666 8.75164 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P2 
0.729299 
 
0.840155 
 
0.110856 
 
10.73485 
 
297.35723 7.98588 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P3 
0.68497 
 
0.785666 
 
0.100696 
 
5.36749 
 
282.62434 11.24547 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P4 
0.647937 
 
0.80234 
 
0.154403 
 
10.73485 
 
272.93763 13.40011 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P5 
0.693425 
 
0.732388 
 
0.038964 
 
13.41852 
 
282.14702 5.11035 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the 
Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P6 
0.634478 
 
0.732943 
 
0.098464 
 
10.73485 
 
262.28835 9.31812 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P7 
0.631535 
 
0.66692 
 
0.035385 
 
13.41852 
 
257.86755 6.05394 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P8 
0.686478 
 
0.77724 
 
0.090762 
 
10.73485 
 
286.54606 11.41454 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.278 
High X:  598.467 
 
Peak 
Area 
435, 
P9 
0.663824 
 
0.77392 
 
0.110095 
 
16.10221 
 
273.96848 6.73963 
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Calcium Imaging, HSMM 
Row B, 439, 20140927 
 
Overview 
Note:  the dish moved shortly after 500 seconds – so the Area Under the Curve data is taken from 
Low X:  201.28 to High X:  499.176, which is different from other tracings. 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
BG 
0.872282 
 
0.881344 
 
0.009062 
 
NA 258.52980 0.22693 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P1 
0.713021 
 
0.748742 
 
0.035721 
 
9.393134 
 
211.92058 1.60567 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P2 
0.697043 
 
0.755549 
 
0.058505 
 
4.025548 
 
207.25405 3.25597 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P3 
0.696838 
 
0.780337 
 
0.083499 
 
4.025548 
 
209.91927 4.98727 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P4 
0.640815 
 
0.754292 
 
0.113478 
 
4.025548 
 
203.30823 10.50028 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P5 
0.545257 
 
0.572074 
 
0.026817 
 
12.07678 
 
163.20380 1.91049 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P6 
0.729192 
 
0.79896 
 
0.069767 
 
4.025548 
 
220.34068 4.23476 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P7 
0.719786 
 
0.754261 
 
0.034475 
 
4.025548 
 
213.05644 1.74251 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P8 
0.793336 
 
0.819345 
 
0.02601 
 
4.025548 
 
237.81068 1.57789 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  499.176 
 
Peak 
Area 
439, 
P9 
0.706709 
 
0.82177 
 
0.115061 
 
8.051186 
 
224.67299 8.76381 
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Calcium Imaging, HSMM 
Row B, 463, 20140927 
 
Overview 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
BG 
0.867208 
 
0.885568 
 
0.01836 
 
NA 346.87033 0.66607 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P1 
0.646351 
 
0.795849 
 
0.149497 
 
2.683529 
 
273.29485 12.11970 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P2 
0.679026 
 
0.763642 
 
 
0.084616 
 
6.709131 
 
285.81634 9.46679 
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Did not use this for the AUC data analysis, due to double peaks 
 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P3 
0.639515 
 
0.781492 
0.737493 
 
0.141977 
0.097978 
 
21.46982 
42.93976 
 
289.80589 16.21174 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P4 
0.647124 
 
0.73818 
 
0.091056 
 
6.709131 
 
272.82097 6.72014 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P5 
0.691482 
 
0.825458 
 
0.133976 
 
4.025529 
 
294.21447 10.34739 
 
 
Did not use this for the AUC data analysis, due to double peaks 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P6 
0.707102 
 
0.805091 
0.803821 
0.097989 
0.096719 
22.81183 
72.46102 
308.29155 12.85289 
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I did not use data from this tracing, as it appears the myotube moved with contraction…. 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P7 
    305.79331 7.02105 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P8 
0.662845 
 
0.825826 
 
0.162981 
 
4.025529 
 
282.57898 13.36376 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak  
Area 
463, 
P9 
0.66274 
 
0.821051 
 
0.158311 
 
4.025529 
 
282.70240 13.69418 
 
 
I did not use this tracing, as the myotube moved with stimulation.  I am also curious what caused the 
spike prior to the caffeine infusion was begun. 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
Peak  
Area 
463, 
P10 
    314.27458 8.00434 
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 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the 
Curve 
Low X:  201.28 
High X:  599.817 
Peak 
Area 
463, 
P11 
0.73589 
 
0.839392 
 
0.103502 
 
4.025529 
 
309.57836 7.92508 
 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
Peak 
Area 
463, 
P12 
0.667905 
 
0.796903 
 
0.128998 
 
4.025529 
 
284.56124 11.99755 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
Peak 
Area 
463, 
P13 
0.717044 
 
0.779566 
 
0.062522 
 
2.683529 
 
296.91013 6.15914 
 
 
 
I did not use the data from this tracing, because the myotube was displaced upon stimulation with 
the 20mM caffeine. 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
Peak 
Area 
463, 
P14 
    298.84627 9.04983 
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I do not plan to use this tracing, as the myotube floated away with stimulation….. 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  599.817 
 
Peak 
Area 
463, 
P15 
    320.20367 4.41991 
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Calcium Imaging, HSMM 
Row B, 480, 20140927 
 
Overview 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
BG 
0.914537 
 
0.921885 
 
0.007347 
 
NA 363.28003 -0.84496 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P2 
0.734021 
 
0.821147 
 
0.087126 
 
10.73492 
 
297.65079 6.22437 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P3 
0.664977 
 
0.72587 
 
0.060892 
 
10.73492 
 
281.07861 12.06196 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P4 
0.609391 
 
0.745605 
 
0.136214 
 
5.36745 
 
257.84482 12.65283 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P5 
0.728701 
 
0.800558 
 
0.071858 
 
5.36745 
 
296.75194 8.26828 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak  
Area 
480,  
P6 
0.669124 
 
0.78251 
 
0.113386 
 
5.36745 
 
277.73645 10.61732 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak  
Area 
480, 
P7 
0.738821 
 
0.821046 
 
0.082225 
 
10.73492 
 
295.95079 5.40545 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak  
Area 
480, 
P8 
0.660438 
 
0.816701 
 
0.156262 
 
5.36745 
 
275.04256 11.55687 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
Peak 
Area 
480, 
P9 
0.773932 
 
0.816886 
 
0.042953 
 
10.73492 
 
308.50199 4.33436 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P10 
0.711182 
 
0.745225 
 
0.034043 
 
5.36745 
 
282.32935 4.15956 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P11 
0.65871 
 
0.751579 
 
0.092869 
 
21.46995 
 
269.03958 7.33642 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P12 
0.714152 0.780583 0.066431 
 
5.36745 
 
287.64080 5.91531 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P13 
0.707212 
 
0.766987 
 
0.059775 
 
5.36745 
 
289.92484 7.97509 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  203.964 
High X:  601.158 
 
Peak 
Area 
480, 
P14 
0.699199 
 
0.817549 
 
0.118351 
 
5.367502 
 
289.78603 9.00156 
 
 
I did not  use the data from this tracing, as the myotube apparently moved with stimulation. 
 Average 
resting level 
Peak ∆ Level Time to 
Peak 
Area Under the Curve Peak 
Area 
     Low X:  203.964 
High X:  601.158 
 
 
480, 
P15 
0.70206 
 
0.755093 
 
0.053032 
 
Unable to 
determine 
293.13022 9.56464 
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Calcium Imaging, HSMM 
482, 20140927 
 
Overview 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
482, 
BG 
0.89016 
 
0.90537 
 
0.01521 
 
NA 353.68479 -0.19022 
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I did not use the data from this tracing due to the unexplained peaks prior to20mM caffeine. 
 Average 
resting level 
(prior to first 
premature 
spike) 
Peak ∆ Level Time to Peak Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
482, 
P1 
0.7272 
 
0.83279 
 
0.105589 
 
5.36748 
 
298.10550 6.83122 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
482, 
P2 
0.705393 
 
0.815412 
 
0.110019 
 
5.367479 
 
293.03694 11.58244 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
482, 
P3 
0.672968 
 
0.76739 
 
0.094421 
 
8.051202 
 
278.07143 10.73985 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
482, 
P4 
0.643841 
 
0.766411 
 
0.12257 
 
13.4187 
 
266.92493 11.86573 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
482, 
P5 
0.679852 
 
0.843902 
 
0.16405 
 
10.73491 
 
289.78241 16.62226 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area  
482, 
P6 
0.655444 
 
0.7935 
 
0.138056 
 
8.051185 
 
277.64755 15.18204 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.28 
High X:  598.475 
 
Peak 
Area  
482, 
P7 
0.649809 
 
0.829643 
 
0.179835 
 
8.051202 
 
281.21981 18.84237 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
482, 
P8 
0.652778 
 
0.766267 
 
0.113489 
 
10.73491 
 
270.88564 11.92615 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area 
482, 
P9 
0.656377 
 
0.810791 
 
0.154414 
 
2.683706 
 
276.77660 14.33207 
 
 
 
 Average 
resting 
level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
482, 
P10 
0.667594 
 
0.818949 
 
0.151354 
 
5.367428 
 
281.31901 14.44325 
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 Average 
resting 
level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
482, 
P11 
0.753203 
 
0.792483 
 
0.03928 
 
2.683774 
 
296.65582 0.68882 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
482, 
P12 
0.651929 
 
0.776972 
 
0.125043 
 
10.73491 
 
275.72802 13.82621 
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Calcium Imaging, HSMM 
489, 20140927 
 
Overview 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak  
Area  
489, 
BG 
0.885414 
 
0.895248 
 
0.009834 
 
NA 351.50493 -0.63925 
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It looks as though this myotube floated out of ROI range with stimulation, so did not use this data. 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P1 
    326.68863 4.53732 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P2 
0.722022 
 
0.846459 
 
0.124437 
 
5.367519 
 
289.02905 6.20696 
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 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the 
Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P3 
0.752488 
 
0.865183 
 
0.112695 
 
5.367497 
 
310.54630 9.23436 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P4 
0.735965 
 
0.757536 
 
0.021571 
 
2.683806 
 
293.25098 2.44157 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P5 
0.746617 
 
0.773257 
0.766897 
 
0.02664 
0.02028 
2.683691 
80.51224 
 
297.40509 3.57629 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P6 
0.702732 
 
0.787571 
 
0.08484 
 
2.683806 
 
289.76956 5.75315 
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 Average 
resting 
level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P7 
0.714466 
 
0.842757 
 
0.128291 
 
13.41871 
 
299.30246 12.48830 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P8 
0.740209 
 
0.858683 
 
0.118474 
 
8.05121 
 
306.26785 9.54928 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P9 
0.66254 
 
0.85132 
 
0.18878 
 
5.367449 
 
282.99484 13.38245 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P10 
0.608372967 0.761803 
 
0.151919 
 
10.73497 
 
254.39080 11.34047 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P11 
0.71078 
 
0.847666 
 
0.136886 
 
2.683806 
 
289.46645 7.83076 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P12 
0.765135 
 
0.857447 
 
0.092312 
 
8.051264 
 
310.55998 4.95591 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P13 
0.784501 
 
0.845871 
 
0.06137 
 
2.683806 
 
314.75113 4.05643 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.28 
High X:  598.475 
 
Peak 
Area 
489, 
P14 
0.66108 
 
0.783728 
 
0.122647 
 
16.1024 
 
280.13071 13.67516 
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Calcium Imaging, HSMM 
495, 20140927 
 
Overview 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
BG 
0.897465 
 
0.91656 
 
0.019095 
 
NA 360.28068 1.50335 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P1 
0.624195 
 
0.780105 
 
0.155909 
 
16.10236 
 
263.87300 15.88514 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P2 
0.695467 
 
0.813328 
 
0.117862 
 
16.10236 
 
293.23368 15.49706 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak  
Area 
495, 
P3 
0.724921 
 
0.814979 
 
0.090058 
 
13.41859 
 
294.18005 6.93120 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P4 
0.742057 
 
0.794196 
 
0.052139 
 
5.367431 
 
304.80446 7.89923 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P5 
0.681793 
 
0.817407 
 
0.135614 
 
13.4186 
 
284.17426 11.19224 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P6 
0.644412 
 
0.832251 
 
0.187839 
 
13.41863 
 
280.12483 18.11291 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
Peak 
Area  
495, 
P7 
0.650416 
 
0.77089 
 
0.120475 
 
16.10232 
 
274.73259 15.71292 
 
 
I will not be using data from this tracing, as it appears the myotube moved once stimulated with 
20mM caffeine. 
 Average resting 
level 
 
Peak Time to Peak Area Under the 
Curve  
Low X:  201.279 
High X:  598.471 
Peak 
ARea 
495, 
P8 
   295.11911 5.63479 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P9 
0.763026 
 
0.802589 
 
0.039563 
 
5.367407 
 
308.87264 5.50282 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the  
Curve  
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P10 
0.682257 
 
0.780962 
 
0.098705 
 
16.10232 
 
280.96170 7.76893 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P11 
0.688793 
 
0.862224 
 
0.173431 
 
10.73488 
 
292.69607 15.35942 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area 
495, 
P12 
0.764523 
 
0.824151 
 
0.059628 
 
8.051109 
 
310.81125 6.77337 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  598.471 
 
Peak 
Area  
495, 
P13 
0.596495 
 
0.755567 
 
0.159072 
 
18.78609 
 
255.78235 14.14028 
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Calcium Imaging, HSMM 
496, 20140927 
 
Overview 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
496, 
BG 
0.896639 
 
0.916308 
 
0.019669 
 
NA 361.95929 0.83373 
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 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area  
496, 
P1 
0.680238 
 
0.744598 
 
0.06436 
 
32.20464 
 
287.31129 12.47064 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
496, 
P2 
0.678724 
 
0.734649 
 
0.055925 
 
28.17917 
 
283.56228 10.65482 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.279 
High X:  599.813 
Peak 
Area 
496, 
P3 
0.648485 
 
0.714055 
 
0.06557 
 
4.025468 
 
271.05829 10.13188 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
Peak 
Area 
496, 
P4 
0.578061 
 
0.715258 
 
0.137197 
 
12.07673 
 
244.62857 11.56956 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
496, 
P5 
0.680736 
 
0.731618 
 
0.050882 
 
Unable to 
measure 
284.47128 8.93895 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
496, 
P6 
0.699627 
 
0.750508 
 
0.050881 
 
8.051152 
 
289.23055 4.86998 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
496, 
P7 
0.721657 
 
0.789803 
 
0.068146 
 
4.025468 
 
295.35119 6.56223 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
496, 
P8 
0.591491 
 
0.754389 
 
0.162898 
 
4.025468 
 
262.43530 20.78314 
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 Average 
resting level 
 
Peak ∆ Level Time to Peak Area Under the 
Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
496, 
P9 
0.624324 
 
0.716835 
 
0.092511 
 
4.025468 
 
262.04399 10.89036 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
 
Peak 
Area 
496, 
P10 
0.59578 
 
0.662596 
 
0.066816 
 
16.10239 
 
251.31642 12.41877 
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 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve  
Low X:  201.279 
High X:  599.813 
Peak 
Area 
496, 
P11 
0.694015 
 
0.719354 
 
 
0.025339 
 
Unable to 
measure 
281.14398 4.81783 
 
 
 
 Average 
resting level 
 
Peak ∆ Level Time to 
Peak 
Area Under the Curve 
Low X:  201.279 
High X:  599.813 
Peak  
Area 
496, 
P12 
0.698606 
 
 
0.773414 
 
0.074808 
 
8.051152 
 
288.21593 8.56422 
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Appendix I 
Data Collected:  HSMM, Flow Cytometry for MUSE ™ Cell Cycle Assay 
 
CNTRL A G0/ G1 S G2/M Debris 
% Gated 84.6 11.5 1.9 77.4 
Mean 3214.6 5506.5 9005.5 24.9 
%CV 6.0 15.4 10.7 400.2 
   
 
CNTRL C G0/ G1 S G2/M Debris 
% Gated 83.2 12.8 2.7 82.1 
Mean 3033.6 5184.7 8803.6 26.4 
%CV 6.2 15.3 12.5 672.0 
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Serum Sample 
228 
G0/ G1 S G2/M Debris 
% Gated 84.3 11.6 2.4 81.3 
Mean 3215.9 5314.5 8757.4 23.4 
%CV 5.5 17.8 11.8 443.4 
   
 
 
Serum Sample 
368 
G0/ G1 S G2/M Debris 
% Gated 83.2 13.8 1.8 69.1 
Mean 3162.3 5434.4 9133.4 25.4 
%CV 5.8 15.6 9.8 603.5 
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Serum Sample 
380 
G0/ G1 S G2/M Debris 
% Gated 79.8 15.4 2.8 77.9 
Mean 3097.4 5186.5 8926.8 46.3 
%CV 5.8 16.7 11.6 415.0 
   
 
Serum Sample 
390 
G0/ G1 S G2/M Debris 
% Gated 85.3 12.5 1.2 78.1 
Mean 3108.5 5202.2 9172.9 31.0 
%CV 5.5 18.3 10.2 563.9 
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Serum Sample 
391 
G0/ G1 S G2/M Debris 
% Gated 85.5 11.7 1.0 79.3 
Mean 3084.5 5124.2 9233.0 27.7 
%CV 5.6 20.2 8.5 500.8 
   
 
 
Serum Sample 
397 
G0/ G1 S G2/M Debris 
% Gated 75.9 17.8 4.9 87.7 
Mean 3004.0 4746.7 8310.9 20.0 
%CV 6.0 18.4 15.5 420.1 
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Serum Sample 
403 
G0/ G1 S G2/M Debris 
% Gated 79.6 15.3 3.0 83.3 
Mean 3041.1 5171.0 8784.1 30.3 
%CV 5.9 17.7 11.8 491.1 
   
 
 
Serum Sample 
428 
G0/ G1 S G2/M Debris 
% Gated 79.5 16.0 2.8 85.4 
Mean 2912.1 4968.0 8946.7 28.0 
%CV 6.1 18.2 11.7 531.0 
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Serum Sample 
435 
G0/ G1 S G2/M Debris 
% Gated 79.4 15.9 3.1 71.2 
Mean 3154.4 5152.2 8753.7 27.9 
%CV 5.4 18.5 12.4 632.3 
   
 
 
 
Serum Sample 
439 
G0/ G1 S G2/M Debris 
% Gated 80.5 14.5 3.0 72.8 
Mean 3117.1 5209.1 8919.5 26.7 
%CV 5.3 18.7 10.9 456.4 
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Serum Sample 
463 
G0/ G1 S G2/M Debris 
% Gated 85.9 10.6 1.9 80.5 
Mean 3123.1 5095.1 8386.7 28.9 
%CV 5.3 17.4 14.8 543.3 
   
 
 
Serum Sample 
480 
G0/ G1 S G2/M Debris 
% Gated 83.8 12.5 2.0 85.1 
Mean 3104.1 5062.3 9142.4 26.6 
%CV 5.7 17.7 10.7 463.3 
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Serum Sample 
482 
G0/ G1 S G2/M Debris 
% Gated 79.8 15.6 2.3 80.2 
Mean 3142.4 5138.2 8977.2 34.1 
%CV 5.7 19.3 9.6 409.4 
   
 
 
 
Serum Sample 
489 
G0/ G1 S G2/M Debris 
% Gated 84.4 13.4 1.2 82.9 
Mean 3117.7 5310.2 8642.0 54.5 
%CV 5.9 17.1 7.8 929.2 
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Serum Sample 
495 
G0/ G1 S G2/M Debris 
% Gated 80.9 13.3 3.8 82.9 
Mean 3008.4 4955.2 8530.3 20.4 
%CV 5.9 16.0 15.7 417.9 
   
 
 
Serum Sample 
496 
G0/ G1 S G2/M Debris 
% Gated 75.9 17.5 4.2 81.9 
Mean 3024.8 5133.9 8781.3 32.3 
%CV 5.4 17.4 12.8 483.8 
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HSMM Flow Cytometry for MUSE™ Cell Cycle Assay, Cell Cycle Analysis 
 
 
 
 
Cell Cycle Analysis 
CNTRL A 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis 
CNTRL C 
G0/ G1
S
G2/M
Debris
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Cell Cycle Analysis 
Serum Sample 228 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis 
Serum Sample 368 
G0/ G1
S
G2/M
Debris
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Cell Cycle Analysis  
Serum Sample 380 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis  
Serum Sample 390 
G0/ G1
S
G2/M
Debris
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Cell Cycle Analysis 
Serum Sample 391 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis 
Serum Sample 397 
G0/ G1
S
G2/M
Debris
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Cell Cycle Analysis 
Serum Sample 403 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis 
Serum Sample 428 
G0/ G1
S
G2/M
Debris
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Cell Cycle Analysis 
Serum Sample 435 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis 
Serum Sample 439 
G0/ G1
S
G2/M
Debris
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Cell Cycle Analysis  
Serum Sample 463 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis 
Serum Sample 480 
G0/ G1
S
G2/M
Debris
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Cell Cycle Analysis  
Serum Sample 482 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis 
Serum Sample 489 
G0/ G1
S
G2/M
Debris
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Cell Cycle Analysis  
Serum Sample 495 
G0/ G1
S
G2/M
Debris
Cell Cycle Analysis  
Serum Sample 496 
G0/ G1
S
G2/M
Debris
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Appendix J 
Comprehensive Tables, Data Collected  
 
 
299 
Table 10.  Comprehensive Table, Fracture Status Groups 
  
CNTRL Group, No Non-Traumatic Fracture 
 
 
CASE Group, Non-Traumatic Fracture Present 
ID # 
 
228 428 435 439 482 489 495 496 CNTRL 
Group, 
AVG 
368 380 390 391 397 403 463 480 CASE 
Group, 
AVG 
Patient Information 
 
Age 
 
73.6 65 57.7 62.2 52.3 60.6 70.1 63.8 63.2 70.8 67.7 59.6 62.2 68.2 66.4 50.7 67.8 64.2 
T-Spine 
 
0.76 -1.32 0.35 -2.09 -1.46 -0.08 0.38 -1.95 -0.68 -1.05 -0.65 -1.91 -2.39 0.83 -0.48 -1.08 -0.70 -0.93 
T-Hip 
 
-0.84 -0.08 -0.43 -0.65 -1.78 -0.95 -0.97 -0.34 -0.75 -1.43 -0.97 -0.57 -1.51 -0.68 -0.92 -1.46 -1.36 -1.11 
Fracture 
(Y/N) 
 
N N N N N N N N  Y Y Y Y Y Y Y Y  
Myogenic Differentiation 
 
Myotube 
Nuclei 
 
856.2 1102.6 1134 1121.4 1220.8 1219.4 1289 1111.8 1131.9* 970.6 938.2 1002.8 901.8 980.2 1036.6 1139.8 1404.2 1046.8* 
Total 
Nuclei 
 
1233.4 1440.4 1348.4 1343.4 1467.8 1467.2 1592 1413.8 1413.3* 1299.4 1259.2 1364.8 1337.2 1291.2 1336.2 1365.6 1649.4 1362.9* 
Fusion 
Index 
 
69.4 76.4 84.2 83.6 83.2 83.2 81.2 78.6 79.98* 74.8 74.4 73.8 67.6 75.8 76.4 83.2 85.0 76.4* 
Intracellular Calcium Homeostasis 
 
Resting 
Level 
 
0.71 0.64 0.67 0.69 0.67 0.72 0.69 0.66 0.68 0.68 0.71 0.68 0.67 0.66 0.69 0.68 0.70 0.68 
Peak Level  
 
0.80 0.76 0.76 0.76 0.80 0.82 0.80 0.74 0.78 0.77 0.79 0.78 0.77 0.76 0.80 0.80 0.78 0.78 
∆ Level 
 
0.08 0.12 0.08 0.07 0.14 0.11 0.12 0.07 0.10 0.10 0.10 0.10 0.10 0.09 0.10 0.10 0.10 0.10 
Time to 
Peak 
 
9.39 7.74 12.08 4.60 7.81 6.10 12.75 12.08 9.07 8.32 7.95 8.07 17.44 8.42 9.07 9.10 8.90 9.66 
Area 
Under the 
Curve 
 
289.79 264.75 278.10 -- 282.18 296.96 287.02 275.06 281.98 279.40 289.54 280.85 278.29 268.92 284.01 286.94 287.62 281.95 
Cell Cycle Analysis 
 
G0/G1 
 
84.35 79.55 79.4 80.53 79.82 84.38 80.95 75.88 80.61 83.24 79.83 85.32 85.52 75.85 79.59 85.95 83.76 82.38 
S 
 
11.55 15.96 15.93 14.47 15.58 13.37 13.29 17.54 14.71 13.79 15.45 12.5 11.7 17.84 15.34 10.6 12.51 13.72 
G2/M 
 
2.36 2.76 3.14 3.04 2.34 1.2 3.8 4.18 2.85 1.75 2.82 1.17 0.98 4.86 3.04 1.87 1.96 2.31 
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Table 11.  Comprehensive Table, T-Score Status Groups 
  
CNTRL Group, T-Score > -1.0 
 
 
CASE Group, T-Score < -1.0 
ID # 
 
228 380 397 403 435 489 495 CNTRL 
Group, 
AVG 
368 390 391 428 439 463 480 482 496 CASE 
Group, 
AVG 
Patient Information 
 
Age 
 
73.6 67.7 68.2 66.4 57.7 60.6 70.1 66.3 70.8 59.6 62.2 65 62.2 50.7 67.8 52.3 63.8 61.6 
T-Spine 
 
0.755 -0.654 0.831 -0.484 0.353 -0.084 0.379 0.157 -1.050 -1.909 -2.390 -1.316 -2.086 -1.081 -0.703 -1.455 -1.948 -1.549 
T-Hip 
 
-0.844 -0.969 -0.682 -0.919 -0.426 -0.954 -0.966 -0.823 -1.432 -0.572 -1.506 -0.077 -0.651 -1.460 -1.362 -1.781 -0.335 -1.020 
Fracture 
(Y/N) 
 
N Y Y Y N N N  Y Y Y N N Y Y N N  
Myogenic Differentiation 
 
Myotube 
Nuclei 
 
856.2 938.2 980.2 1036.6 1134 1219.4 1289 1064.8 970.6 1002.8 901.8 1102.6 1121.4 1139.8 1404.2 1220.8 1111.8 1108.4 
Total 
Nuclei 
 
1233.4 1259.2 1291.2 1336.2 1348.4 1467.2 1592 1361.1 1299.4 1364.8 1337.2 1440.4 1343.4 1365.6 1649.4 1467.8 1413.8 1409.1 
Fusion 
Index 
 
69.4 74.4 75.8 76.4 84.2 83.2 81.2 77.8 74.8 73.8 67.6 76.4 83.6 83.2 85.0 83.2 78.6 78.5 
Intracellular Calcium Homeostasis 
Resting 
Level 
 
0.71 0.71 0.66 0.69 0.67 0.72 0.69 0.69* 0.68 0.68 0.67 0.64 0.69 0.68 0.70 0.67 0.66 0.67* 
Peak  
Level 
 
0.80 0.79 0.76 0.80 0.76 0.82 0.80 0.79* 0.77 0.78 0.77 0.76 0.76 0.80 0.78 0.80 0.74 0.77* 
∆ Level 
 
0.079 0.098 0.086 0.095 0.084 0.105 0.116 0.949 0.096 0.101 0.103 0.117 0.066 0.096 0.097 0.135 0.068 0.977 
Time to 
Peak 
 
9.393 7.953 8.417 9.068 12.077 6.099 12.748 9.394 8.324 8.065 17.444 7.742 4.601 9.100 8.899 7.807 12.077 9.340 
Area 
Under the 
Curve 
 
289.792 
 
289.540 268.924 284.013 278.095 296.956 287.021 284.906 279.397 280.846 278.287 264.753 --- 286.942 287.620 282.180 275.064 279.386 
Cell Cycle Analysis 
 
G0/G1 
 
84.35 79.83 75.85 79.59 79.4 84.38 80.95 80.62 83.24 85.32 85.52 79.55 80.53 85.95 83.76 79.82 75.88 82.17 
S 
 
11.55 15.45 17.84 15.34 15.93 13.37 13.29 14.68 13.79 12.5 11.7 15.96 14.47 10.6 12.51 15.58 17.54 13.85 
G2/M 
 
2.36 2.82 4.86 3.04 3.14 1.2 3.80 3.03 1.75 1.17 0.98 2.76 3.04 1.87 1.96 2.34 4.18 2.23 
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